International Society for Heart and Lung Transplantation
30th Anniversary Meeting and Scientific Sessions
April 21-24, 2010
Convening at the Hilton Chicago, Chicago, Illinois

Program as of February 15, 2010

We are most grateful for the support of our corporate partners toward this meeting:

Gold Partner
ASTELLAS

Silver Partner
ACTELION
GILEAD
GENENTECH
NOVARTIS
XDX

Bronze Partner
UNITED THERAPEUTICS

Corporate Partner
GENZYME

SCIENTIFIC PROGRAM

All meetings and activities will take place at the Hilton Chicago unless otherwise specified. All papers will be presented in English. Speakers and Chairs have been invited but not confirmed as of the date of the printing of this program. Meeting room assignments are subject to change. The Final Program, which is distributed on site, will reflect the latest session schedule and room assignments.

TUESDAY, APRIL 20, 2010

8:00 AM – 1:00 PM
ISHLT Board of Directors Meeting (Grand Tradition)

Noon – 8:00 pm
Poster Mounting (Southwest Exhibit Hall)

2:00 PM – 4:00 PM
Thoracic Registry Steering Committee Meeting (PDR 2)
Education Committee Meeting (PDR 4)

2:00 PM – 6:00 PM
ISHLT/ERS/ATS CLAD Meeting (Joliet)

4:30 PM – 6:30 PM
Communications Committee Meeting (PDR2)
Standards and Guidelines Committee Meeting (PDR 4)

5:00 PM – 8:00 PM
Registration Desk Open (8th Street Registration)

5:00 PM – 8:00 PM
Slide Ready Room Open (Grand Tradition)

WEDNESDAY, APRIL 21, 2010

6:00 AM – 7:00 PM
Registration Desk Open (8th Street Registration)

6:00 AM – 7:00 PM
Slide Ready Room Open (Grand Tradition)

7:00 AM – 8:00 AM
CORPORATE COUNCIL BREAKFAST MEETING (PDR 2)

7:00 AM – 8:00 AM
SUNRISE SYMPOSIUM 1: VADs Gone Bad Case Presentations (International Ballroom)
Chairs: O. Howard Frazier, MD and Joseph G. Rogers, MD

7:00 AM Suicide Case, Nicholas G. Smedira, MD, Cleveland Clinic Foundation, Cleveland, OH
7:15 AM RV Failure Case, Renzo Cecere, MD, Royal Victoria Hospital, Montreal, Quebec, Canada
7:30 AM Strike Case, Stuart D. Russell, MD, Johns Hopkins Hospital, Baltimore, MD
7:45 AM Infection Case, Martin Strueber, MD, Hannover Medical School, Hannover, Germany

7:00 AM – 8:00 AM
SUNRISE SYMPOSIUM 2: Clinical Challenges in the Management of Right Ventricular Failure
(Continental A/B)
Chairs: Evelyn Horn, MD and Srinivas Murali, MD
This session will cover the clinical challenges associated with right ventricular failure from
pathophysiology, diagnosis, and treatment considerations in RV failure associated with secondary PH in
patients with pulmonary and cardiac disorders. Specific focus will be placed on management of RV
dysfunction in lung transplant and heart transplant candidates.

7:00 AM Assessment of RV Function: Why is it Important and How Do You Do It?, Mardi Gomberg
Maitland, MD, MSc, University of Chicago, Chicago, IL
7:20 AM Optimal Timing for Lung Transplant and the Implications of LAS in Pulmonary Arterial
Hypertension – Is It Ever Too Late? Adaani Frost, MD, Baylor University, Houston, TX
7:40 AM Pulmonary Hypertension Therapies and VAD Support: Do They Improve Candidacy for Heart
Transplant Candidates?, Teresa De Marco, MD, FACC, University of California, San Francisco, CA

7:00 AM – 8:00 AM
SUNRISE SYMPOSIUM 3: Surgical Approaches for Lung Transplantation – Is There Still a Debate?
(Boulevard)
Chairs: Thomas K. Waddell, MD, PhD and Gilbert Massard, MD
7:00 AM Clamshell With Tricks, Duane Davis, MD, Duke University, Durham, NC
7:16 AM Sternal Sparing Clamshell, Bryan F. Meyers, MD, Washington University School of Medicine, St. Louis, MO
7:32 AM Sternotomy With Tricks, John Dark, MD, FRCS, Freeman Hospital, Newcastle, United Kingdom
7:42 AM Antero-Axillary Approach, Yoshiya Toyoda, MD, University of Pittsburgh Medical Center, Pittsburgh, PA

7:00 AM – 8:00 AM
SUNRISE SYMPOSIUM 4: Technical Issues in Mechanical Support in the Pediatric Patient Case Presentations (Continental C)
Chairs: David Morales, MD and Victor O. Morell, MD

7:00 AM, MCS in the Pediatric Patient with Aortic Insufficiency, Kimberly L. Gandy, MD, PhD, Children's Hospital of Wisconsin, Milwaukee, WI
7:12 AM, A Unique Case of Pediatric MCS, Kirk R. Kanter, MD, Emory University, Atlanta, GA
7:24 AM, MCS of the Single Ventricle Population, Bennett Pearce, MD, University of Alabama at Birmingham, AL
7:36 AM, MCS in the Failing Fontan, Kristine Guleserian, MD, Children's Medical Center, Dallas, TX
7:48 AM, MCS in the Single Ventricle Patient after Bidirectional Glen, Asif Hasan, MD, Freeman Hospital, Newcastle Upon Tyne, United Kingdom

7:00 AM – 8:00 AM
SUNRISE SYMPOSIUM 5: Clinical Challenges for Nursing and Allied Health: What Would You Do? Case Presentations (Marquette)
Chairs: Annemarie Kaan, MCN, RN and Michael G. Petty, PhD(c), RN, CCNS, CNS
Health care practitioners consistently report in our educational survey difficulty translating clinical research outcomes into practice. In this session, through a case-study methodology, participants will be offered the opportunity to discuss with experienced healthcare professionals the application of such learning to specific care challenges.

7:00 AM VAD Candidate with Psychosocial Warning Signs that Coping with a VAD May be a Challenge: Lack of Caregiver, Lack of Resources, Non-adherence, Accepted as a Device Candidate as a Bridge to Decision, Daniela Roefe, RN, Heart Center NW, Bad Oeynhausen, Germany,
7:20 AM Pediatric Patient Whose Parents have been Non-adherent Presents as an Adult for Re-transplant, Corby D’Amico, RN, MN, Emory University Hospital, Atlanta, GA,
7:40 AM Patients Revisiting the Dark Side: Resumption of Drug, Alcohol, Tobacco Abuse after Transplant: How Does the Caregiving Nurse Cope? Christine Hartley, MS, NP, Stanford University Medical Center, Palo Alto, CA,

8:00 AM – 10:00 AM
Poster Mounting (Southwest Exhibit Hall)

8:15 AM – 10:15 AM
SATELLITE SYMPOSIUM 1: The Ultimate VAD Symposium (International Ballroom)
Chairs: James W. Long, MD, PhD and George M. Wieselthaler, MD
This session will provide the participant with an overview of mechanical circulatory support from patient and device selection, RV function assessment and management, bridge to recovery – role of clenbuterol, bridge to candidacy in the morbidly obese, destination therapy in the elderly, and management of the VAD recipient with hypertension.

8:15 AM Which Device for Which Patient, Michiel Morshuis, MD, Heart Center NRW, Bad Oeynhausen, Germany
8:35 AM RV Failure: Prediction, Prevention and Treatment, Vivek Rao, MD, PhD, Toronto General Hospital, Toronto, Ontario, Canada
8:55 AM Clenbuterol: Myth or Magic?, Francis D. Pagani, MD, PhD, University of Michigan Hospital, Ann Arbor, MI
9:10 AM VADs: Are They the Ultimate Weight Loss Machines? Robert L. Kormos, MD, University of Pittsburgh Medical Center, Pittsburgh, PA
9:25 AM VAD: Are You Ever Too Old?, Thomas Krabatsch, MD, PhD, German Heart Institute, Berlin, Germany
9:55 AM Panel Discussion

8:15 AM – 10:15 AM
SATellite Symposium 2: Innovations in Pulmonary Hypertension: Advances in Medical and Surgical Therapies (Continental A/B)
Chairs: Myung H. Park, MD and Omar Minai, MD
This session will focus on the most current up-to-date innovations in diagnosis, management, and research in pulmonary arterial hypertension (PAH). In 2009, the ACCF/AHA Executive Summary and reports from the 4th World Symposium were published. This session will feature highlights from those meetings and present updates on the current guidelines in combination therapy, surgical therapy and upcoming new treatments in PAH.

8:15 AM New Mandates From The ACCF/AHA Expert Consensus and 4th World Symposium On Pulmonary Hypertension, Vallerie McLaughlin, MD, University of Michigan, Ann Arbor, MI
8:30 AM Combination Therapy in Pulmonary Hypertension: Do We Have the Evidence for it and Is it the Best Approach? Jean-Luc Vachiery, MD, Erasme University Hospital-ULB, Brussels, Belgium
8:45 AM Risk Modeling in Pulmonary Arterial Hypertension - Are the Current Approaches Adequate? Robert P. Frantz, MD, Mayo Clinic, Rochester, MN
9:00 AM New Therapies on the Horizon in Pulmonary Arterial Hypertension – Going Beyond the Three Pathways, Paul A. Corris, MB FRCP, Freeman Hospital, Newcastle, United Kingdom
9:15 AM Beyond Medical Therapy – Surgical and Cellular Options for Pulmonary Hypertension, Robert J. Schilz, MD, Case Western Reserve University, Cleveland, OH

8:15 AM – 10:15 AM
SATellite Symposium 3: Getting to Yes – Increasing Lung Donors (Boulevard)
Chairs: Dirk Van Raemdonck, MD, PhD and Bartley P. Griffith, MD
Donor lung utilization is still unacceptably low and varies enormously between regions. Current donor utilization is only 15-20% of existing donors. This session will examine possible approaches (clinical as well as investigational) to improve organ availability.

8:15 AM Introduction - What are the Barriers? Where are the Opportunities? Duane Davis, MD, Duke University, Durham, NC
8:20 AM How To Optimize Donor Lung Procurement, Charles W. Hoopes, MD, University of California San Francisco, CA
8:40 AM Transplant Program Donor Management – Increasing the Donor Pool, Gregory I. Snell, FRACP, MBB, Alfred Hospital, Melbourne, Australia
9:00 AM DCD Donors, Robert B. Love, MD, Loyola University Medical Center, Maywood, IL
9:20 AM State of the Art Ex Vivo Lung Perfusion, Shaf Keshavjee, MD, FRCSC, Toronto General Hospital, Toronto, Ontario, Canada
9:40 AM Resuscitation of the Donor Lung, Florian M. Wagner, MD, University Heart Center Hamburg Eppendorf, Hamburg, Germany

8:15 AM – 10:15 AM
SATellite Symposium 4: Management of the Sensitized Patient and Antibody Mediated Rejection: Part 1 (Continental C)
Chairs: Nancy L. Reinsmoen, PhD and Steven D. Zangwill, MD
Several reports have demonstrated that pre-transplant sensitization to HLA antigens leads to a decrease in graft survival, an increase in rejection episodes, and the development of cardiac allograft vasculopathy (CAV) after heart transplantation and bronchiolitis obliterative syndrome (BOS) after lung transplantation. Further, the percentage of sensitized thoracic organ candidates receiving transplants is far less than
nonsensitized patients leading to increased time on the waitlists and increased death on the waitlists. This session is designed to address the assessment and impact of HLA specific antibodies in thoracic organ transplantation. New cutting edge technologies allow for the identification of donor antigens to be avoided to increase the donor pool for these sensitized patients. UNOS is implementing a calculated PRA to screen donors with unacceptable antigens and to indicate what percentage of the donor pool would be expected to be incompatible for a given patient. Other desensitization therapies are being used to decrease the strength and breadth of the antibody load again to increase the donor pool. Post-transplant monitoring strategies are being utilized to identify patients at risk for immune complications and allow for therapeutic intervention. Several investigators are studying the pathology and clinical implication of donor HLA specific antibodies and efficacy of treatment. This program will attempt to address these issues relevant to thoracic transplantation.

8:15 AM Biology of Antibody Mediated Rejection, Elaine F. Reed, PhD, UCLA Immunogenetics Center, Los Angeles, CA
8:35 AM Techniques for Pre- and Post-Transplant Antibody Surveillance, Adriana Zeevi, PhD, University of Pittsburgh Medical Center, Pittsburgh, PA
9:05 AM The Crossmatch: How to do it and how to Interpret it, Josef Stehlik, MD, MPH, University of Utah, Salt Lake City, UT
9:25 AM Post-Op Monitoring and Diagnosis of Antibody Mediated Rejection, Margaret M. Burke, FRCPath, Harefield Hospital, Harefield, Middlesex, United Kingdom
9:45 AM Access for Sensitized Patients – A National Algorithm, Lori J. West, MD, DPhil, University of Alberta, Edmonton, Canada
10:05 AM Panel Discussion

8:15 AM – 10:15 AM
SATELLITE SYMPOSIUM 5: Cardiac Allograft Vasculopathy: From Bench to Bedside (Waldorf)
Chairs: Jeffrey L. Platt, MD and Hannah A. Valantine, MD
Despite the availability of new immunosuppressive therapies, graft vasculopathy remains a leading cause of graft loss following cardiac transplantation. This symposium is designed to bring together researchers from all perspectives to develop new approaches to the treatment of this problem. This session will educate the basic scientist, translational researcher and clinician about the pathophysiology, clinical manifestations, treatment and outcomes of graft vasculopathy in the heart transplant recipient.

8:15 AM The Role of Innate Immunity in the Development of Allograft Vasculopathy, Timothy D. Lee, PhD, Dalhousie University Halifax, Nova Scotia
8:30 AM Adaptive Immunity in Allograft Vasculopathy, Marlene Rose, PhD, Harefield Hospital, Harefield, United Kingdom
8:45 AM Prevalence, Detection, and Prognosis of Graft Vasculopathy in Children, Elfriede Pahl Schuette, MD, Children's Memorial Hospital, Chicago, IL
9:00 AM Non-Angiographic Imaging Modalities for the Diagnosis of Graft Vasculopathy, Jignesh Patel, MD, PhD, UCLA University CV Medical Group, Los Angeles, CA
9:15 AM How to Treat Graft Vasculopathy: Medical and Catheter Based Therapies, Howard J. Eisen, MD, Drexel University College of Medicine, Philadelphia, PA
9:30 AM Retransplantation: The Ultimate Treatment, Clifford Chin, MD, Stanford University, Palo Alto, CA
9:45 AM Panel Discussion

8:15 AM – 10:15 AM
SATELLITE SYMPOSIUM 6: Emerging Infectious Diseases: Donor Management Issues and Recipient Sequelae (Marquette)
Chairs: Kate Gould, FRCPath and Stanley I. Martin, MD
The recent pandemic influenza and the SARS outbreak experience provide a natural “springboard” to discuss 1) the unfolding of an emerging pathogen threatening cardiothoracic transplant activities concerning donor, recipient, transplant teams and community; 2) donor management issues to identify the risks/testing- and its limitations; 3) resources available, should donor transmitted infection be suspected: UNOS/ CDC-donor derived infection advisory board, etc.; 4) how a donor- derived infection presents post transplantation and how to diagnose and manage the recipient.
8:15 AM Novel 2009 Influenza H1N1 Influenza Pandemic as a Model for an Emerging Infection's Impact on Cardiothoracic Transplant Centers: The Australian Experience, Glen P. Westall, FRACP, PhD, Melbourne, Australia

8:35 AM Donor Derived Infections: Clinical Relevance and How to Avoid It – Evaluation and Management at Time of Donation. The SARS Experience, Atul Humar, MD, University of Alberta, Edmonton, Canada

8:55 AM Donor Derived Infections: Resources to Sort Out the Answers, Michael G. Ison, MD, MS, UNOS, DTAC, Northwestern University, Chicago, IL

9:15 AM Donor Infections: Diagnostic Testing and Management to Minimize Risk, Paolo A. Grossi, MD, University of Insubria, Varese, Italy

9:30 AM Transmission of Tropical or Geographically Restricted Infections During Solid Organ Transplantation: Clinical Presentation, Diagnostic Testing, and Outcome, Patricia Munoz, MD, Hospital General University Gregorio Marano, Madrid, Spain

10:00 AM Panel Discussion

10:00 AM – 7:45 PM Exhibit Hall Open (Southeast Exhibit Hall)
Internet Café Open (Southeast Exhibit Hall)
Poster Viewing (Southwest Exhibit Hall)

10:15 AM – 10:30 AM Coffee Break (Southeast Exhibit Hall)

Chairs: Heather J. Ross, MD, MHSc, FRCP(c) and Hans B. Lehmkuhl, MD
This session will provide an overview of the major ethical issues that come into daily practice.

10:30 AM Re-Transplantation, Maryl R. Johnson, MD, University of Wisconsin, Madison, WI
10:45 AM Multiorgan Transplant - One for You, Two or Three for Me, Mark Siegler, MD, University of Chicago, IL
11:00 AM End of Life/ Palliative Care After Organ Transplantation, Savitri E. Fedson, MD, University of Chicago Hospitals, Chicago, IL
11:15 AM When Do I Turn the VAD Off?, Jane MacIver, RN, MSc, Toronto General Hospital, Toronto, Ontario, Canada
11:30 AM When to Say No – Does It Keep You up at Night?, Mary Amanda Dew, PhD, University of Pittsburgh School of Medicine, Pittsburgh, PA
11:45 AM Mechanical Circulatory Support Devices +/- Transplant in Congenital Heart Patients - Yes Or No?, Beth D. Kaufman, MD, Children’s Hospital of Philadelphia, PA
12:00 PM Panel Discussion

10:30 AM – 12:30 PM SATELLITE SYMPOSIUM 8: Universal Issues in Tackling Pulmonary Vascular Disease – Where Do We Stand? (Continental A/B)
Chairs: Raymond L. Benza, MD and Deborah J. Levine, MD
This session will cover key topics discussing diagnosis and management of a secondary PH commonly seen in clinical practice such as PH associated with lung disease, chronic thromboembolic disease and congenital heart disease, as well as the current "hot" topic of exercise and PH.

10:30 AM Report From the REVEAL Registry – What Constitutes the “Real” World Pulmonary Hypertension Patient Population? Harrison W. Farber, MD, Boston University School of Medicine, Boston, MA
10:50 AM Significance of Pulmonary Hypertension in Parenchymal Lung Disease – Implications and Treatment, Reda Girgis, MB BCH, Johns Hopkins University, Baltimore, MD
11:10 AM Chronic Thromboembolic Pulmonary Hypertension – When Does Medical Therapy Have a Place?, Marion Delcroix, MD, University Hospital Leuven, Belgium
11:30 AM Congenital Heart Disease and Pulmonary Hypertension, Curt J. Daniels, MD, Ohio State University, Columbus, OH
11:50 AM Exercise and Pulmonary Hypertension – How Far Can We Push Our Patients? Ronald J. Oudiz, MD, LA Biomedical Research Institute, Torrance, CA

10:30 AM – 12:30 PM
SATELLITE SYMPOSIUM 9: The Significance of Airways Inflammation in Lung Allograft Dysfunction (Boulevard)
Chairs: Andrew J. Fisher, FRCP, PhD and Sangeeta M. Bhorade, MD
Airway inflammation is widely recognized in patients developing lung allograft dysfunction, however the role this plays in the pathogenesis of Bronchiolitis Obliterans Syndrome and the best approach to its management remains unclear. Better understanding of lymphocytic bronchiolitis has been identified by the ISHLT pulmonary council educational survey as a key area for improved understanding. This session will explore the pathology of airway inflammation in the transplanted lung, examine any association between airway inflammation and acute and chronic rejection and discuss the evidence to support approaches to management.

10:30 AM The Pathology of Airways Inflammation in the Transplanted Lung, Susan Stewart, FRCP, Papworth Hospital, Cambridge, United Kingdom
10:55 AM Is Airways Inflammation a Form of Acute Rejection, Martin P. Iversen, MD, PhD, Rigshospitalet, Copenhagen, Denmark
11:15 AM Airways Inflammation as a Risk Factor for Bronchiolitis Obliterans Syndrome (BOS), Allan R. Glanville, MD, FRACP, Sydney, Australia
11:35 AM Treating Airways Inflammation in the Lung Allograft, Geert M. Verleden, MD, PhD, University Hospital Gasthuisberg, Leuven, Belgium
11:55 AM Panel Discussion

10:30 AM – 12:30 PM
SATELLITE SYMPOSIUM 10: Management of the Sensitized Patient and Antibody Mediated Rejection: Part 2 (Continental C)
Chairs: J. David Vega, MD and Uwe Schulz, MD
Several reports have demonstrated that pre-transplant sensitization to HLA antigens leads to decreased graft survival, an increase in rejection episodes, and the development of cardiac allograft vasculopathy (CAV) after heart transplantation and bronchiolitis obliterative syndrome (BOS) after lung transplantation. Further, the percentage of sensitized thoracic organ candidates receiving transplants is far less than nonsensitized patients leading to increased time on the waitlists and increased death on the waitlists. This proposed session is designed to address the assessment and impact of HLA specific antibodies in thoracic organ transplantation. New cutting edge technologies allow for the identification of donor antigens to be avoided to increase the donor pool for these sensitized patients. UNOS is implementing a calculated PRA to screen donors with unacceptable antigens and to indicate what percentage of the donor pool would be expected to be incompatible for a given patient. Other desensitization therapies are being used to decrease the strength and breadth of the antibody load again to increase the donor pool. Post-transplant monitoring strategies are being utilized to identify patients at risk for immune complications and allow for therapeutic intervention. Several investigators are studying the pathology and clinical implication of donor HLA specific antibodies and efficacy of treatment. This program will address these issues relevant to thoracic transplantation.

10:30 AM Management of the Sensitized Adult Heart Candidate, Stuart D. Russell, MD, Johns Hopkins Hospital, Baltimore, MD
10:50 AM Management of the Sensitized Pediatric Heart Candidate, Steven A. Webber, MB ChB, Children’s Hospital, Pittsburgh, PA
11:10 AM Managing the Sensitized Lung Candidate, Kenneth R. McCurry, MD, Cleveland Clinic Foundation, Cleveland, OH
11:30 AM Clinical Perspective of Antibody Mediated Rejection, A.G. Kfoury, MD, FACC, Intermountain Medical Center, Murray, UT
11:50 AM Results of the ISHLT Consensus Discussion Regarding AMR in Heart Transplantation: Implications for Treatment, Jon Kobashigawa, MD, Cedars-Sinai Heart Institute, Los Angeles, CA
12:10 PM Panel Discussion

10:30 AM – 12:30 PM
SATELLITE SYMPOSIUM 11: The ISHLT Guidelines for Heart Transplant Recipients: Towards an International Consensus (Waldorf)
Chairs: James K. Kirklin, MD and Mandeep R. Mehra, MD
Currently there are no published consensus practice guidelines addressing the care of heart transplant recipients. ISHLT has just completed development of such a set of guidelines. This session is intended to share with the ISHLT membership the key consensus recommendations for the care of heart transplant recipients, including early post-operative care, Immunosuppression and long term care.

10:30 AM Introduction and Overview of the Process, Maria Rosa Costanzo, MD, FACC, FAHA, Midwest Heart Specialists, Naperville, IL
10:40 AM Perioperative Care of Heart Transplant Recipients: Report From Task Force 1, Anne I. Dipchand, MD, Hospital for Sick Children, Toronto, Ontario, Canada
11:00 AM Immunosuppression: Report From Task Force 2, David O. Taylor, MD, Cleveland Clinic Foundation, Cleveland, OH
11:20 AM Long Term Care fo Transplant Recipients: Report From Task Force 3, Sharon A. Hunt, MD, Stanford University Medical Center, Palo Alto, CA
11:40 AM Closing Remarks from Panel
11:45 AM Moderated Panel Discussion

10:30 AM – 12:30 PM
SATELLITE SYMPOSIUM 12: Transforming Transplant Care Through Evidence-Based Practice (Marquette)
Chairs: Linda Ohler, MSN, FAAN and Daniela Roefe, RN
There is little information addressing evidence-based nursing and allied health care in MCSD and transplant patients. A gap exists between the evidence that supports transplant nursing and allied health care and daily care of the transplant patient. This symposium will present definitions, the gaps in the literature, and current evidence-based nursing and allied health practice in transplantation. It will also foster audience dialogue on these topics.

10:30 AM Best Practice in Transplant Care: A Road More or Less Traveled, Connie White-Williams, PhD, University of Alabama at Birmingham, AL
10:40 AM Lung Transplantation: Evidence Based Nursing Practice: Are We There Yet? Susan M. Chenenko, RN, MN, NP, Toronto General Hospital, Toronto, Ontario, Canada
10:55 AM Care Management in the Pediatric Transplant Patient: Where is the Evidence?, Karen C. Uzark, PhD, Children’s Hospital Heart Center, Cincinnati, OH
11:10 AM Evidence Based Practice of Self-Care Management in the Adult Mechanical Circulatory Support and Transplant Patient: Is Your Transplant Program Evidence Based?, Kathleen L. Grady, PhD, APN, FAAN, Northwestern Memorial Hospital, Chicago, IL
11:25 AM Mechanical Circulatory Support Infection Control Guidelines: The Disconnect of Science and Practice, Anne E. Dierlam, RN, Berlin Heart GmbH, Berlin, Germany
11:40 AM Transitioning the VAD Patient to Independence: Concept vs. Reality, Annemarie Kaan, MCN, RN, St. Paul’s Hospital, Vancouver, British Columbia, Canada
11:55 AM Professional Development and Contributions of the VAD Coordinator, Anthony W. Martin, APRN-BC, Newark Beth Israel Medical Center, Newark, NJ
12:10 AM Panel Discussion

12:30 PM – 2:30 PM
Lunch Break
1:00 PM – 2:00 PM
MINI ORAL SESSION I (Boulevard)

Chairs: Robert L. Kormos, MD and Leslie W. Miller, MD

1:00 PM (1) Battling the Achilles’ Heel of Left Ventricular Assist Devices: A Novel Technique To Reduce Drive Line Infections; G.B. Pelz, Z.A. Hashmi, R.J. Moraca, S. Murali, R.L. Benza, G.G. Sokos, G.J. Magovern, Jr., S.L. Slutz, S.H. Bailey, D.A. Dean. Allegheny General Hospital, Pittsburgh, PA; Allegheny General Hospital, Pittsburgh, PA.

1:05 PM (2) Echocardiographic and Hemodynamic Changes during Interruption of Left Ventricular Assist Device May Predict Outcomes after Weaning from the Device; S. Saito, G. Matsumiya, Y. Sakata, T. Sakaguchi, Y. Miyagawa, Y. Yoshikawa, T. Yamauchi, T. Kuratani, Y. Sawa. Osaka University Graduate School of Medicine, Suita, Osaka, Japan; Osaka University Graduate School of Medicine, Suita, Osaka, Japan.

1:10 PM (3) Tricuspid Valve Repair at the Time of Left Ventricular Assist Device Implantation: Is It Warranted?; D. Saeed, S. Shalli, T. Kidambi, I. Mikati, C. Malaisrie, R. Lee, W.G. Cotts, P.M. McCarthy, E.C. McGee. Northwestern Memorial Hospital, Chicago; Northwestern Memorial Hospital, Chicago.

1:15 PM (4) Less Frequency of Aortic Valve Opening and Continuous Flow Device Are Risk Factors for Late Onset of Aortic Regurgitation in Patients with Left Ventricular Assist Device; M. Hatano, K. Kinugawa, T. Shiga, A. Yao, Y. Hirata, T. Nishimura, S. Kyo, M. Ono, N. Nagai. The University of Tokyo, Tokyo, Japan; The University of Tokyo, Tokyo, Japan; The University of Tokyo, Tokyo, Japan.


1:25 PM (6) Neurological Adverse Events (NAEs) and Proposed Mechanisms in a Single Center Experience with Continuous-Flow Left Ventricular Assist Devices (LVADs); C.M. Halley, G.V. Gonzalez-Stawinski, E.C. Chu, P.M. Eckman, N.S. Smedira, R.C. Starling, M.M. Mountis. Cleveland Clinic Foundation, Cleveland, OH; Cleveland Clinic Foundation, Cleveland, OH.


1:50 PM (11) Quality of Life in HeartMate II LVAD Patients; Destination Therapy Compared to Post Transplant Bridge to Transplant Therapy at 1 Year; J.M. Aho, E.A. Ziemba, M.J. Schnaus, K. Liao, M.R. Pritzker, M.M. Colvin-Adams, R. John. University of Minnesota, Minneapolis, MN; University of
Delayed Sternal Closure Following LVAD Implantation Is a Safe Alternative to Primary Sternal Closure; I.-W. Wang,¹ T. Guthrie,¹ G.A. Ewald,² E.M. Geltman,² S. Joseph,² N. Moazami.¹
¹Washington University School of Medicine, Saint Louis, MO; ²Washington University School of Medicine, Saint Louis, MO.


PVRI <9 W.U. x m² Does Not Predict Early Postoperative Mortality in Pediatric Cardiac Transplantation for Cardiomyopathy; P. Chiu,¹ M.J. Russo,¹ R.R. Davies,¹ L.J. Addonizio,¹ M.E. Richmond,¹ J.M. Chen.² ¹Columbia University, College of Physicians and Surgeons, New York, NY; ²Weill Medical College of Cornell University, New York, NY.


Dynamics in Lipid Profile Subfractions in Patients Undergoing Cardiac Transplantation; F.H. Cheema,² T. Khawaja,² K.J. Schaeffe,² V.K. Topkara,² S. Yaman,² A. Chokshi,² G. Magda,² M. Argenziano,² Y. Naka,² P.C. Schulze.¹ ¹Columbia University Medical Center, New York, NY; ²Columbia University Medical Center, New York, NY.

The Treatment of Postpartum Cardiomyopathy with the Use of Mechanical Assist Devices and Cardiac Transplantation; H. Zimmerman, R. Bose, R.G. Smith, J.G. Copeland. University of Arizona, Tucson, AZ.

Efficacy Outcome in De-Novo HTxR: Comparison of 6 Immunosuppressive (IS) Regimens (ISR); H.J. Eisen,¹ J.F. Delgado,² G. Junge,³ A. Karpov,³ H. Lehmkuhl,⁴ C. Pellegrini,⁵ J. Kobashigawa,⁶ H. Schwende,³ A. Zuckermann,⁷ ¹Drexel University College of Medicine, Philadelphia; ²Madrid Hospital, Madrid, Spain; ³Novartis Pharma, Basel, Switzerland; ⁴Deutsches Herzzentrum Berlin, Berlin, Germany; ⁵Policlinico S. Matteo–IRCCS Università degli Studi di Pavia, Pavia, Italy; ⁶Cedars-Sinai Heart Institute, Los Angeles, CA; ⁷Medical University of Vienna, Vienna, Austria.

Use of Sildenafil for Prevention of Right Heart Failure in Heart Transplant Recipients with Pulmonary Hypertension; H. Bedanova,¹ M. Orban,¹ J. Ondrasek,¹ E.D. Petrikovits,² L. Spinarova,³ P. Nemec.¹ ¹Center of Cardiovascular and Transplant Surgery, Brno, Czech Republic; ²Cardiocenter Vysochina, Jihlava, Czech Republic; ³1st. Department of Internal Medicine–Cardioangiology, Brno, Czech Republic.

Heart Transplant Survival at Age 70 and Older Similar to Younger Patients; D. Daneshvar,¹ A. Phan,¹ L. Czer,¹ M. De Robertis,¹ J. Mirocha,¹ E. Schwarz,¹ R.M. Kass,¹ S. Simsin,¹ A. Trento.¹ ¹Cedars-Sinai Heart Institute, Cedars-Sinai Medical Center, Los Angeles, CA; ²Cedars-Sinai Medical Center, Los Angeles, CA.

Repetitive Episodes of Rejection Is Associated with Reduction of mRNA Expression of Myocardial Sarcoplasmic Reticulum Ca²⁺-ATPase and Ryanodine Receptor-2 in Transplanted Hearts; T.S. Kato,¹ K. Hashimura,¹ Y. Sata,¹ H. Ueda,² T. Nakatani,³ T. Shishido,² K. Komamura,⁴ ¹National Cardiovascular Center, Osaka, Japan; ²National Cardiovascular Center, Osaka, Japan; ³National


Use of Ventricular Assist Device as a Bridge to Simultaneous Heart and Kidney Transplantation; R. Yanagida,1,3 A. Ruzza,1,3 R. Vespignani,1,3 L. Czer,1,3 E. Schwarz,1,3 S. Simsir,1,3 S. Jordan,2,3 J.L. Cohen,2,3 A. Trento,1,3 1Cedars-Sinai Heart Institute, Cedars-Sinai Medical Center, Los Angeles, CA; 2Cedars-Sinai Medical Center, Los Angeles, CA; 3Cedars-Sinai Medical Center, Los Angeles, CA.

Donor Specific Antibody (DSA) as a Time Dependent Predictor Shows a Significant Negative Impact on Survival in Lung Recipients (Recips) Regardless of Pretransplant (Pretx) Antibody (Ab) Status; N.L. Reinsmoen,1 D. Chen,2 M. James,1 S. Palmer,2 A. Finlen-Copeland,2 R.D. Davis.2 1Cedars-Sinai Health System, LA, CA; 2Duke University, Durham, NC.

Novalung Enables Protective Ventilation in Primary Graft Dysfunction; C.P. Searl, T.A. Butt, A. Samuel, N. Wrightson, A.J. Fisher, J.H. Dark. Freeman Hospital, Newcastle upon Tyne, United Kingdom.

Lung Transplantation as Treatment for Pulmonary Graft Versus Host Disease Following Allogeneic Hematopoietic Stem Cell Transplantation: A Single-Centre Experience; C. Fegbeutel,1 I. Kropivnitskaya,1 G. Warnecke,1 J. Gottlieb,2 S. Fischer,1 M. Strueber,1 A. Haverich,1 A.R. Simon.1 1Hannover Medical School, Hannover, Germany; 2Hannover Medical School, Hannover, Germany.

Optimizing Renal Function through Minimizing Calcineurin Inhibitor Exposure – Long term Results from a Calcineurin Inhibitor-Everolimus Based Immunosuppression; B. Zweytick, B. Ghanim, J. Sillipp, G. Boehmig, P. Jaksh, W. Klepetko. Medical University of Vienna, Vienna, Austria.

Elevations in Troponin-I (Tn-I) Following Lung Transplantation Predict Survival; R. Celis,2 J.D. Estep,1 C. Orrego,1 L. Semones,1 R. Kasevan,3 H. Seethamraju,3 G.P. Noon,3 M. Loebe,3 G. Torre.1 1TMH, Houston, TX; 2UTMH, Galveston, TX; 3Baylor College of Medicine, Houston, TX.

Enoxaparin for the Treatment of Venous Thromboembolism in Lung Transplant Recipients; M.-Y. Huang,1 C. Hui,1 L.E. Beard,2 R.F. Boettger,1 J.P. Singer.2 1University of California, San Francisco, San Francisco, CA; 2University of California, San Francisco, San Francisco, CA.

Outcome of Lung Transplant Candidates on Mechanical Ventilation or Extracorporeal Support; J. Gottlieb,1 A.R. Simon,2 J. Hadem,3 M. Dierich,1 O. Wiesner,3 M. Strueber,2 T. Welte.1 1Hannover Medical School, Hannover, Germany; 2Hannover Medical School, Hannover, Germany; 3Hannover Medical School, Hannover, Germany.

Role of ImmuKnow Assay Following Lung Transplantation; M.R. Morrell, E.P. Trulock, R.R. Hachem. Washington University/Barnes-Jewish Hospital, St. Louis, MO.
1:40 PM (33) A Single-Centre Experience with the Use of Posaconazole for Invasive Fungal Infections in Lung and Heart-Lung Transplant Recipients; B.J.H. Ng, P.M.A. Hopkins, F.D. Kermeen, D.C. Chambers. The Prince Charles Hospital, Chermside, QLD, Australia.


1:50 PM (35) The Australian Experience with Combined Heart-Lung-Liver Transplantation; A. Fiene, K.D. McNeil, F.D. Kermeen, D.C. Chambers, K. Stuart, J. Fawcett, R. Tam, G.J. Hart, P.M.A. Hopkins. The Prince Charles Hospital, Brisbane, QLD, Australia; The Princess Alexandra Hospital, Brisbane, QLD, Australia; The Princess Alexandra Hospital, Brisbane, QLD, Australia; Townsville Base Hospital, Townsville, QLD, Australia.


1:00 PM – 2:00 PM
MINI ORAL SESSION 4 (Marquette)

1:00 PM (37) Recipient Cytokine Levels Are Associated with Early Allograft Dysfunction in Human Lung Transplantation; J.G. Allen, M.T. Lee, G.J. Arnaoutakis, C.A. Merlo, Barbara Detrick, PhD, D(ABMLI), A.S. Shah. Johns Hopkins Medical Institutions, Baltimore, MD; Immunology Laboratory/ Cytokine Laboratory Department of Pathology Johns Hopkins Medical Institutions, Baltimore, MD.

1:05 PM (38) Preservation Enhances Rat Cardiac Allograft Vasculopathy by Advancing Innate Immune and Dendritic Cell Activation, and Inducing IL-17 Production; S.O. Syrjala, R. Krebs, R. Tuuminen, M.A. Keranen, A.I. Nykanen, K.B. Lemstrom. Haartman Institute, University of Helsinki, Helsinki, Finland.


1:20 PM (41) Results of a Randomized Phase 2 Trial of ALN-RSV01, an RNAi Therapeutic, Lung Transplant (LTX) Patients Infected with Respiratory Syncytial Virus (RSV); M.R. Zamora, M. Budev, M. Rolfe, J. Gottlieb, J. DeVincenzo, J. Chehelsky, G. Albert, S. Nocher, A. Vaishnaw, A. Glanville. University of Colorado Health Sciences Center, Aurora, CO; Cleveland Clinic, Cleveland, OH; Tampa General Hospital, Tampa, FL; Kliniken fur Pneumonologie Medizinische Hochschule, Hannover, Germany; University of Tennessee Center for Health Sciences, Memphis, TN; Alnylam Pharmaceuticals, Cambridge, MA; St. Vincent’s Hospital, Darlinghurst, NSW, Australia.


1:30 PM (43) Prognostic Value of Immune Cell Function Assay on Biopsy Results and Infection in Cardiac Transplant Patients; R. Dancel, C. Wiesen, P. Chang. University of North Carolina, Chapel Hill, NC.


1:45 PM (46) Evolutionary Improvements in the Jarvik 2000 Heart Technology; C. Selzman, S. McConchie, K. Gandhi, D. Perry, M. Blinder, B. Griffith, R. Jarvik. 1 University of Utah, Salt Lake City, UT; 2 Jarvik Heart, Inc., New York, NY; 3 University of Maryland Medical Center, Baltimore, MD.

1:50 PM (47) Mortality and Readmission Rates with Dobutamine and Milrinone in Pulmonary Hypertension and Right Ventricular Failure; A. Rabinovitz, R. Zolty. 1 Jacobi Medical Center, Bronx, NY; 2 Montefiore Medical Center, Bronx, NY.

1:55 PM (48) The Adverse Effects of Sirolimus in Heart Transplant Patients: Is It Worth It?; M. Kittleson, J. Patel, J. Moriguchi, A. Moradzadeh, M. Kawano, S. Davis, A. Ardehali, J. Kobashigawa. 1 David Geffen School of Medicine at UCLA, Los Angeles, CA; 2 Cedars-Sinai Heart Institute, Los Angeles, CA.

2:00 PM (49) Pulmonary Artery Hypertension: Heart Failure and ACE Inhibition; E.M. Bader, R. Zolty. 1 Jacobi Medical Center, Albert Einstein College of Medicine, Bronx, NY; 2 Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, NY.

1:00 PM – 2:00 PM MINI ORAL SESSION 5 (PDR2 )

1:00 PM (50) Everolimus (Certican) after Heart Transplantation: 2 Years’ Single Center Follow-Up in Calcineurin Inhibitor-Free Immunosuppression; M.A. Engelen, H. Welo, J.R. Sindermann, S. Amler. 1 University Hospital of Munster, Munster, Germany; 2 University Hospital Munster, Munster, Germany.

1:05 PM (51) Identifying PKC Epsilon as a Target Molecule To Control Intimal Hyperplasia; T. Deuse, T. Koyanagi, H. Reichenspurner, R.C. Robbins, D. Mochly-Rosen, S. Schreper. 1 University Heart Center Hamburg, Hamburg, Germany; 2 Stanford University School of Medicine, Stanford, CA; 3 Stanford University School of Medicine, Stanford, CA.

1:10 PM (52) Sirolimus as Primary Immunosuppression Is Associated with Improved Renal Function and Survival Compared with Calcineurin Inhibitors in Stable Cardiac Transplant Recipients; M.A. Al-Omari, E. Raichlin, N.L. Pereira, B.S. Edwards, A.L. Clavell, R.J. Rodeheffer, R.P. Frantz, J.A. Schirger, S.S. Kushwaha. Mayo Clinic, Rochester, MN.


1:20 PM (54) Balancing Volume in Advanced Heart Failure before Heart Transplant: Mismatch between Right and Left Filling Pressures; P. Campbell, M.H. Drazner, M. Kato, N. Lakdawala, A. Nohria, L.W. Stevenson. 1 Brigham and Women’s Hospital, Boston, MA; 2 University of Texas, Southwest Medical Center, Dallas, TX.

K. Altland,5 H.A. Katus,1 T.J. Dengler.1 1University of Heidelberg, Heidelberg, Germany; 2University of Heidelberg, Heidelberg, Germany; 3University of Heidelberg, Heidelberg, Germany; 4University of Kiel, Kiel, Germany; 5University of Giessen, Giessen, Germany.

1:30 PM (56) Characteristics of Patients Receiving Ventricular Assist Devices as a Bridge to Cardiac Transplant Candidacy; S. Emani,1 L.B. Louis,2 A. Hasan,1 C. Sai-Sudhaker,2 B. Sun.2 1The Ohio State University, Columbus, OH; 2The Ohio State University, Columbus, OH.

1:35 PM (57) Influence of Pulsatile and Non-Pulsatile Perfusion on Kidney Function; H.A. Welp,1 B. Nafz,2 P.B. Perssson,2 S.R. Jurgen,1 H.H. Scheld,1 A. Hoffmeier.1 1University Hospital Münster, Münster, NRW, Germany; 2Ferris University of Berlin, Berlin, Germany.

1:40 PM (58) Thyroid Deficiency Is Common in Advanced Heart Failure and Associated with Increased Operative Mortality after Assist Device Implantation; N. Uriel,1 S.-W. Pak,2 P. Colombo,1 R. Song,3 D. Mancini,1 Y. Naka,2 U.P. Jorde.1 1Columbia University, New York, NY; 2Columbia University, New York, NY.

1:45 PM (59) Nesiritide Worsens Renal Insufficiency in Patients with Right Ventricular Failure Due to Pulmonary Hypertension; I. Kelesidis, P. Velankar, R. Chaudhari, R. Zolty. Albert Einstein College of Medicine, Bronx, NY.

1:50 PM (60) Impact of Pre-Transplant Pulmonary Hypertension on Post-Transplant Outcomes in IPF; S.C. Mathai,1 R.E. Girgis,1 A. Shah,2 P.M. Hassoun,1 J.F. McDyer,1 J.B. Orens,1 C.A. Merlo.1 1Johns Hopkins University School of Medicine, Baltimore, MD; 2Johns Hopkins University School of Medicine, Baltimore, MD.

1:55 PM (61) Correlation of Right Heart Catheterization (RHC) Parameters and Functional Tests after 16 Weeks of Bosentan-Based Therapy in Patients with Pulmonary Arterial Hypertension (PAH): The COMPASS-3 Study; F. Torres,1 S. Murali,2 F.J. Soto,3 H. Gupta,4 M.H. Park,5 N. Frey,6 R.L. Benza.2 1University of Texas Southwestern Medical Center, Dallas, TX; 2Allegheny General Hospital, Pittsburgh, PA; 3Prevea Health, Sheboygan, WI; 4University of Alabama at Birmingham, Birmingham, AL; 5University of Maryland School of Medicine, Baltimore, MD; 6Actelion Pharmaceuticals US, Inc., South San Francisco, CA.

2:30 PM – 4:45 PM OPENING PLENARY SESSION (International Ballroom) Chairs: James K. Kirklin, MD and Hermann Reichenspurner, MD, PhD

2:30 PM President’s Welcome, James K. Kirklin, MD, University of Alabama at Birmingham, AL
2:35 PM Program Chair’s Report, Hermann Reichenspurner, MD, PhD, University Heart Centre Hamburg, Germany
2:50 PM ISHLT International Thoracic Registry Report, Marshall I. Hertz, MD, University of Minnesota, Minneapolis, MN
3:20 PM INTERMACS Report, James K. Kirklin, MD, University of Alabama at Birmingham, AL
3:30 PM The Evolution of Lung Transplantation, Alec Patterson, Washington University School of Medicine, St. Louis, MO
3:50 PM Presidential Address, James K. Kirklin, MD, University of Alabama at Birmingham, AL
4:20 PM Margaret E. Billingham, MD Memoriam/Lifetime Achievement Award Lecture, Dr. John Billingham and Bruce A. Reitz, MD, Stanford University, CA

4:45 PM – 5:15 PM Coffee Break (Southeast Exhibit Hall)

5:15 PM – 6:45 PM CONCURRENT SESSION 1: Patients, Pumps and Outcomes (International Ballroom) Chairs: Katherine Lietz, MD, PhD and Aly El Banayosy, MD
5:15 PM (62) Strategies for LVAD Therapy in INTERMACS: Intent Rate v. Event Rate; J.J. Teuteberg, 2 G.C. Stewart, 1 M. Jessup, 3 R.L. Kormos, 3 B. Sun, 4 O.H. Frazier, 5 D.C. Naftel, 6 L.W. Stevenson. 7 Brigham and Women’s Hospital, Boston, MA; 2 University of Pittsburgh Medical Center, Pittsburgh, PA; 3 University of Pennsylvania, Philadelphia, PA; 4 Ohio State University Medical Center, Columbus, OH; 5 Texas Heart Institute, Houston, TX; 6 University of Alabama at Birmingham, Birmingham, AL.

5:30 PM (63) INTERMACS Profiles of Nutrition and Organ Function in Relation to Outcomes; M. Liszkowski, 1 J.J. Teuteberg, 2 S.L. Myers, 3 J.G. Rogers, 3 R. Starling, 5 D.D. Ascheim, 6 L.W. Stevenson, 1 Brigham and Women’s Hospital, Boston, MA; 2 University of Pittsburgh Medical Center, Pittsburgh, PA; 3 University of Alabama at Birmingham, Birmingham, AL; 4 Duke University Medical Center, Durham, NC; 5 Cleveland Clinic Foundation, Cleveland, OH; 6 Mount Sinai School of Medicine, New York, NY.

5:45 PM (64) Rapidly Changing Characteristics of Patients Receiving Mechanically Assisted Circulatory Support in INTERMACS; F.D. Pagani, 1 D.C. Naftel, 2 K.D. Aaronson, 1 M.K. Parides, 3 D.J. Farrar, 4 S.V. Pamboukian, 2 J.K. Kirklin. 1 University of Michigan, Ann Arbor, MI; 2 University of Alabama at Birmingham, Birmingham, AL; 3 Mount Sinai School of Medicine, New York, NY; 4 Thoratec Corporation, Pleasanton, CA.

6:00 PM (65) Changing Patterns and Regional Differences in the Use of Ventricular Assist Devices as a Bridge-to-Transplant: An Analysis of UNOS Data; S. Lee, 1 F. Kamdar, 2 R. John. 1 University of Minnesota, Minneapolis, MN; 2 University of Minnesota, Minneapolis, MN.

6:15 PM (66) Destination Therapy: Improving Outcomes with Continuous Flow LVADs; M.S. Slaughter, 1 J.G. Rogers, 3 L. Blue, 3 A.J. Lodge, 4 A.J. Tatooles, 3 G. Bhat, 6 M. Sobieski, 7 C.A. Milano. 1 University of Louisville, Louisville, KY; 2 Duke University Medical Center, Durham, NC; 3 Duke University Medical Center, Durham, NC; 4 Advocate Christ Medical Center, Oak Lawn, IL; 5 Advocate Christ Medical Center, Oak Lawn, IL; 6 University of Louisville, Louisville, KY; 7 Duke University Medical Center, Durham, NC.


5:15 PM – 6:45 PM CONCURRENT SESSION 2: Heart Transplant Outcome; Does the Donor Matter? (Continental A/B) Chairs: Roberto Fiocchi, MD, PhD and Keith D. Aaronson, MD


5:30 PM (69) Artificial Neural Networks – A Method for Optimal Donor-Recipient Matching. Large Scale Simulation of Survival after Heart Transplantation; J. Nilsson, 1 M. Ohlsson, 2 P. Hoglund, 3 B. Ekmeht, 4 B. Kou. 1 Clinical Science in Lund, Lund, Sweden; 2 Theoretical Physics, Lund, Sweden; 3 Clinical Science in Lund, Lund, Sweden; 4 Clinical Science in Lund, Lund, Sweden.

5:45 PM (70) De Novo Formed Donor-Specific Antibodies Adversely Affect Patient Survival after Cardiac Transplantation; J.D. Smith, 1 N.R. Banner, 2 I.M. Hamour, 2 M. Ozawa, 3 A. Goh, 3 P. Terasaki, 3 M.L. Rose. 1 Harefield Hospital, Harefield, Middlesex, United Kingdom; 2 Harefield Hospital, Harefield, Middlesex; 3 Terasaki Foundation, Los Angeles, CA.

6:00 PM (71) Are Donors Presenting with Cardiac Arrest but Successfully Resuscitated a Contraindication for Organ Donation in Heart Transplant?; P. Bonde, C. Bermudez, R. Kormos, J. Bhama, B. Sareyyupoglu, T. Horai, S. Tabata, N. Shigemura, D. McNamara, Y. Toyoda. University of Pittsburgh Medical Center, Pittsburgh, PA.
6:15 PM (72) Donor Cardiopulmonary Resuscitation Does Not Impact Overall Survival and Cardiac Allograft Function in Heart Transplant Recipients; M. Pollet,1 D.W. Markham,2 M.H. Drazner,3 J.M. Dimaio,1 C.R. Ayers,2 D.M. Meyer,1 W.S. Ring,1 B.T. Bethea,1 1University of Texas Southwestern, Dallas, TX; 2University of Texas Southwestern, Dallas, TX.

6:30 PM (73) Domino Heart Transplantation: Long Term Outcome of Recipients and Their Living Donors. Single Centre Experience; G.M. Raffa, C. Pellegrini, A.M. D’Armini, M. Vigano’. San Matteo Hospital IRCCS, University of Pavia, Pavia, Italy.

5:15 PM – 6:45 PM CONCURRENT SESSION 3: Observations on Candidate Selection for Lung Transplant (Boulevard Room)
Chairs: Geert M. Verleden, MD, PhD and Federica Meloni, MD


5:30 PM (75) ECMO as a Bridge to Lung Transplantation: The Cleveland Clinic Experience; J.J. Yun,1 A.A. Mangi,1 L.C. Benjamin,1 S. Murthy,1 M.M. Budev,2 D.P. Mason,1 G.B. Pettersson,1 K.R. McCurry,1 1Cleveland Clinic, Cleveland, OH; 2Cleveland Clinic, Cleveland, OH.

5:45 PM (76) Predictors of Outcome in Ventilated Lung Transplant Recipients; C. Schreiber, G. Lang, S. Taghavi, C. Aigner, G. Marta, A. Scheed, L. Hatos, P. Jaksch, W. Klepetko. Vienna Medical University, Vienna, Austria.

6:00 PM (77) The Impact of Recipient Body Mass Index on Outcomes Following Lung Transplantation; J.G. Allen,1 G.J. Arnaoutakis,1 E.S. Weiss,1 C.A. Merlo,2 J.V. Conte,1 A.S. Shah,1 1Johns Hopkins Medical Institutions, Baltimore, MD; 2Johns Hopkins Medical Institutions, Baltimore, MD.

6:15 PM (78) WITHDRAWN

6:30 PM (79) Insurance Status and Education Level Are Independent Predictors of Survival after Lung Transplantation; J.G. Allen,1 G.J. Arnaoutakis,1 J.F. McDyer,2 J.B. Orens,2 A.S. Shah,1 C.A. Merlo,2,3 1Johns Hopkins University School of Medicine, Baltimore, MD; 2Johns Hopkins University School of Medicine, Baltimore, MD; 3Johns Hopkins School of Public Health, Baltimore, MD.

5:15 PM – 6:45 PM CONCURRENT SESSION 4: Nursing Science: And Then We Were Done: Patient Experience Following Surgical Interventions for Heart and Lung Failure (Continental C)
Chairs: Sharon A. Beer, RN, MSc and Michael G. Petty, PhD, RN, CCNS, CNS

5:15 PM (80) Quality of Life and Predictors of Medication Adherence in Pediatric Heart Transplant Recipients; K. Uzark,1 M. Zamberlan,2 P. Murphy,3 C. Nasman,4 R. Rodriguez,5 J. Dupuis,6 S. Rodgers,6 Y. Wang,7 R. Ittenbach,1 Cincinnati Children’s Hospital Medical Ctr, Cincinnati, OH; 2University of Michigan Medical Ctr, Ann Arbor, MI; 3St Louis Children’s Hospital, St. Louis, MO; 4Cleveland Clinic Foundation, Cleveland, OH; 5Columbia University Medical Ctr, New York, NY; 6Children’s Hospital of Michigan, Detroit, MI; 7Children’s Memorial Hospital, Chicago, IL.

5:30 PM (81) Timing of Transplant Following Mechanical Circulatory Support in 375 Patients: Lessons from a Single Center Experience; K.J. Hoercher, N.G. Smedira, G. Gonzalez-Stawinski, D. Yoon, J. Rajeswaran, E.H. Blackstone. Cleveland Clinic, Cleveland, OH.

6:00 PM (83) Transition of Pediatric Heart Transplant Patients to the Adult Heart Transplant Program: Are They Doomed To Be Rejected?; C. Burch, A. Amegatcher, J. Patel, M. Kittleson, M. Kawano, S. Davis, Z. Goldstein, J. Moriguchi, A. Ardehali, J. Kobashigawa. David Geffen School of Medicine at UCLA, Los Angeles, CA; Cedars-Sinai Heart Institute, Los Angeles, CA.


6:30 PM (85) A High-Intensity Exercise Program Decreases Self-Reported Anxiety in Cardiac Transplant Recipients: A Randomized Study; S.B. Christensen, C.H. Dall, T. Hermann, E. Prescott, F. Gustafsson. Rigshospitalet, Copenhagen, Denmark; Bispebjerg Hospital, Copenhagen, Denmark.

5:15 PM – 6:45 PM CONCURRENT SESSION 5: Improving Donor and Recipient Selection in Pediatric Transplantation (Waldorf Room) Chairs: Lori J. West, MD, DPhil and TBD

5:15 PM (86) Outcomes of Children Implanted with Ventricular Assist Device Therapy: Analysis of the Interagency Registry for Mechanical Circulatory Support (INTERMACS); E.D. Blume, D.N. Rosenthal, J.M. Chen, C.S.D. Almond, P.D. Wearden, D.C. Naftel, J.K. Kirklin. Children’s Hospital, Boston, MA; Stanford University Medical Center, Palo Alto, CA; Morgan Stanley Children’s Hospital of New York-Presbyterian, New York, NY; Children’s Hospital of Pittsburgh, Pittsburgh, PA; University of Alabama at Birmingham, Birmingham, AL.


6:15 PM (90) Body Mass Index and Its Impact on Outcome in Children after Lung Transplantation: An Analysis of the ISHLT Pediatric Lung Transplant Registry; C. Benden, D.A. Ridout, S.C. Sweet, A. Boehler. University Hospital Zurich, Zurich, Switzerland; UCL Institute of Child Health, London, United Kingdom; Washington University School of Medicine, St. Louis, MO.

6:30 PM (91) Validation of a Risk Prediction Model for In-hospital Mortality Following Pediatric Heart Transplantation; C.S. Almond, K. Gauvreau, C. Canter, G.E. Piercey, T.P. Singh. Children’s Hospital Boston, Boston, MA; St. Louis Children’s Hospital, St. Louis, MO.

5:15 PM – 6:45 PM
5:15 PM (92) Detection of C4d Deposition in Cardiac Allografts: A Comparative Study of Immunofluorescence and Immunoperoxidase Methods; D.V. Miller, A.C. Roden, J.D. Gamez, H.D. Tazelaar. Utah Transplant Affiliated Hospitals (UTAH), Salt Lake City, UT; Mayo Clinic, Rochester, MN; Mayo Clinic, Scottsdale, AZ.

5:30 PM (93) Clinical Risk-Prediction of a Novel Thrombosis/Activation (TA) Score to Prognosticate Long-Term Cardiac Allograft Vasculopathy (CAV) in Heart Transplant Patients; C.A. Labarrere, J.R. Woods, J.W. Hardin, G.L. Campana, M.A. Ortiz, B.R. Jaeger, B. Reichart, L.A. Baldridge, J.M. Bonnin, A. Currin, S.K. Cosgrove, P.C. Kirlin, J.A. O'Donnell, D.A. Hormuth, T.C. Wozniak. Clarian Health Partners, Indianapolis, IN; University of South Carolina, Columbia, SC; Dr Stein und Kollegen, Monchengladbach, Germany; Ludwig-Maximilians-Universitat, Munchen, Germany; Indiana University School of Medicine, Indianapolis, IN; Clarian Health Partners, Indianapolis, IN; Krannert Institute of Cardiology, Indianapolis, IN.

5:45 PM (94) Phosphoproteomic Analysis of Cardiac Allograft Biopsies Reveals Novel Markers of Antibody Mediated Rejection; C. Lai, J. Wei, F. Li, Q. Zhang, D. Gjertson, J.A. Kobashigawa, M.C. Fishbein, E.F. Reed. David Geffen School of Medicine at UCLA, Los Angeles, CA; Cedars-Sinai Heart Institute, Los Angeles, CA.

6:00 PM (95) C4d Methodology and Interpretation in Biopsy Diagnosis of Cardiac Antibody-Mediated Rejection: A European Survey from the Transplant Working Group of the Association for European Cardiovascular Pathology (AECVP); M. Burke, C. Andersen, M. Ashworth, F. Black, P. Bruneval, G. De Maglio, H. Doran, M. Fedrigo, M. Goddard, M. Gonzalez-Cuesta, R. Gouveia, S. Hoyer, M. Kment, S. Lantuejoul, O. Leone, F. Lopez-Rubio, N. Monsef, D. Neil, F. Paraf, J. Pardo, A. Raisanen-Sokolowski, J. Ramirez, D. Rassl, F. Reinholdt, S. Rotman, S. Stewart, B. Weynand, F. Yilmaz, G. Thieme, A. Angelini. Harefield Hospital, London, United Kingdom; Rigshospitalet, Copenhagen, Denmark; Great Ormond Street Hospital for Children, London, United Kingdom; Freeman Hospital, Newcastle upon Tyne, United Kingdom; Hôpital Européen Georges Pompidou, Paris, France; S. M. della Misericordia, Udine, Italy; Wythenshawe Hospital, Manchester, United Kingdom; University of Padua, Padua, Italy; Papworth Hospital, Cambridge, United Kingdom; University Hospital La Coruna, Spain; Hospital de Santa Cruz, Lisbon, Portugal; University Hospital, Aarhus, Denmark; Institute for Clinical and Experimental Medicine, Prague, Czech Republic; University Hospital A Michallon, Grenoble, France; Orsola-Malpighi, Bologna, Italy; University Hospital Reine Sofia, Cordoba, Spain; Lund University Hospital, Lund, Sweden; Queen Elizabeth University Hospital, Birmingham, United Kingdom; Centre Hospitalier Universitaire Dupuytren, Limoges, France; University of Navarra, Pamplona, Spain; Helsinki University Central Hospital, Helsinki, Finland; Hospital Clinic, Barcelona, Spain; Papworth Hospital, Cambridge, United Kingdom; University Hospital, Oslo, Norway; Institut Universitaire de Pathologie, Lausanne, Switzerland; Papworth Hospital, Cambridge, United Kingdom; Cliniques Universitaires St Luc, Brussels, Belgium; University of Ege, Izmir, Turkey; University of Padua, Padua, Italy; University of Padua, Padua, Italy; University of Padua, Padua, Italy; University of Padua, Padua, Italy; University of Padua, Padua, Italy.

6:15 PM (96) C4d in Heart Transplant Biopsies Does Not Appear to Represent Poor Outcome; C. Lai, J. Patel, M. Fishbein, M. Kittleson, M. Share, S. Davis, M. Kawano, J. Moriguchi, A. Ardehali, J. Kobashigawa. David Geffen School of Medicine at UCLA, Los Angeles, CA; Cedars-Sinai Heart Institute, Los Angeles, CA.


5:30 PM – 6:30 PM Past President’s Council Meeting (Joliet)
6:45 PM – 7:45 PM
EXHIBIT HALL OPENING RECEPTION (Southeast Exhibit Hall)

THURSDAY, APRIL 22, 2010

7:00 AM – 7:00 PM
Registration Desk Open (8th Street Registration)

7:00 AM – 7:00 PM
Slide Ready Room Open (Grand Tradition)

7:00 AM – 7:00 PM
Mechanical Circulatory Support Scientific Council Meeting (Marquette Room)
Pulmonary Arterial Hypertension Scientific Council Meeting (Joliet Room)
Pathology and Basic Science Scientific Council Meeting (PDR-2)
Infectious Disease Scientific Council Meeting (PDR-4)

8:30 AM – 10:15 AM
PLENARY SESSION (International Ballroom)
Chairs: Mandeep R. Mehra, MD and John Wallwork, FRCS

8:30 AM INVITED LECTURE, The 2010 ISHLT Post Heart Transplantation Guidelines, Maria Rosa Costanzo, MD, FACC, FAHA, Midwest Heart Specialists, Naperville, IL

8:45 AM FEATURED ABSTRACT (98) Comparison of Gene Expression Profiling and Endomyocardial Biopsy for Surveillance of Acute Cardiac Cellular Rejection: Results from the IMAGE Trial; M.X. Pham,1,2 J.J. Teuteberg,4 A.G. Kfoury,5 R.C. Starling,6 M.C. Deng,3 T.P. Cappola,6 A. Kao,9 A.S. Anderson,1 W.G. Cotts,10 G.A. Ewald,13 D.A. Baran,12 R.C. Bogaev,1 H. Baron,14 J. Yee,14 H.A. Valantine,1 1Stanford University Medical Center, Stanford; 2VA Palo Alto Health Care System, Palo Alto; 3Columbia University Medical Center, New York; 4University of Pittsburgh Medical Center, Pittsburgh; 5Intermountain Medical Center and Intermountain Healthcare, Salt Lake City, UT; 6Cleveland Clinic, Cleveland, OH; 7University of Chicago Medical Center, Chicago, IL; 8Hospital of the University of Pennsylvania, Philadelphia; 9Mid America Heart Institute, Saint Luke’s Hospital, Kansas City; 10Northwestern Medical Center, Chicago; 11Texas Heart Institute, Houston; 12Newark Beth Israel Medical Center, Newark, NY; 13Washington University School of Medicine, St. Louis, MO; 14X Dx Inc., Brisbane.

8:55 AM INVITED DISCUSSANT, Jayan Parameshwar, FRCP, Papworth Hospital, Cambridge, United Kingdom

9:00 AM FEATURED ABSTRACT(99) Risk of Bronchiolitis Obliterans Syndrome Is Twice as High in Cyclosporine Treated Patients in Comparison to Tacrolimus 3 Years after Lung Transplantation: Results of a Prospective Randomized International Trial of 248 Patients; H. Treede,1 A. Glanville,2 W. Klepetko,3 R. Lama,4 C. Bravo,5 M. Estenne,6 J.-D. Aubert,7 C. Aboyoun,8 H. Reichenspurner.1 1University Heart Center Hamburg, Hamburg, Germany; 2St. Vincent’s Hospital, Sydney, NSW, Australia; 3University Hospital Vienna, Vienna, Austria; 4University Hospital Reina Sofia, Cordoba, Spain; 5Hospital Vall d’Hebron, Barcelona, Spain; 6Erasmus University Hospital, Brussels, Belgium; 7University Hospital Lausanne, Lausanne, Switzerland.

9:10 AM FEATURED DISCUSSANT, Steven A. Webber, MB, ChB, Children’s Hospital of Pittsburgh, Pittsburgh, PA

9:15 AM INVITED LECTURE, Prospect of Xenotransplantation, Bruno Reichart, MD, University of Munich/Grosshadern, MUNICH, GERMANY


9:45 AM INVITED DISCUSSANT, John C. Lockhart, MB, FRCP, Children’s Hospital of Pittsburgh, Pittsburgh, PA

9:50 AM FEATURED ABSTRACT (101) Are Recipients from Heart Donors Listed as Homeless at Increased Risk for Poor Outcome after Heart Transplantation?; D. Lockhart,2 L. Doering,1 C. Burch,1 S. Montgomery,1 A. Velleca,1 J. Patel,1 M. Kittleson,1 S. Davis,4 M. Kawano,1 Z. Goldstein,1 A. Moradzadeh,2
J. Moriguchi, A. Ardehali, J. Kobashigawa. 1David Geffen School of Medicine at UCLA, Los Angeles, CA; 2Cedars-Sinai Heart Institute, Los Angeles, CA.

10:00 AM INVITED DISCUSSANT, Duane Davis, MD, Duke University, Durham, NC

10:00 AM – 4:30 PM
Exhibit Hall Open (Southeast Exhibit Hall)
Internet Café Open (Southeast Exhibit Hall)

10:15 AM – 10:45 AM
Coffee Break (Southeast Exhibit Hall)

10:45 AM – 12:15 PM
CONCURRENT SESSION 7: Battle of the Sexes - PT Selection (International Ballroom)
Chairs: Roberta C. Bogaev, MD, FACC and Eric A. M. Verschuuren, MD, PhD


11:00 AM (103) Sex Differences in Usage of Mechanical Circulatory Support and Pre-Implant Baseline Characteristics Using the INTERMACS Database; K. O’Callaghan, M. Camacho, T. Martin, K.L. Lockard, M.A. Miller, J.B. Young. Food and Drug Administration, Silver Springs, MD; Newark Beth Israel Medical Center, Newark, NJ; University of Pittsburgh Medical Center, Pittsburgh, PA; National Heart Lung and Blood Institute, Bethesda, MD; Cleveland Clinic Foundation, Cleveland, OH.

11:15 AM (104) Survival after Implant of a Left Ventricular Assist Device: Is It the Device or Is It the Patient?: J.G. Rogers, F.D. Pagani, J.K. Kirklin, D.C. Naftel, R.J. Morris, W.P. Dembitsky, M.S. Blood, J.B. Young. Duke University Medical Center, Durham, NC; University of Michigan Medical Center, Ann Arbor, MI; University of Alabama at Birmingham, Birmingham, AL; University of Pennsylvania, Philadelphia, PA; Sharp Memorial Hospital, San Diego, CA; Cleveland Clinic Foundation, Cleveland, OH.

11:30 AM (105) Decreased Survival after Bi-VAD Implant: Is It the Bi-VAD or the Patient?: J. Cleveland, T.B. Reece, D.C. Naftel, J.F. Antaki, M.A. Murray, J.K. Kirklin, R.L. Kormos. University of Colorado at Denver, Aurora, CO; University of Alabama at Birmingham, Birmingham, AL; Carnegie Mellon University, Pittsburgh, PA; University of Wisconsin Hospital and Clinic, Madison, WI; University of Pittsburgh Medical Center, Pittsburgh, PA.

11:45 AM (106) Equivalent Outcomes of Ventricular Assist Device (VAD) Patients by Gender in the Modern Era of Mechanical Support; E.A. Genovese, M.A. Dew, J.J. Teuteberg, C.A. Bermudez, D.M. McNamara, S. Winowich, A. Weimer, R.L. Kormos. University of Pittsburgh School of Medicine, Pittsburgh, PA; University of Pittsburgh School of Medicine, Pittsburgh, PA; University of Pittsburgh Medical Center, Pittsburgh, PA; University of Pittsburgh Medical Center, Pittsburgh, PA.

12:00 PM (107) Sex-Specific Differences in Outcome and Adverse Events with Primary Left Ventricular Assist Device Support Using the INTERMACS Database; E.M. Hsich, D.C. Naftel, S.L. Myers, K.L. Grady, D. Schum, K.L. Ulisney, J.B. Young. Cleveland Clinic Foundation, Cleveland, OH; University of Alabama at Birmingham, Birmingham, AL; Bluhm Cardiovascular Institute, Chicago, IL; National Heart, Lung and Blood Institute, Bethesda, MD.

10:45 AM – 12:15 PM
CONCURRENT SESSION 8: Heart Transplantation Outcome (Continental A/B)
Chairs: Giuseppe Faggian, MD and Randall C. Starling, MD, MPH

10:45 AM (108) Usefulness of INTERMACS Profiles To Predict Postoperative Outcomes in Critically Ill Patients Undergoing Urgent Heart Transplantation; E. Barge-Caballero, M.G. Crespo-Leiro, M.J.

11:15 AM (110) Outcomes after Heart Transplantation for Chemotherapy-Induced Cardiomyopathy: Results from a Multi-Center Registry; B.W. Hardaway, A.Y. Kucheryavaya, L.B. Edwards, J. Stehlik, D.O. Taylor. Cleveland Clinic, Cleveland, OH; United Network for Organ Sharing, Richmond, VA; University of Utah, Salt Lake City, UT.


12:00 PM (113) Impact of 1 Year Creatinine on Long-Term Survival after Cardiac Transplantation; A.Z. Aliabadi, S.L. Mahr, D. Dunkler, M. Groemmer, F.A. Eskandary, D. Zimpfer, M. Grimm, G. Laufer, A.O. Zuckermann. Medical University of Vienna, Vienna, Austria.

10:45 AM – 12:15 PM CONCURRENT SESSION 9: Donor Influences on Outcomes After Lung Transplant (Boulevard Room)

10:45 AM (114) The Role of Chronic Alcohol Abuse in the Development of Primary Graft Dysfunction (PGD) in Lung Transplant (LTx) Recipients; A. Pelaez, N. Shah, S.D. Force, E.C. Lawrence, A.M. Ramirez, D.C. Neuahr, P.O. Mitchell, D.M. Guidot. Emory University School of Medicine, Atlanta, GA; Emory University School of Medicine, Atlanta, GA; Emory University School of Medicine, Atlanta, GA.

11:00 AM (115) Successful Lung Transplant Outcomes with “High Risk Donors”; S. Novosad, S.M. Palmer, R.D. Davis, S. Lin, D.W. Zaas. Duke University, Durham, NC; Duke University, Durham, NC.


11:45 AM (118) Donation after Cardiac Death (DCD) Lung Allografts Have a Low Incidence of Primary Graft Dysfunction (PGD) after Transplantation (LTx); C.H. Wigfield, J.W. Smith, C.G. Alex, A. D’Allesandro, R.B. Love. Loyola University Medical Center, Maywood, Chicago, IL; Loyola University Medical Center, Maywood, Chicago, IL; University of Wisconsin Hospitals and Clinics, Madison, WI.
**12:00 PM (119)** Long Term Pulmonary Graft Function in Pediatric Recipients after Living-Donor Lobar Lung Transplantation; M. Yamane, S. Toyooka, T. Oto, Y. Sano, S. Miyoshi. Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan.

**10:45 AM – 12:15 PM**
**CONCURRENT SESSION 10: Novel Genomic, Proteomic & Clinical Risk Markers in PAH (Continental C)**
**Chairs:** Juergen Behr, MD and Keith McNeil, FRACP

**10:45 AM (120)** Gene Expression Signature in the Explanted Lung Is a Better Predictor of Primary Graft Dysfunction after Lung Transplantation than Pulmonary Artery Pressures in Patients with Pulmonary Fibrosis; M. Mura,1,2 M. Anraku,1,2 Z. Yun,1 C. Chaparro,2 K. McRae,2 M. Liu,1 M. Hutcheon,2 T.K. Waddell,1,2 L.G. Singer,2 J.T. Granton,2,3 S. Keshavjee,1,2 M. de Perrot.1,2,3 Latner Thoracic Surgery Research Laboratories, Toronto, ON, Canada; "Toronto Lung Transplant Program, Toronto, ON, Canada; 3Pulmonary Hypertension Program, Toronto, ON, Canada.

**11:00 AM (121)** Soluble ST2 Is Associated with Right Heart Failure and Is Independently Predictive of Event Free Survival in Pulmonary Arterial Hypertension; J.E. Rame,1 D. McGlothlin,2 A.H.B. Wu,3 J.O. Hernandez,2 E. Kobashigawa,2 T. De Marco.2 1University of Pennsylvania, Philadelphia, PA; 2University of California San Francisco, San Francisco, CA; 3University of California San Francisco, San Francisco, CA.

**11:15 AM (122)** Therapy-Related Shifts in NT-proBNP Correlate with Changes in 6MWD and cMRI Parameters in Bosentan-Treated Patients with PAH: The COMPASS-3 Study; M.H. Park,1 S. Murali,2 F.J. Soto,3 F. Torres,4 H. Gupta,3 N. Frey,3 R.L. Benza.2 1University of Maryland School of Medicine, Baltimore, MD; 2Allegheny General Hospital, Pittsburgh, PA; 3Prevea Health, Sheboygan, WI; 4University of Texas Southwestern Medical Center, Dallas, TX; 5University of Alabama at Birmingham, Birmingham, AL; 6Actelion Pharmaceuticals US, Inc., South San Francisco, CA.

**11:30 AM (123)** Association between Serial 6-Minute Walk Distance (6MWD) Assessments and the REVEAL Pulmonary Arterial Hypertension (PAH) Risk Score Calculator; R.L. Benza,1 D.P. Miller,2 R.P. Frantz,3 A.J. Foreman,2 H.W. Farber,4 A.E. Frost,5 R.J. Barst,6 C.G. Elliott,6 M.D. McGoon,3 Al Shengy General Hospital, Pittsburgh, PA; 2Iconis Research, San Francisco, CA; 3Mayo Clinic, Rochester, MN; 4Boston University Medical Center, Boston, MA; 5Baylor College of Medicine, Houston, TX; 6Columbia University College of Physicians and Surgeons, New York, NY; 7Intermountain Medical Center, Murray, UT; 8University of Utah, Salt Lake City, UT.

**11:45 AM (124)** Clinical, Echocardiographic, and Prognostic Significance of Pericardial Effusions in Patients with Pulmonary Arterial Hypertension: Outcomes with Pericardiocentesis; E.R. Fenstad,1 R.J. Le,1 L.J. Sinak,2 H. Maradit-Kremers,3 N.M. Ammass,2 H.R. Villanueva,2 J.K. Oh,4 R.P. Frantz,2 R.B. McCully,2 M.D. McGoon,2 G.C. Kane.2 1Mayo Clinic, Rochester, MN; 2Mayo Clinic, Rochester, MN.

**12:00 PM (125)** RV Function Is Essential for Accurate Estimation of Right Ventricular Systolic Pressure by Transthoracic Doppler Echocardiography; A.J. Rieth, V. Mitrovic. Kerckhoff Heart and Thorax Center, Bad Nauheim, Germany.

**10:45 AM – 12:15 PM**
**CONCURRENT SESSION 11: Stem Cells: Basic and Translational Approaches (Waldorf Room)**
**Chairs:** Joseph Woo, MD and Terrence M. Yau, MD, MSC

**10:45 AM (126)** Adipocyte Sheets Derived from Stromal Vascular Cells Ameliorate Left Ventricular Dysfunction through Suppression of Inflammatory Response in Autoimmune Myocarditis Rats; S. Kamata,1 T. Sakaguchi,1 S. Miyagawa,1 Y. Yoshikawa,1 T. Yamauchi,2 S. Saito,1 Y. Shudo,1 Y. Imanishi,1 A. Saito,1 N. Maeda,1 T. Ueno,1 T. Kuratani,1 Y. Sawa.1 Osaka University Graduate School of Medicine, Osaka, Japan; 2Osaka University Graduate School of Medicine, Osaka, Japan.
11:00 AM (127) Tolerance Induction with Stem and Progenitor Cells: Potential Role for Regulatory T Cells; L. Sun,¹ K. Trapp,¹ E. Inagaki,¹ J. Domen,¹ K. Gandy.¹ ¹Children’s Research Institute, Milwaukee, WI; ²Children’s Hospital of Wisconsin (Herma Heart Center), Milwaukee, WI; ³Medical College of Wisconsin, Milwaukee, WI.

11:15 AM (128) Immunogenicity of Fetal Mesenchymal Stem Cells from the Umbilical Cord Line for Regenerative Therapies; K.R. Tang-Quan,¹ M.V.V. Kolk,¹ T. Deuse,¹ N. Philipp,³ M. Kay,³ R.C. Robbins,² H. Reichenspurner,¹ S. Schrepfer.¹ ¹University Heart Center Hamburg, Hamburg, Germany; ²Stanford University School of Medicine, Stanford, CA; ³Stanford University, Stanford, CA.

11:30 AM (129) Autologous Bone Marrow Cell Implantation Attenuates Left Ventricular Remodeling and Improves Heart Function in Porcine Myocardial Infarction: An Echocardiographic, Six-Month Angiographic, and Molecular-Cellular Study; F.-Y. Lee,¹ H.-K. Yip,² C.-K. Sun,³ J.-J. Sheu,¹ L.-T. Chang,⁴ C.-M. Yuen,⁵ C.-H. Yiang,⁶ S.-F. Ko,⁶ S.-N. Pei,⁹ S. Chua,² A.A. Youssef,¹⁰ C.-J. Wu.¹ ¹Chang Gung Memorial Hospital-Kaohsiung Medical Center; Chang Gung University College of Medicine, Kaohsiung, Taiwan; ²Chang Gung Memorial Hospital-Kaohsiung Medical Center; Chang Gung University College of Medicine, Kaohsiung, Taiwan; ³Chang Gung Memorial Hospital-Kaohsiung Medical Center; Chang Gung University College of Medicine, Kaohsiung, Taiwan; ⁴Chang Gung Memorial Hospital-Kaohsiung Medical Center; Chang Gung University College of Medicine, Kaohsiung, Taiwan; ⁵Meiho Institute of Technology, Pingtung, Taiwan; ⁶Chang Gung Memorial Hospital-Kaohsiung Medical Center; Chang Gung University College of Medicine, Kaohsiung, Taiwan; ⁷National Pingtung University of Science and Technology, Pingtung, Taiwan; ⁸Chang Gung Memorial Hospital-Kaohsiung Medical, Kaohsiung, Taiwan; ⁹Chang Gung Memorial Hospital-Kaohsiung Medical, Kaohsiung, Taiwan; ¹⁰Suez Canal University Hospital, Ismailia, Egypt.

11:45 AM (130) Circulating Mesenchymal Stem Cells Are Associated with Cardiac Allograft Vasculopathy; S. Aharinejad,¹ M. Salama,¹ O. Andrukhova,² A. Thomas,² S. Rodler,² A. Zuckermann,¹ G. Laufer,¹ M. Grimm.¹ ¹Medical University of Vienna, Vienna, Austria; ²Medical University of Vienna, Vienna, Austria.

12:00 PM (131) Changes in Gene Expression and Improvement in Perioperative Outcomes after Orthotopic Cardiac Xenotransplantation; C.G.A. McGregor,¹ M. Vlasin,¹ R.C. Walker,¹ H.D. Tazelaar,¹ K. Chandrasekaran,¹ B.A. Boilson,¹ G.W. Byrne.¹ ¹Mayo Clinic, Rochester, MN; ²University College London, London, United Kingdom.


Chairs: Bruno M. Meiser, MD and Allen S. Anderson, MD, FACC

10:45 AM (132) Everolimus Introduction with CNI Minimization Significantly Improves Renal Function in Thoracic Transplant Recipients: A Scandinavian Multicenter, Randomized Study; L. Gullestad,¹ B. Rundqvist,² S.A. Mortensen,² H. Eiskjaer,⁴ G.C. Riise,¹ L. Mared,⁶ O. Bjortuft,² B. Ekmeahag,² K. Jansson,⁷ S. Simonsen,¹ E. Gude,¹ H. Fagertun,² D. Solbu,⁶ M. Iversen,³ Oslo University Hospital, Rikshospitalet, Oslo, Norway; ²Sahlgrenska University Hospital, Göteborg, Sweden; ³Rigshospitalet, Copenhagen, Denmark; ⁴Aarhus University Hospital, Aarhus, Denmark; ⁵University of Lund, Lund, Sweden; ⁶Oslo University Hospital, Rikshospitalet, Oslo, Norway; ⁷University Hospital Linköping, Linköping, Sweden.

11:00 AM (133) Tacrolimus in Combination, Tacrolimus Alone Compared: 5 Year Results of the TICTAC Trial; D.A. Baran,¹ M.J. Zucker,¹ M.E. Goldschmidt,¹ J. Prevost-Fernandez,¹ C. Carr,¹ S. Pardi,¹ V. Hou,¹ M. Binetti,¹ M.G. San Agustin,¹ J. Ebuenga,¹ A. Gass,² M. Camacho.¹ ¹Newark Beth Israel Medical Center, Newark, NJ; ²Westchester Medical Center, Westchester, NY.

11:15 AM (134) A Randomized Study Using Humanized Monoclonal Antibody Against Cd52 (Campath-1h) and Tacrolimus in Heart Transplant Recipients; S.M. Pham,¹ B.M. Bednar,¹ A. Panos,¹ E.J. Bauerlein,¹ F. Jimenez,² E. Rosenkrantz,¹ M. Ricci,¹ P. Rusconi,³ S. Chaparro,² M.A. Ayac,² R.
11:30 AM (135) Experimental Transplantation: Novel Immunosuppression Using the JAK3-Inhibitor R348; T. Deuse,1,2 E. Masuda,3 V. Taylor,1 G. Park,2 D. Carroll,3 H. Reichenspurner,1 J. Velotta,2 R. Robbins,2 S. Schrepefer,1,2 1University Heart Center Hamburg, Hamburg, Germany; 2Stanford University School of Medicine, Stanford, CA; 3Rigel, San Francisco, CA.

11:45 AM (136) Effect of Everolimus Introduction and Calcineurin Inhibitor Reduction on Graft Vasculopathy in Heart Transplant Recipients; S. Arora,1 B. Wennerblom,2 B. Rundqvist,2 H. Eiskjaer,3 H.E. Botker,3 S.-A. Mortensen,4 K. Saunamki,4 B. Ekmechag,5 K. Jansson,4 S. Simonsen,1 E. Gude,1 K. Endresen,6 D. Solbu,7 L. Gulstad,7 1Oslo University Hospital, Oslo, Norway; 2Sahlgrenska University Hospital, Gothenburg, Sweden; 3Skeby University Hospital, Aarhus, Denmark; 4Rigshospitalet, Copenhagen, Denmark; 5Lund Hospital, Lund, Sweden; 6Heart Center University Hospital, Linkoping, Sweden; 7Novartis Norge AS, Oslo, Norway.

12:00 PM (137) Proteinuria after Conversion to Sirolimus-Based Immunosuppresssion in Cardiac Transplant Recipients: A Five Year Analysis; E. Raichlin,2 M.A. Al-Omari,1 B.S. Edwards,1 R.F.P. Frntz,1 A.C.L. Clavell,1 N.L. Pereira,1 J.A. Schirger,1 S.S. Kushwaha.1 1Mayo Clinic, Rochester, MN; 2University of Nebraska Medical Center, Omaha, NE.

12:15 PM – 2:15 PM Lunch Break

12:15 PM – 2:15 PM Junior Faculty and Trainee Council Mentor Lunch (advance ticket purchase required)

2:30 PM – 4:00 PM CONCURRENT SESSION 13: Device Disasters: Can We Avoid Them? (International Ballroom)
Chairs: Jan F. Gummert, MD, PhD and Finn Gustafsson, MD, PhD

2:30 PM (138) Neurocognitive Evaluation of Destination Therapy Pateints Receiving Continuous Flow Left Ventricular Assist Devices; R.J. Petrucci,1 J.G. Rogers,2 L. Blue,2 C.T. Gallagher,3 S.D. Russell,4 D. Dordunoo,5 B.E. Jaski,3 S. Chillcott,3 B.C. Sun,6 T.L. Yannsen,6 A.J. Tatoole,3 L. Koundakjian,7 D.J. Farrar,7 M.S. Slaughter,8 1Drexel University College of Medicine, Philadelphia, PA; 2Duke University, Durham, NC; 3Advocate Christ Medical Center, Oak Lawn, IL; 4Johns Hopkins University Medical Center, Baltimore, MD; 5Sharp Memorial Hospital, San Diego, CA; 6Ohio State University, Columbus, OH; 7Thoratec Corporation, Inc., Pleasanton, CA; 8University of Louisville, Louisville, KY.

2:45 PM (139) Reducing Adverse Neurological Events in LVAD Patients: Pulsatile vs. Continuous Flow?; S.J. Park,1 D.C. Naftel,2 M.S. Slaughter,3 M.A. Sobiesk,3 L.L. Staley,4 J.A. Tallaj,4 J.T. Baldwin,5 J.K. Kirklin,5 1Mayo Clinic, Rochester, MN; 2University of Alabama at Birmingham, Birmingham, AL; 3University of Louisville, Louisville, KY; 4Mayo Clinic, Phoenix, AZ; 5National Heart, Lung and Blood Institute, Bethesda, MD.

3:00 PM (140) Standardized Psychosocial Evaluation Prior to LVAD May Predict Mortality and Length of Stay; P.M. Eckman,1,2 G.V. Gonzalez-Stawinski,1 K. Kendall,1 D. Racicki,1 W. Tang,1 R.C. Starling,1 M.M. Mountis.1 1Cleveland Clinic Foundation, Cleveland, OH; 2University of Minnesota, Minneapolis, MN.

3:15 PM (141) Infection during Mechanical Circulatory Support: Can We Really Expect a Better Outlook with Continuous Flow Technology; C.A. Milano,1 D.C. Naftel,2 R.F. Padera,3 R.C. Starling,4 D.M. McNamara,5 S.V. Pamboukian,6 S.L. Myers,6 R.L. Kornos,5 1Duke University Medical Center, Durham, NC; 2University of Alabama at Birmingham, Birmingham, AL; 3Brigham and Women’s Hospital, Boston, MA; 4Cleveland Clinic, Cleveland, OH; 5University of Pittsburgh Medical, Pittsburgh, PA.
3:30 PM (142) Lead Fractures in Left Ventricular Assist Devices – A Multi-Institutional Experience; Y. Ravi,† R. John,*, C. Salerno,† Y. Tamara,‡ S. Wissman,† M. Firstenberg,† B. Sun,† L. Louis,† C.B. Sai Sudhakar. † The Ohio State University Medical Center, Columbus, OH; ‡University of Minnesota, Minneapolis, MN; *St. Vincent’s Hospital, Indianapolis, OH.

3:45 PM (143) Pump Replacement for LVAD Failure Can Be Done Safely and Is Associated with Low Mortality; N. Moazami,† B. Sun,‡ C. Milano,† R. John,*, J. Conte,§ R. Adamson,§ F. Pagani,§ O.H. Frazier,§ D. Farrar,§ M. Slaughter. †Washington University School of Medicine, St. Louis, MO; §Ohio State University, Columbus, OH; ¶Duke University Medical Center, Durham, NC; ‡University of Minnesota, Minneapolis, MN; ¶Johns Hopkins University, Baltimore, MD; §Sharp Memorial Hospital, San Diego, CA; †University of Michigan, Ann Arbor, MI; §Texas Heart Institute, Houston, TX; ‡Thoratec Corporation, Pleasanton, CA; ¶University of Louisville, Louisville, KY.

2:30 PM – 4:00 PM
CONCURRENT SESSION 14: Heart Transplantation Post Op Dilemma (Continental A/B)
Chairs: Brooks S. Edwards, MD and Donald S. Esmore, MBBS, FRACS

2:30 PM (144) The Association between Cytomegalovirus Immune Globulin (CMVIG) Use and Long-Term Recipient and Graft Survival in Pediatric and Adult Heart Transplantation Recipients; D.R. Snydman,† G.E. Bergman,‡ J. Vensak.† Tufts Medical Center, Tufts University School of Medicine, Boston, MA; ‡CSL Behring, King of Prussia, PA.

2:45 PM (145) Does a Normal Angiogram Further from Heart Transplantation Confer Less Chance To Develop CAV? Should We Still Do Annual Angiograms Late after Transplantation?: J. Patel,‡ M. Kittleson,‡ B. Azarbal,‡ A. Hage,‡ M. Kawano,§ S. Davis,‡ J. Moriguchi,‡ A. Ardehali,† J. Kobashigawa.‡ †David Geffen School of Medicine at UCLA, Los Angeles, CA; ‡Cedars-Sinai Heart Institute, Los Angeles, CA.

3:00 PM (146) High-Intensity Aerobic Exercise Improves Forearm Flow Mediated Dilatation and Blood Pressure Control Late after Cardiac Transplantation; T. Hermann,† C.H. Dall,‡ S. Christensen,† S. Boesgaard,† F. Gustafsson.† Rigshospitalet, Copenhagen, Denmark; ‡Bispebjerg Hospital, Copenhagen, Denmark.

3:15 PM (147) Safety and Efficacy of High Dose vs. LDL-Driven Adjustments of Fluvastatin in Heart Transplant Recipients: A Randomized, IVUS-Based Study; L. Potena, F. Grigioni, F. Fabbrì, G. Magnani, P. Ortolani, M. Masetti, F. Fallani, F. Coccolo, A. Russo, A. Branzi. University of Bologna, Bologna, Italy.

3:30 PM (148) Are Circulating Antibodies Necessary To Make a Diagnosis of Antibody-Mediated Rejection?: J. Patel,‡ M. Kittleson,‡ Q. Zhang,† E. Reed,† M. Kawano,§ S. Davis,‡ M. Cecka,† C. Burch,† A. Velleca,† E. Stimpson,‡ J. Moriguchi,‡ A. Ardehali,† J. Kobashigawa,‡ †David Geffen School of Medicine at UCLA, Los Angeles, CA; ‡Cedars-Sinai Heart Institute, Los Angeles, CA.

3:45 PM (149) Combinatorial Biomarkers of Cardiac Allograft Vasculopathy; D. Lin,† G. Cohen Freue,‡ Z. Hollander,† M. Sasaki,§ N. Opushneva,§ C. Imai,§ A. Ignaszewski,§ A. Mui,§ J. Wilson-McManus,§ R. Balshaw,‡ R.T. Ng,§ P.A. Keown,‡ R. McMaster,‡ B.M. McManus.† †The University of British Columbia, Vancouver, BC, Canada; ‡The University of British Columbia, Vancouver, BC, Canada; §PROOF Centre of Excellence, Vancouver, BC, Canada; ¶St. Paul’s Hospital/The University of British Columbia, Vancouver, BC, Canada; ¶The University of British Columbia, Vancouver, BC, Canada; ¶The University of British Columbia, Vancouver, BC, Canada; ¶The University of British Columbia, Vancouver, BC, Canada.

2:30 PM – 4:00 PM
CONCURRENT SESSION 15: Clinical Investigation in Acute and Chronic Rejection After Lung Transplantation (Boulevard Room)
Chairs: Scott M. Palmer, MD and Jonathan B. Orens, MD
2:30 PM (150) Flow Cytometric Parameters of CD8 Lavage Cells in Detection of Acute Cellular Rejection in Lung Transplant; D.C. Neujahr, A. Mohammed, O. Ulukpo, A. Pelaez, A. Ramirez, E.C. Lawrence, S.D. Force, A.A. Gal, C.P. Larsen, A.D. Kirk. Emory University School of Medicine, Atlanta, GA; Emory University School of Medicine, Atlanta, GA; Emory University School of Medicine, Atlanta, GA; Emory University School of Medicine, Atlanta, GA.

2:45 PM (151) SaLUTaRy: Survey of Lung Transplant Rejection; I.O. Gordon, S. Bhorade, W.T. Vigneswaran, P.J. McShane, E.R. Garrity, A.N. Husain. The University of Chicago, Chicago, IL; The University of Chicago, Chicago, IL; The University of Chicago, Chicago, IL.

3:00 PM (152) Humoral Immune Responses in Acute Phase of Living Double Lobar Lung Transplantation: Donor-Specific IgM Can Predict Onset of Acute Rejection; K. Miyoshi, Y. Sano, M. Yamane, T. Oto, S. Miyoshi. Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan.


3:45 PM (155) Immunological Correlates of Clinical Efficacy in BOS Patients Treated with Extracorporeal Photopheresis; F. Meloni, C. Perotti, T. Oggioni, M. Morosini, N. Solari, F. Bini, A. De Silvestri, C. Tinelli, A.M. Fietta. University of Pavia, Foundation IRCCS San Matteo, Pavia, Italy; Foundation IRCCS San Matteo, Pavia, Italy.

2:30 PM – 4:00 PM CONCURRENT SESSION 16: Every Breath I Take is Now Better (Continental C)


2:45 PM (157) Low Potassium Dextran Is Superior to University of Wisconsin Solution in High Risk Lung Transplant Recipients; G.J. Arnaoutakis, J.G. Allen, C.A. Merlo, J.V. Conte, A.A. Shah. The Johns Hopkins Hospital, Baltimore, MD; The Johns Hopkins Hospital, Baltimore, MD.

3:00 PM (158) Prevention of Primary Graft Dysfunction in Lung Transplantation by N-Acetylcysteine after Prolonged Cold Ischemia; I. Inci, B. Erne, S. Arni, J. Wolfgang, S. Hillinger, B. Leskosek, W. Weder. University Hospital, Zurich, Switzerland.

3:15 PM (159) Transcriptional Signatures in Donor Lungs before and after Transplantation: A Functional Pathway Analysis of Donation after Cardiac Death (DCD) vs. Donation after Brain Death (DBD); C.H. Kang, M. Anraku, M. Cypei, J. Yeung, S. Gharib, A. Pierre, M. de Perrot, T. Waddell, M. Liu, S. Keshavjee. 1 Seoul National University Hospital / University Health Network, Seoul, Republic of Korea; Toronto General Hospital, Toronto, ON, Canada; University of Washington, Seattle, WA.

3:30 PM (160) Evaluation of the Lung Allocation Score in High Urgent and Urgent Lung Transplant Candidates in Eurotransplant; J.M. Smits, G.D. Nossent, A.O. Rahmel, G. Lauffer, J. Gottlieb. Eurotransplant, Leiden, Netherlands; UMCG, Groningen, Netherlands; University Hospital, Vienna, Austria; Hannover Medical School, Hannover, Germany.
3:45 PM (161) Initial Topical Cooling Followed by Backtable Celsior Flush Perfusion Provides Excellent Early Graft Function in Porcine Single Lung Transplantation after 24 Hours of Cold Ischemia; B. Gohrbandt,1 M. Avsar,1 G. Wannecke,1 S.P. Sommer,2 A. Haverich,1 M. Streeber.1 1Hannover Medical School, Hannover, Germany; 2University Hospital of Wuerzburg, Wuerzburg, Germany.

2:30 PM – 4:00 PM
CONCURRENT SESSION 17: Quality of Life and Social Sciences: Have We Done the Right Thing?: Assessing Quality of Life Following Cardiothoracic Transplantation (Waldorf Room)
 Chairs: Bronwyn J. Levey, RN and Corby L. D’Amico, RN, MN

2:30 PM (162) The Obligation To Say Thank-You; J. Poole,1 M. Shildrick,2 P. McKeever,3 H. Ross,4 O. Mauthner,4 E. De Luca,4 S. Abbey,5 1Ryerson University, Toronto, ON, Canada; 2Queen’s University Belfast, Belfast, Ireland; 3Bloorview Kids Rehab, Toronto, ON, Canada; 4University Health Network–Toronto General Hospital, Toronto, ON, Canada; 5University Health Network–Toronto General Hospital, Toronto, ON, Canada.

2:45 PM (163) Predictors and Outcomes Associated with Quality of Life (QOL) in Family Caregivers to Cardiothoracic Transplant Recipients; M.A. Dew,1 L. Myaskovsky,2 A.J. DeVito Dabbs,3 A.F. DiMartini,4 Y. Toyoda,5 R. Zomak,6 R.L. Kormos.5 1University of Pittsburgh School of Medicine, Pittsburgh, PA; 2University of Pittsburgh School of Medicine, Pittsburgh, PA; 3University of Pittsburgh School of Nursing, Pittsburgh, PA; 4University of Pittsburgh School of Medicine, Pittsburgh, PA; 5University of Pittsburgh Medical Center, Pittsburgh, PA; 6University of Pittsburgh Medical Center, Pittsburgh, PA.

3:00 PM (164) The Relationships among Satisfaction with Heart Transplant on Quality of Life (QOL) Outcomes 5 to 10 Years after Heart Transplantation(HT); C. White-Williams,1 K.L. Grady,2 E. Wang,3 D.C. Naftel,4 J.K. Kirklin,5 S. Myers,6 B. Rybarczyk,7 J.B. Young,8 J. Czerr,9 D. Peleglin,10 J. Kobashigawa,11 J. Chait,12 A. Heroux,13 R. Higgins.14 1University of Alabama at Birmingham, Birmingham, AL; 2Northwestern Memorial Hospital, Chicago, IL; 3Northwestern Memorial Hospital, Chicago, IL; 4University of Alabama at Birmingham, Birmingham, AL; 5University of Alabama at Birmingham, Birmingham, AL; 6University of Alabama at Birmingham, Birmingham, AL; 7Virginia Commonwealth University, Richmond, VA; 8The Cleveland Clinic, Cleveland, OH; 9The Cleveland Clinic, Cleveland, OH; 10The Cleveland Clinic, Cleveland, OH; 11Cedars-Sinai Heart Institute, Los Angeles, CA; 12UCLA Medical Center, Los Angeles, CA; 13Loyola University Medical Center, Maywood, IL; 14Rush University Medical Center, Chicago, IL.

3:15 PM (165) Pre-Transplant Smoking in Heart Transplant Patients: A Marker for Long Term Outcome?; E. Moreno,7 A. Velleca,2 C. Burch,1 J. Patel,2 M. Kittleson,2 M. Kawano,2 S. Davis,2 J. Moriguchi,2 A. Ardehali,2 J. Kobashigawa.2 1David Geffen School of Medicine at UCLA, Los Angeles, CA; 2Cedars-Sinai Heart Institute, Los Angeles, CA.


2:30 PM – 4:00 PM
CONCURRENT SESSION 18: Tissue Gene Regulation and Protection From Injury (Marquette Room)
 Chairs: Stephan M. Ensminger, MD, PhD and Michael P. Fischbein, MD

2:30 PM (168) A Novel Model for the Focused Study of Functional and Genomic Recovery from Decompensated Heart Failure; N.M. Andersen,1 R. Tang,1 W.E. Stansfield,1 M. Rojas,1 C.H. Seizman.2 1University of North Carolina, Chapel Hill, NC; 2University of Utah, Salt Lake City, UT.
Connective Tissue Growth Factor Gene Expression in the Failing Human Heart; N. Patel, T. Kim, A. McElligott, K.K. Henderson, B. Pavlovic-Surjancev, A.L. Heroux, A.M. Samarel. Loyola University Medical Center, Maywood, IL; Loyola University Medical Center, Maywood, IL; Loyola University Chicago, Maywood, IL.

Hypoxia Inducible Factor-1 Preconditioning Protects Transplanted Hearts Against Ischemia-Reperfusion Injury through Effects on Remote Tissues; M.A.I. Keranen, R. Tuuminen, R. Krebs, L.A. Flippin, M. Arend, A.I. Nykanen, K.B. Lemstrom, University of Helsinki, Helsinki, Finland; FibroGen Inc., San Francisco, CA; Helsinki University Central Hospital, Helsinki, Finland.

Nebulized Nitrite Protects Rat Lung Grafts from Ischemia/Reperfusion Injury; T. Okamoto, X. Tang, S.C. Erzurum, C. Farver, M.T. Gladwin, K.R. McCurry, Lerner Research Institute Cleveland Clinic, Cleveland, OH; Cleveland Clinic, Cleveland, OH; Cleveland Clinic, Cleveland, OH; University of Pittsburgh, Pittsburgh, PA.


The Use of Gene Expression Profiling Post Heart Transplant in the Real World: The Mid America Experience; A. Kao, K. St Clair, S.L. Lawhorn, A. Magalski, T.L. Stevens, A.M. Borkon. Mid America Heart Institute, Kansas City, MO; Mid America Heart Institute, Kansas City, MO.

Highly Sensitized LVAD Patients Can Be Safely Transplanted with Non-Crossmatched Hearts Using Plasmapheresis and Alemtuzumab: A Contemporaneous Case-Control Series; S.D. Lick, K.K. Kislingbury, A.C. Kollar, N.A. Barbagelata, M.M. Koerner, V.G. Valentine. University of Texas, Medical Branch, Galveston, TX.

Accommodation after Heart Transplantation: Does It Exist?; M. Kittleson, J. Patel, E. Reed, D. Gjertson, M. Kawano, S. Davis, C. Burch, A. Velleca, E. Stimpson, J. Moriguchi, A. Ardehali, J. Kobashigawa, David Geffen School of Medicine at UCLA, Los Angeles, CA; Cedars-Sinai Heart Institute, Los Angeles, CA.

Normalization of Heart Failure Genomic Markers after Transplantation; Z. Hollander, D. Lin, R. Ng, J. Wilson-McManus, A. Ignaszewski, R. Balshaw, R. McMaster, P. Keown, B. McManus. The University of British Columbia, Vancouver, BC, Canada; PROOF Centre of Excellence, Vancouver, BC, Canada; The University of British Columbia, Vancouver, BC, Canada; The University of British Columbia, Vancouver, BC, Canada; The University of British Columbia, Vancouver, BC, Canada.

Frequency of Gene Expression Profiling Use in Lieu of Endomyocardial Biopsy Post Heart Transplant Increases with Familiarity: The Mid America Experience; A. Kao, K. St Clair, S.L. Lawhorn, A. Magalski, T.L. Stevens, A.M. Borkon. Mid America Heart Institute, Kansas City, MO; Mid America Heart Institute, Kansas City, MO.
5:45 PM (179) Interplay between Graft-Function and Intravascular Deposition of C4d in Heart Transplant Recipients; F. Fabbri, T. Ionico, L. Potena, P. Prestinenzi, G. Magnani, M. Masetti, O. Leone, F. Fallani, F. Coccolo, F. Grigioni, A. Branzi, Cardiovascular Department, University of Bologna, Bologna, Italy; Pathology Department, University of Bologna, Bologna, Italy.

4:30 PM – 6:00 PM
CONCURRENT SESSION 20: Getting Back to the Basics: MCSD and the Myocyte (Continental A/B)
Chairs: Paul W. M. Fedak, MD, PhD, FRCSC and Pascal Leprince, MD, PhD

4:30 PM (180) The Time-Course of Unloading-Induced Cardiac Improvement in Patients with Chronic Non-Ischemic Cardiomyopathy Predicts the Outcome after Weaning from Ventricular Assist Devices; M. Dandel, Y. Weng, H. Siniawski, T. Krabatsch, H.B. Lehmkuhl, E. Potapov, C. Knosalla, R. Hetzer, Deutsches Herzcentrum Berlin, Berlin, Germany.

4:45 PM (181) Plasma Galectin 3 Is Increased in Terminal Heart Failure Patients and Is Elevated in Patients Not Surviving Mechanical Circulatory Support; G. Erkilet, S. Schulte-Eistrup, M. Morshuis, B. Bohms, D. Roefe, J. Gummert, H. Milting, Herz- und Diabeteszentrum NRW, Bad Oeynhausen, NRW, Germany; Herz- und Diabeteszentrum NRW, Bad Oeynhausen, NRW, Germany.

5:00 PM (182) Regulation of Collagen and Prolyl-4-Hydroxylase during Ventricular Assist Device (VAD) Support: Collagen Regulation during VAD-Support Depends on the Degree of Remodelling at the Time of VAD-Implantation; A. Gaertner, A. Kassner, S. Schulte-Eistrup, M. Morshuis, A. El-Banayosy, J. Gummert, Herz- und Diabeteszentrum NRW, Bad Oeynhausen, NRW, Germany; Herz- und Diabeteszentrum NRW, Bad Oeynhausen, NRW, Germany; Penn State Milton S. Hershey Medical Center, Hershey, PA.

5:15 PM (183) The Role of Cathepsin K in Extra Cellular Matrix Remodeling in Patients with End Stage Heart Failure; P. van der Weide, A.H. Bruggink, D.F. van Wichen, J. van Kuik, N. de Jonge, J.R. Lahpor, M.E.I. Schipper, University Medical Center, Utrecht, Netherlands; University Medical Center, Utrecht, Netherlands.

5:30 PM (184) Myocardial Recovery Is Associated with Low Levels of Circulating MMP8 at LVAD Implantation; J. Beale, R.S. George, J. Smith, A. Khaghani, M.H. Yacoub, E.J. Birks, P. Barton, Imperial College, Harefield, Middlesex, United Kingdom; Royal Brompton and Harefield NHS Foundation Trust, Harefield, Middlesex, United Kingdom.

5:45 PM (185) Myocardial Recovery from Advanced Heart Failure Using the Heartmate II LVAD Combined with Drug Therapy: Results from a Prospective Study; E.J. Birks, R.S. George, M. Hedger, A. Firouzi, T. Bahrami, M. Amrani, M.H. Yacoub, G. Dreyfus, A. Khaghani, Royal Brompton and Harefield NHS Foundation Trust, Harefield, Middlesex, United Kingdom; Imperial College, Harefield, Middlesex, United Kingdom.

4:30 PM – 6:00 PM
CONCURRENT SESSION 21: From Bench to Bedside Update in Transplant Infections (Boulevard Room)
Chairs: Margaret M. Hannan, MD and Martha L. Mooney, MD

4:30 PM (186) CD8+ pp65-Specific T Cell Responses and T-Bet Levels Predict Relapsing Viremia Following Primary CMV Infection in Lung Transplant Recipients; M.R. Pipeling, E.R. John, N. Lechtzin, J.F. McDyer, Johns Hopkins University School of Medicine, Baltimore, MD.

4:45 PM (187) CMV Reactivation within the Lung Allograft Is Associated with Bronchiolitis Obliterans Syndrome Following Lung Transplantation; M.A. Paraskeva, B. Levvey, A. Griffiths, M. Bailey, T.C. Kotsimbos, G.I. Snell, G.P. Westall, Alfred Hospital, Melbourne, Vic, Australia; School Public Health Preventive Medicine, Monash University Alfred, Melbourne, Vic, Australia.
5:00 PM (188) Development of Cytomegalovirus (CMV) Infection during Ongoing Valganciclovir Therapy; J. Patel,1 M. Kittleson,1 B. Kubak,1 M. Kawano,2 S. Davis,2 J. Moriguchi,2 A. Ardehali,1 J. Kobashigawa.2 1David Geffen School of Medicine at UCLA, Los Angeles, CA; 2Cedars-Sinai Heart Institute, Los Angeles, CA.

5:15 PM (189) Subtherapeutic Ganciclovir Levels Result in Resistant CMV in Lung Transplantation Patients; J.P. Gagermeier,1 C.G. Alex,1 D.F. Dilling,1 J. Rusinak,1 P. O’Keefe,1 N.S. Lurain,2 C.H. Wigfield,2 R.B. Love.2 1Loyola University Medical Center, Maywood, IL; 2Loyola University Medical Center, Maywood, IL; 3Rush University, Chicago, IL.

5:30 PM (190) RSV and Human Metapneumovirus Are Not Associated with Obliterative Bronchiolitis or Inferior Survival Post Lung Transplantation; P.M.A. Hopkins, F.D. Kermeen, H. Seale, T.M. Leisfield, S.T. Yerkovich, D.C. Chambers. The Prince Charles Hospital, Brisbane, QLD, Australia.

5:45 PM (191) Importance of VAD Insertion Site Colonisation; D. Wearmouth,1 L. Reed,1 G. MacGowan,2 T. Pillay,2 S. Schueller,2 N. Wrightson,2 K. Gould.1 1Freeman Hospital, Newcastle upon Tyne, United Kingdom; 2Freeman, Newcastle upon Tyne, United Kingdom.

4:30 PM – 6:00 PM CONCURRENT SESSION 22: Immunosuppression After Lung Transplantation: From Mouse to Man (Continental C)

4:30 PM (192) Mechanisms behind Local Immunosuppression Using Inhaled Tacrolimus in Preclinical Models of Lung Transplantation; T. Deuse,1,2 R. Sista,3 D. Weill,3 H. Reichenspurner,1 R.C. Robbins,2 S. Schrepper,1,2 1University Heart Center Hamburg, Hamburg, Germany; 2Stanford University School of Medicine; 3Stanford University School of Medicine, Stanford, CA.

4:45 PM (193) Lung Deposition of a Liposomal CyclosporineA Inhalation Solution in Patients after Lung Transplantation; J. Behr,1 G. Zimmermann,1 R. Baumgartner,1 H. Leuchte,1 C. Neurohr,1 P. Brand,2 C. Herpich,3 K. Sommerer,2 J. Seitz,2 M. Keller,2 1Ludwig-Maximilians-University, Munich, Germany; 2Pari-Pharma GmbH, Munich, Germany; 3Imaged Research GmbH, Gauting, Germany.

5:00 PM (194) Inhaled Cyclosporine Is Well Tolerated in the CYCLIST Clinical Trial; B.A. Johnson,1 M. Rolfe,2 C. Johnson,3 W. Verret,3 T. Breen,3 J. Golden,4 1University of Pittsburgh, Pittsburgh, PA; 2Tampa General Hospital, Tampa, FL; 3APT Pharmaceuticals, Burlingame, CA; 4University of California San Francisco, San Francisco, CA.

5:15 PM (195) Omental Stromal Cells (OSC) Abrogate Acute Lung Injury Associated with Allogenic Transplant in Absence of Immunosuppression; R.K. Braun,1 A.A. Martin,1 P. Sethupathi,1 M.G. Medina,1 W. Jungraithmayr,2 C.H. Wigfield,1 M. Iwishima,3 R.B. Love.1 1Loyola University Medical Center, Maywood, IL; 2University Hospital Zurich, Zurich, Switzerland; 3Loyola University Medical Center, Maywood, IL.

5:30 PM (196) Identifying the Potassium Channel KCa3.1 as a New Therapeutic Target To Prevent Chronic Airway Allograft Rejection; D. Meyberg,1 T. Deuse,1,2 H. Wulff,2 R. Kohler,2 H. Reichenspurner,1 S. Schrepper,1,2 X. Hua,1 1University Heart Center Hamburg, Hamburg, Germany; 2Stanford University School of Medicine, Stanford, CA; 3University of California, Davis, Davis; 4Centrum for Internal Medicine, Marburg, Germany.


4:30 PM – 6:00 PM
CONCURRENT SESSION 23: Pediatric Transplantation in Unique Patient Populations (Waldorf Room)
Chairs: Stuart C. Sweet, MD, PhD and Michael Burch, MD

4:30 PM (198) White, Black and Hispanic Children Have Benefited Equally from Improvement in Early Post-Transplant Survival in Pediatric Heart Transplantation; T.P. Singh, C.S. Almond, K. Gauvreau. Children’s Hospital Boston, Boston, MA.

4:45 PM (199) Use of Induction Agents and Incidence of Infection and Malignancy Following Pediatric Heart Transplantation; R.J. Gajarski, E.D. Blume, K. Schechtman, J. Zheng, L.J. West, S. Urschel, S. Miyamoto, L. Altmirano, D. Naftel, J.K. Kirklin, M.C. Zamberlan, C. Canter. C.S. Mott Children’s Hospital, University of Michigan Health System, Ann Arbor, MI; St. Louis Children’s Hospital, Washington University School of Medicine, St. Louis, MO; Children’s Hospital of Colorado, Aurora, CO; University of Alberta, Edmonton, AB, Canada; Washington University School of Medicine, St. Louis, MO; University of Alabama, Birmingham, AL.

5:00 PM (200) Center-Specific Outcomes for Pediatric Heart Transplantation: Do Past Outcomes Predict Future Performance?; W.T. Mahle, K.R. Kanter, R.N. Vincent. Children’s Healthcare of Atlanta, Atlanta, GA.

5:15 PM (201) Lung Transplantation in Children after Hematopoietic Stem-Cell Transplantation; S. Yousef, T. Benda, T. Frischer, G. Westall, S. Goldfarb, M. Ballman, P. Aurora, G. Doherty, D. Boyer, G. Visser, M. Woo, M.G. Michaels, S.C. Sweet, M.G. Schechter, G.B. Mallory, O. Eledemir. University of Miami, Miami, FL; Baylor College of Medicine, Houston, TX; University Hospital Zurich, Zurich, Switzerland; Children’s Hospital of Philadelphia, Philadelphia, PA; Hannover Medical School, Hannover, Germany; Great Ormond Street Hospital, London, United Kingdom; Harvard University, Boston, MA; University of Vienna, Vienna, Austria; Children’s Hospital of Pittsburgh, Pittsburgh, PA; Washington University, St. Louis, MO; Alfred Hospital and Monash University, Melbourne, Vic, Australia.


5:45 PM (203) Comparison of Risk Factors and Outcomes for Pediatric Patients Listed for Heart Transplantation after Bidirectional Glenn and after Fontan: A Multi-Institutional Study; J.R. Kovach, E.D. Blume, D.C. Naftel, F.B. Pearce, M.T. Fouhsee, E.R. Edens, J.H. Shuhaiber, F. Fynn-Thompson, J.K. Kirklin, S.D. Zangwill. Medical College of Wisconsin, Milwaukee, WI; University of Alabama at Birmingham, Birmingham, AL; University of Alabama at Birmingham, Birmingham, AL; University of Iowa Children's Hospital, Iowa City, IA; Cincinnati Children's Hospital, Cincinnati, OH; Children's Hospital Boston, Boston, MA.

4:30 PM – 6:00 PM
CONCURRENT SESSION 24: Heart Failure: Prognostication and Outcomes (Marquette Room)
Chairs: Tuvia Ben Gal, MD and Donna M. Mancini, MD

4:45 PM (205) Cardiac Resynchronization Therapy (CRT) Induced Cellular Reverse Cardiac Remodeling Similar to Left Ventricular Assist Devices; C.M. Orrego, J. Florez, K. Youker, G. Torre-Amione. The Methodist Hospital, Houston, TX.

5:00 PM (206) Sildenafil Is More Selective Pulmonary Vasodilator than PGE1 in Patients with Severe Pulmonary Hypertension Secondary to Heart Failure; H. Al-Hiti, V. Melenovsky, J. Kettner, J. Kautzner. IKEM, Prague, Czech Republic.

5:15 PM (207) Electrocardiogram QRS Duration Predicts Recovery of Left Ventricular Ejection Fraction after Renal Transplant; P.S.D. Yeo, R. Fatica, W.W.H. Tang. Cleveland Clinic, Cleveland, OH; 2Cleveland Clinic, Cleveland, OH.

5:30 PM (208) Gamma-Glutamyltransferase (GGT) Rather than Bilirubin Is of Prognostic Significance in Chronic Heart Failure; M. Ess, C. Mussner-Seeber, H. Ulmer, M. Frick, G. Poelzl. University Hospital, Innsbruck, Austria; 2Innsbruck Medical University, Innsbruck, Austria.

5:45 PM (209) Hemodynamic and Echocardiographic Correlations of Peak VO2; M. Guglin, F. Matar, H. Khan. University of South Florida, Tampa, FL.

6:00 PM – 7:00 PM
Pulmonary Transplantation Council Quality of Life Workforce Meeting (Joliet Room)
Junior Faculty and Trainee Council Meeting (PDR-2)

6:00 PM – 7:00 PM
MINI ORAL SESSION 6 (Boulevard)
Chairs: Angelika Costard-Jaeckle, MD and Sean P. Pinney, MD

6:00 PM (210) Review of 12,703 Endomyocardial Biopsies: The Truth of Quilty Lesions in the Cyclosporine and Tacrolimus Era; M. Kawano, M. Kittleson, M. Fishbein, C. Lai, J. Patel, S. Davis, J. Moriguchi, A. Ardehali, J. Kobashigawa, David Geffen School of Medicine at UCLA, Los Angeles, CA; Cedars-Sinai Heart Institute, Los Angeles, CA.

6:05 PM (211) The Importance of Anti-HLA DQ Antibodies as a Risk Factor for the Development of Transplant Coronary Artery Disease (TCAD) after Heart Transplantation; J. Patel, M. Kittleson, E. Reed, G. Aguas, M. Kawano, S. Davis, C. Burch, A. Velleca, E. Stimpson, J. Moriguchi, A. Ardehali, J. Kobashigawa, David Geffen School of Medicine at UCLA, Los Angeles, CA; Cedars-Sinai Heart Institute, Los Angeles, CA.

6:10 PM (212) Heart Transplantation Is Associated with Impaired Peripheral Artery Function and Chronic Endothelial Dysfunction; M.M. Colvin-Adams, N. Harcourt, Y. Sonbol, G. Raveendran, M. Pritzker, D. Duprez. University of Minnesota, Minneapolis, MN.


6:20 PM (214) Analysis of Impact of Post Transplant Neoplastic Disease on Long-Term Follow up Following Heart Transplant; P. Totaro, M. Savasta, S. Nicolardi, N. Ippoliti, C. Pellegrini, C. Goggi, A.M. D’Armini, M. Vigano. IRCCS Foundation S Matteo, Pavia, Italy; University School of Medicine, Pavia, Italy.

6:25 PM (215) Serum Neutrophil Gelatinase-Associated Lipocalin (NGAL) Level Correlates with Kidney Dysfunction in Heart Allograft Recipients; P. Przybyłowski, J.M. Małyszko, J. Małyszko, Collegium Medicum, Jagiellonian University, Krakow, Poland; Medical University Białystok, Białystok, Poland.
6:30 PM (216) Extra-Corporeal Membrane Oxygenation for Primary Graft Failure after Cardiac Transplantation. Six-Year Single Center Experience; C. D’Alessandro, J.L. Golmard, S. Aubert, A. Julien, E. Barreda, P. Leprince, G. Irajd, P. Alain. La Pitie Hospital, Paris, France; La Pitie Hospital, Paris, France; La Pitie Hospital, Paris, France.

6:35 PM (217) A High-Intensity Exercise Program Improves Peak VO2 and Reduces Markers of Systemic Inflammation in Cardiac Transplant Recipients: A Randomized Study; C.H. Dall, S.B. Christensen, T. Hermann, E. Prescott, F. Gustafsson. Rigshospitalet, Copenhagen, Denmark; Bispebjerg Hospital, Copenhagen, Denmark.

6:40 PM (218) The Use of Neurohormonal Antagonists Is Not Associated with Vasoplegia in Post-Orthotopic Heart Transplant Patients; M.M. Patarroyo, C.A. Simbaqueba, R. Wong, D.O. Taylor, W.H.W. Tang, K. Shrestha. Cleveland Clinic Foundation, Cleveland, OH; Cleveland Clinic Foundation, Cleveland, OH; Cleveland Clinic Foundation, Cleveland, OH.

6:45 PM (219) Conversion to Everolimus in Heart Transplant Patients with Calcineurininhibitor (CNI)-Associated Myopathy; S. Meyer, M. Adam, A. v Stritzky, F.M. Wagner, T. Deuse, H. Reichen spurner, A. Costard-Jaeckle. University Heart Center, Hamburg, Germany; University Heart Center, Hamburg, Germany.

6:50 PM (220) A Web-Based Pilot Study of Inter-Pathologist Reproducibility Using the ISHLT 2004 Classification System for Biopsy Diagnosis of Acute Cardiac Allograft Rejection: The European Experience on Behalf of the Transplant Working Group of the Association for European Cardiovascular Pathology; A. Angelini, C. Andersen, G. Bartoloni, F. Black, P. Bishop, H. Doran, M. Pedrigo, J. Fries, M. Goddard, H. Goebel, D. Neil, O. Leone, A. Marzullo, M. Ortmann, F. Paraf, S. Rotman, N. Turhan, A.C. Frigo, F. Grigoletto, A. Gasparetto, R. Mencarelli, G. Thiene, M. Burke. Pathological Anatomy-Cardiovascular Pathology, Padua, Italy; Frederik V’s vej 11, Copenhagen, Denmark; Settorato Int. via Palermo, 47, P.O. Garibaldi Nesima, Catania, Italy; Freeman Cardiothoracic Centre, Newcastle upon Tyne NHS Hospitals Trust, Royal Victoria Infirmary, Queen Victoria Road, Newcastle, United Kingdom; Wythenshawe Hospital, UHSM, Southmoor Road, Manchester, United Kingdom; Wythenshawe Hospital, Manchester, United Kingdom; Pathological Anatomy-Cardiovascular Pathology, Padua, Italy; Kerpener Strasse 62, Cologne, Germany; Papworth Everard, Cambridge, United Kingdom; Kerpener Strasse 62, Cologne, Germany; University Hospital Birmingham, Medical School, Edgbaston, Birmingham, United Kingdom; S. Orsola-Malpighi Hospital, Bologna, Italy; University of Bari, Policlinico p.za G. Cesare 11, Bari, Italy; Kerpener Strasse 62, Cologne, Germany; Centre Hosp Univ Dupuytren, Limoges, France; Institut Universitaire de Pathologie de Lausanne, Lausanne, Switzerland; Yüksel Ihtisas Hospital, Ankara, Turkey; University of Padua, Padua, Italy; University of Padua, Padua, Italy; Azienda ULSS 18, Rovigo, Italy; Azienda ULSS 18, Rovigo, Italy; Pathological Anatomy-Cardiovascular Pathology, Padua, Italy; Harefield, Midtx, Harefield, United Kingdom.

6:55 PM (221) Patterns and Predictors of Stress and Coping from 5 to 10 Years after Heart Transplantation; K.L. Grady, E. Wang, C. White-Williams, D. Naftel, S. Myers, J.K. Kirklin, J.B. Young, D. Pelegrin, J. Czerr, J. Kobashigawa, J. Chait, B. Rybarczyk, A. Heroux, R. Higgins. Northwestern Memorial Hospital, Chicago, IL; Northwestern Memorial Hospital, Chicago, IL; The Cleveland Clinic, Cleveland, OH; David Geffen School of Medicine at UCLA/Cedars-Sinai Heart Institute, Los Angeles, CA; Virginia Commonwealth University, Richmond, VA; Loyola University Medical Center, Maywood, IL; Rush University Medical Center, Chicago, IL; University of Alabama at Birmingham, Birmingham, AL; University of Alabama at Birmingham, Birmingham, AL.

6:00 PM – 7:00 PM
MINI ORAL SESSION 7 (Continental C)
Chairs: Michiel E. Erasmus, MD, PhD and Hendrik Treede, MD
6:00 PM (222) Underutilized Donor Pool for Lung Transplantation: Drowning Victims; **F. Zafar, J.S. Heine, G.B. Mallory, M.G. Schecter, O. Eldemir, D.L.S. Morales. Baylor College of Medicine, Houston, TX; Baylor College of Medicine, Houston, TX.**


6:15 PM (225) Survival and Status Transition of Patients Initially Listed UNOS Status 2: The Effect of Physician Decisions; **T.F. Dardas, K.D. Aaronson, F.D. Pagani. Department of Internal Medicine, Division of Cardiology, Ann Arbor, MI; University of Michigan Health System, Ann Arbor, MI.**


6:25 PM (227) Novel Observations of Differences in Lung Inflammatory Gene Expression Profiles between Donation after Cardiac Death vs. Donation after Brain Death; Inflammation-Specific Microarray Study; **C.-H. Kang, M. Anraku, M. Cypel, J.C. Yeung, A.F. Pierre, M. de Perrot, T.K. Waddell, M. Liu, S. Keshavjee. Toronto General Hospital, University of Toronto, Toronto, ON, Canada; Seoul National University Hospital, Seoul National University, Seoul, Korea.**


6:35 PM (229) Activated Omental Stromal Cells Ameliorate Bleomycin Induced Acute Lung Injury; **A.A. Martin, B.K. Braun, M.G. Medina, S. Shah, P. Sethupathi, C. Wigfield, R.B. Love. Loyola University Medical Center, Maywood, IL; Loyola University Medical Center, Maywood, IL.**

6:40 PM (230) Size Reduced Lung Transplantation –9 Years of Experience by a Single Centre; **M.A. Hoda, B.D. Ghani, M. Winter, P. Jaksch, A. Scheed, C. Aigner, S. Taghavi, G. Lang, K. Walter. Medical University Vienna, Vienna, Austria.**


6:00 PM – 7:00 PM
Mini Oral Session 8 (Waldorf)
Chairs: Robert P. Frantz, MD and Tobias Deuse, MD, PhD

6:00 PM (233) Impact-DCM: A Randomized, Controlled, Multi-Center Phase II Trial Utilizing Expanded Autologous Bone Marrow As Sole Therapy for Dilated Cardiomyopathy; **B.A. Bruckner, D. Bull, B. Hammond, G. Ali, B. Elmar, L. Matthias, R.J. Michael, L. Perryman, N. Smidra, O. Lattouf, R.R. Bunge, A. Patel. The Methodist Hospital DeBakey Heart and Vascular Center, Houston, TX; Aastrom Biosciences, Inc., Ann Arbor, MI; Baylor University Medical Center, Dallas, TX; The University of Utah.
School of Medicine, Salt Lake City, UT; 5Cleveland Clinic Heart and Vascular Institute, Cleveland, OH; 6Emory University Hospital Midtown, Atlanta, GA.

6:05 PM (234) WITHDRAWN

6:10 PM (235) Strategies for Cardiac Xenotransplantation Provide Technologies for Improved Calcium Resistant Bioprosthetic Heart Valves; C.G.A. McGregor,1,2 N. Lila,3 M. Vlasin,1 B.S. Wiseman,1 J.S. Logan,1 G.W. Byrne.1,2 Mayo Clinic, Rochester, MN; 2University College London, London, United Kingdom; 3University of Paris, Paris, France.

6:15 PM (236) Immunosuppressive Agents Differently Suppress T Cell Subpopulations; T. Deuse,1,2 H. Reichenspurner,1 R.C. Robbins,2 S. Schreper,1,2 X. Hua.1 University Heart Center Hamburg, Hamburg, Germany; 2Stanford University School of Medicine, Stanford, CA.

6:20 PM (237) HGF or VEGF Gene Transfer Maximizes Mesenchymal Stem Cell-Based Myocardial Salvage after Acute Myocardial Infarction; T. Deuse,1,2 P. Fedak,3 R.C. Robbins,2 H. Reichenspurner,1 S. Schreper.1,2 University Heart Center Hamburg, Hamburg, Germany; 2Stanford University School of Medicine, Stanford, CA; 3University of Calgary, Calgary, Canada.

6:25 PM (238) Imaging of Transplanted Bone Marrow Derived Stem Cells for Therapy of Ischemic Cardiomyopathy; B. Bruckner,1 A. Ghodsizad,2 C. Piechaczek,2 A. Ruhiparwar,2 M. Karck,2 M. Loebe,1 G. Noon,1 M. Reardon,1 R. Basel,1 W. Jones,1 L. Morales,1 M. Donovan,1 R. Bunge,1 L. Perryman,1 The Methodist Hospital DeBakey Heart and Vascular Center, Houston, TX; 2University of Heidelberg, Heidelberg, Germany.

6:30 PM (239) CD14 and CD36 Restrain Inducible T reg Generation and Prevent Costimulatory Blockade Extension of Allograft Survival; H. Shen, D. Goldstein. Yale University School of Medicine, New Haven, CT.


6:40 PM (241) Risk Factors for Nontuberculous Mycobacterial (NTM) Infections in Heart and Lung Transplant Recipients; S.A. Longworth,1 C. Vinnard,1 I. Lee,1 T. Barton,1 K. Sims,1 M. Synnestvedt,2 E. Blumberg.1 Hospital of the University of Pennsylvania, Philadelphia, PA; 2University of Pennsylvania School of Medicine, Philadelphia, PA.

6:45 PM (242) Pre-B-Cell Colony Enhancing Factor (PBEF) Is a Novel target in Hypoxia-Induced Murine Pulmonary Hypertension; R.F. Machado,1 L. Moreno-Vinasco,1 R. Zaidi,1 S. Sammani,1 J.G.N. Garcia.1 University of Chicago, Chicago, IL; 2, Chicago, IL; 3, Chicago, IL.

6:50 PM (243) Impact of Mechanical Unloading on Myocardial Endothelium and Microvasculature; S. Drakos,1,2,3,4 E. Hammond,2,3 S. Clayson,1,3 M.P. Revelo,2,3 S. Stoker,1,3 A. McCormick,1,3 H. Smith,1,2 C. Selzman,2,3 D.R. Verma,1,2,3 D. Budge,1,3 J. Stellick,1,2,3 D. Li,2 A. Kfoury.1,2,3 1Utah Artificial Heart Program, Intermountain Medical Center, Salt Lake City, UT; 2University of Utah, Salt Lake City, UT; 3UTAH Cardiac Transplant Program, Salt Lake City, UT; 43rd Cardiology Department, University of Athens, Athens, Greece.

6:55 PM (244) Effect of Mechanical Unloading on Fibrosis and Hypertrophy during Cardiac Remodeling in Humans; S. Drakos,1,2,3 E. Hammond,2,3 B. Reid,1,2,3 S. Stoker,1,3 M.P. Revelo,2,3 B. Rasmusson,1,3 C. Selzman,2,3 R. Alhareethi,1,3 A. McCormick,1,2 E. Gilbert,2,3 D. Miller,3 D. Li,2 A. Kfoury.1,2,3 1Utah Artificial Heart Program, Salt Lake City, UT; 2University of Utah, Salt Lake City, UT; 3UTAH Cardiac Transplant Program, Salt Lake City, UT.
6:00 PM – 7:00 PM
MINI ORAL SESSION 9 (Marquette)
Chairs: Christian Benden, MD and Kristine Guleserian, MD

6:00 PM (245) Allomap Use in Cardiac Transplantation: Single Center Experience; I. Dumitru, S. Radio, D. Tayama. UNMC, Omaha, NE; XDX, Brisbane, CA.

6:05 PM (246) Switch to Sirolimus and Dose Reduced Calcineurin-Inhibitor after Cardiac Transplantation Is Safe and Results in Renal Stability over the Ensuing Three Years; S. Khandhar, H. Shah, M. Rebel, C. Newman, D. Tayama. University of Pittsburgh Medical Center, Pittsburgh, PA; University of Pittsburgh Medical Center, Pittsburgh, PA.

6:10 PM (247) Relationship between Microvascular and Macrovascular Disease in Heart Transplant Recipients; M.S. Abu-Qaoud, D. Chen, J. Kerstetter, L.N. Stoletniy, R.G. Pai. Loma Linda University Medical Center, Loma Linda, CA; Loma Linda University Medical Center, Loma Linda, CA.


6:20 PM (249) A Randomized, Open-Label Study To Compare the Safety and Efficacy of Conversion From a Calcineurin Inhibitor (CNI) to Sirolimus Versus Continued Use of a CNI in Cardiac Transplant Recipients with Mild to Moderate Renal Insufficiency; A. Zuckermann, A. Keogh, M.G. Crespo-Leiro, D. Mancini, F. Gonzalez-Vilchez, L. Almenar, S. Brozena, H. Eisen, S. See Tai, S. Kushwaha, AKH Wien, Vienna, Austria; St. Vincent’s Hospital, Darlinghurst, NSW, Australia; Complexo Hospitalario Universitario A Coruña, Coruña, Spain; Columbia University Medical Center, New York, NY; Hospital Marques de Valdecilla, Santander, Cantabra, Spain; Hospital La Fe, Valencia, Spain; University of Pennsylvania, Philadelphia, PA; Drexel University College of Medicine, Philadelphia, PA; Wyeth Pharmaceuticals, Collegeville, PA; Mayo Clinic Rochester, Rochester, MN.

6:25 PM (250) Conversion to Everolimus in Persistent Cytomegalovirus or Herpes simplex Viremia Following Thoracic Organ Transplantation; S. Meyer, M. Adam, A. v Stritzky, F.M. Wagner, T. Deuse, H. Reichenspurner, A. Costard-Jaeckle. University Heart Center, Hamburg, Germany; University Heart Center, Hamburg, Germany.

6:30 PM (251) Surveillance HLA Antibody Screening Post Cardiac Transplant – A Single Center Pediatric Experience; S. Zangwill, G. Stendahl, K. Tillman, S. Berger, T. Ellis, K. Gandy, M. Mitchell, J. Tweddell. Medical College of Wisconsin, Milwaukee, WI; Blood Center of Wisconsin, Milwaukee, WI; Medical College of Wisconsin, Milwaukee, WI.


6:45 PM (254) Lung Transplantation for Childhood Interstitial Lung Disease; M.G. Schecter, J.A. Rama, E.D. McKenzie, S. Heine, D.L. Morales, G.B. Mallory, O. Elidemir. Baylor College of Medicine, Houston, TX; Baylor College of Medicine, Houston, TX.
Rapid Reduction in Donor Specific Antibodies with Bortezomib in Pediatric Heart Transplant Recipients with Positive Crossmatch and Antibody Mediated Rejection; W.R. Morrow,1 E.A. Frazier,1 W.T. Mahle,2 H.O. Terry,1 S.E. Pye,1 R.L. Saylors,1 X. Garcia,1 R.D.B. Jaquiss.1 1Arkansas Children’s Hospital, Little Rock, AR; 2Sibley Heart Center, Atlanta, GA.

Risk Factors for Renal Dysfunction in Pediatric Heart Transplantation: A Multi-Institutional Study; B. Feingold,1 J. Zheng,2 Y. Law,3 W.R. Morrow,4 T.M. Hoffman,5 K.B. Schechtman,6 C. Canter.6 1Children’s Hospital of Pittsburgh of UPMC, Pittsburgh, PA; 2Washington University, St. Louis, MO; 3Seattle Children’s Hospital, Seattle, WA; 4Arkansas Children’s Hospital, Little Rock, AR; 5Nationwide Children’s Hospital, Columbus, OH; 6Washington University, St. Louis, MO.
9:50 AM INVITED LECTURE, RNAi and Heart Transplantation—note title change, Weiping Min, MD, PhD, University of Western Ontario, London, Ontario, Canada

9:00 AM – 5:00 PM
Press Office Open

10:00 AM – 4:30 PM
Exhibit Hall Open (Southeast Exhibit Hall)
Internet Café Open (Southeast Exhibit Hall)

10:15 AM – 10:45 AM
ANNUAL BUSINESS MEETING (International Ballroom) Members only.

10:15 AM – 10:45 AM
Coffee Break (Southeast Exhibit Hall)

10:45 AM – 12:15 PM
CONCURRENT SESSION 25: Cost Effectiveness and Long-Term Outcomes (International Ballroom)

Chairs: Carmelo A. Milano, MD and Robert F. Padera, MD, PhD


11:00 AM (262) Changing Costs of Mechanical Circulatory Support: Impact of Era and Device; M.S. Slaughter, R. Bostic, J.G. Rogers, M.J. Russo, L.W. Miller. 1 University of Louisville, Louisville, KY; 2 Thoratec Corporation, CA; 3 Duke University Medical Center, Durham, NC; 4 Columbia University, New York, NY; 5 Georgetown University, Washington, DC.


11:45 AM (265) Quality of Life in Patients Supported 2 Years with a Continuous Flow Left Ventricular Assist Device as Destination Therapy; L.A. Coyle, C.T. Gallagher, G. Bhat, P.S. Pappas, M.S. Slaughter, A.J. Tatooles. 1 Advocate Christ Medical Center, Oak Lawn, IL; 2 University of Louisville, Louisville, KY.

12:00 PM (266) The Type of Ventricular Assist Device Implanted Does Not Affect Post-Heart Transplant Renal Function; A.C. Alba, V. Rao, H.J. Ross, D.H. Delgado, F. Gustafsson, A.S. Jensen, K. Sander. 1 University Health Network, Toronto, ON, Canada; 2 Rigshospitalet, Copenhagen, Denmark.

10:45 AM – 12:15 PM
CONCURRENT SESSION 26: Assessing the Risk of Heart Transplantation (Continental A/B)

Chairs: John V. Conte, MD and Paul J. Mohacsi, MD

10:45 AM (267) Minimizing Infection and Rejection Death: Clues Acquired from 19 Years of Multiinstitutional Cardiac Transplantation Data; J.F. George, D.O. Taylor, E.D. Blume, J.K. Kirkin, D.C. Naffel, R.N. Brown, A.I. Dipchand, J.A. Tallaj. 1 University of Alabama at Birmingham, Birmingham, AL; 2 Cleveland Clinic, Cleveland, OH; 3 Children’s Hospital, Boston, MA; 4 Hospital for Sick Children, Toronto, ON, Canada.
11:00 AM (268) Has the Risk Abated in the Current Era? A 15 Year Multi-institutional Analysis; R.S.D. Higgins,1 P.P. Chang,2 R.C. Starling,3 G.A. Ewald,4 J.A. Tallaj,5 R.N. Brown,5 N.M. Kirklin.5 1Rush University Medical Center, Chicago, IL; 2University of North Carolina at Chapel Hill, Chapel Hill, NC; 3Cleveland Clinic Foundation, Cleveland, OH; 4Washington University School of Medicine, St. Louis, MO; 5University of Alabama at Birmingham, Birmingham, AL.

11:15 AM (269) Heart Transplant Rejection with Cardiogenic Shock Supported with Extracorporeal Membrane Oxygenation (ECMO): Outcome from a Single Center Experience; M. Kittleson,2 J. Patel,2 J. Moriguchi,3 M. Kawano,2 K. Patel,1 S. Davis,2 A. Hage,2 M. Hamilton,2 A. Ardehali,1 J. Kobashigawa,2 1David Geffen School of Medicine at UCLA; 2Cedars-Sinai Heart Institute, Los Angeles, CA.

11:30 AM (270) BMI Is an Independent Risk Factor for Surgical Wound Complication in de-novo Heart Transplant Recipients (HTxR) Regardless of the Immunosuppressive Therapy; M.J. Barten,1 J.M. Arizon,2 G. Dong,3 H. Eisen,4 J. Kobashigawa,3 H. Lehmkuhl,3 H. Ross,7 M. Vigano,8 S.-S. Wang,9 A. Zuckermann.10 1University of Leipzig, Heart Center, Leipzig, Germany; 2Reina Sofia University Hospital, Cordoba, Spain; 3Novartis Pharmaceuticals Corporation, East Hanover, NJ; 4Drexel University College of Medicine, Philadelphia, PA; 5Cedars-Sinai Heart Institute, Los Angeles, CA; 6Deutsches Herzzentrum Berlin, Berlin, Germany; 7University Health Network, Toronto General Hospital, Toronto, ON, Canada; 8Università degli Studi di Pavia, Pavia, Italy; 9National Taiwan University, Taipei, Taiwan; 10University of Vienna, Vienna, Austria.

11:45 AM (271) QTc-Interval and Molecular Gene Expression Profiling Test Score in Cardiac Allograft Dysfunction after Heart Transplantation; K. Shahzad,1 J. He,1 Q.A. Aziz,1 M. Cadeiras,1 F. Latif,1 A. Sinha,1 S. Auerbach,2 S. Mital,4 S. Restaino,1 C.C. Marboe,3 L.J. Addonizio,2 M.C. Deng.1 1Columbia University Medical Center, New York, NY; 2Columbia University Medical Center, New York, NY; 3Columbia University Medical Center, New York, NY; 4University of Toronto, Calgary, Canada.

12:00 PM (272) Persistent Pulmonary Hypertension in Heart Transplant Patients: Is This a Recipe for Long-Term Failure?; J. Patel,2 M. Kittleson,2 M. Share,4 M. Kawano,2 S. Davis,2 J. Moriguchi,2 A. Ardehali,1 J. Kobashigawa,2 1David Geffen School of Medicine at UCLA; 2Cedars-Sinai Heart Institute, Los Angeles, CA.

10:45 AM – 12:15 PM CONCURRENT SESSION 27: Bronchiolitis Obliterans Syndrome (BOS): Risk Factors and Prevention (Boulevard Room)

10:45 AM (273) The Impact of Air Pollution on Bronchiolitis Obliterans Syndrome and Mortality after Lung Transplantation; B. Vanaudenaerde,1,2 T. Nawrot,3 R. Vos,2 S. Verleden,1,2 L. Jacobs,2 C. Faes,3 P. Hoet,4 D. Van Raemdonck,1,2 L. Dupont,1,2 B. Nemery,2 G. Verleden,1,2 1Universitair Ziekenhuis Gasthuisberg, Leuven, Belgium; 2Katholieke Universiteit Leuven, Leuven, Belgium; 3University Hasselt, Hasselt, Belgium.

11:00 AM (274) Molecular Typing of Pseudomonas aeruginosa Isolated from CF Lung Transplant Recipients: Implications for BOS Risk; A. Nicholson,1 J.D. Perry,1 S. Peart,1 A. Fisher,2 K.F. Gould.1 1Freeman Hospital, Newcastle upon Tyne, Tyne and Wear, United Kingdom; 2Freeman Hospital, Newcastle upon Tyne, Tyne and Wear, United Kingdom.


11:30 AM (276) Epstein Barr Virus Reactivation in the Lung Allograft Is Inversely Associated with Histopathological Acute Rejection in the Current Era of Routine Antiviral Prophylaxis; D.T. Keating.1 A.

12:00 PM (278) 1-Year Results of the CeMyLungs Study, a 3-Year Randomised, Open Label, Multi-Centre Investigator Driven Study Comparing De Novo Enteric Coated Mycophenolate Sodium with Delayed Onset Everolimus, Both Arms in Combination with Cyclosporin (Using C2 Monitoring) and Corticosteroids for the Prevention of the Bronchiolitis Obliterans Syndrome in Heart-Lung, Bilateral Lung and Single Lung Transplant Recipients; A.R. *Glanville*,¹ C.L. *Aboyoun*,¹ W. Klepetko,² H. Reichenspurner,³ H. Treede,³ E.A. Verschuuren,⁴ A. Boehler,⁵ C. Benden,⁵ P. Hopkins,⁵ P.A. Corris.⁷ ¹St.Vincent's Hospital, Sydney, NSW, Australia; ²University of Vienna, Vienna, Austria; ³University Heart Center, Hamburg, Germany; ⁴University Medical Center, Groningen, Netherlands; ⁵University Hospital, Zurich, Switzerland; ⁶The Prince Charles Hospital, Brisbane, Australia; ⁷Newcastle University, Newcastle, United Kingdom.

10:45 AM – 12:15 PM
CONCURRENT SESSION 28: Making a Better Breath (Continental C)

10:45 AM (279) The Effect of Ex-Vivo Perfusion on the Microbiological Profile of the Donor Lung; D.M. *Karamanou*,¹² J. Perry,² H.R. Walden,¹ A.J. Simpson,³ P. Corris,¹² K. Gould,² A.J. Fisher,¹² J.H. Dark.¹,² ¹Newcastle University, Newcastle upon Tyne, United Kingdom; ²Freeman Hospital, Newcastle upon Tyne, United Kingdom; ³University of Edinburgh, Edinburgh, Scotland, United Kingdom.

11:00 AM (280) Post-Mortem and Ex-Vivo Carbon Monoxide (CO) Ventilation Reduces Ischemia-Reperfusion Injury (IRI) in Rat Lungs Transplanted from Non-Heart-Beating Donors (NHBDs); B. *Dong*, T. Egan. School of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC.


11:30 AM (282) Ex Vivo Donor Lung Evaluation Using Multi-Detector Row Computed Tomography; W.R. *Lynch*,¹ S.K. *Alford*,² A.J. *Schmidt*,³ A.F. *Halaweish*,² E.A. *Hoffmann*.² ¹University of Iowa, Iowa City, IA; ²University of Iowa, Iowa City, IA; ³University of Iowa, Iowa City, IA.


10:45 AM – 12:15 PM
CONCURRENT SESSION 29: Pulmonary Hypertension; Innovative Therapy (Waldorf Room)

11:00 AM (286) Effect of 16 Weeks of Bosentan-Based Therapy on Cardiac MRI (cMRI) Derived Ventricular Function, 6-Minute Walk Test Distance (6MWD) and Borg Dyspnea Index (BDI) in Patients with Pulmonary Arterial Hypertension (PAH): Results from the COMPASS-3 Study; S. Murali, S.G. Lloyd, H. Gupta, F.J. Soto, M.H. Park, F. Torres, N. Frey, R.L. Benza, Allegheny General Hospital, Pittsburgh, PA; University of Alabama at Birmingham, Birmingham, AL; Prevea Health, Sheboygan, WI; University of Maryland School of Medicine, Baltimore, MD; University of Texas Southwestern Medical Center, Dallas, TX; Actelion Pharmaceuticals US, Inc., South San Francisco, CA.

11:15 AM (287) Endothelin Receptor Antagonists Are a Effective Long Term Treatment Option in Pulmonary Arterial Hypertension Associated with Congenital Heart Disease with or without Trisomy 21; F. Kermeen, C. Franks, K. O’Brien, H. Seale, K. Hall, K. McNeil, D. Radford, The Prince Charles Hospital, Brisbane, QLD, Australia; The Prince Charles Hospital, Brisbane, QLD, Australia.

11:30 AM (288) Aldosterone Antagonism in Pulmonary Hypertension and Right Heart Failure; J.A. Mazurek, A. Rabinovitz, R. Zolty, Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, NY; Jacobi Medical Center, Albert Einstein College of Medicine, Bronx, NY.

11:45 AM (289) Comparison of Aprotinin and Tranexamic Acid in Pulmonary Thromboendarterectomy Surgery – Review of 161 Consecutive Patients; M. Berman, D. Cardone, K. Goldsmith, A. Vuylsteke, A. Klein, Ç. Gerrard, J. Dunning, S. Tsui, D. Jenkins, Papworth Hospital, Cambridge, United Kingdom; Papworth Hospital, Cambridge, United Kingdom; Papworth Hospital, Cambridge, United Kingdom.

12:00 PM (290) Impact of Aggressive Management on Outcome in Patients with idiopathic Pulmonary Arterial Hypertension Listed for Lung Transplantation; M. de Perrot, J. Granton, A.F. Pierre, T.K. Waddell, C. Yasufuku, C. Whytehead, M. Hutcheon, L.G. Singer, S. Keshavjee. Toronto General Hospital, Toronto, ON, Canada.

10:45 AM – 12:15 PM CONCURRENT SESSION 30: Clinical Case Dilemmas in Thoracic Transplantation (Marquette)

10:45 AM Introduction, Lorriana E. Leard, MD and Daniel F. Dilling, MD

10:50 AM Challenges in Lung Transplantation
Moderator: Daniel F. Dilling, MD, Loyola University Medical Center, Maywood, IL
Panelists: Robert B. Love, MD, Loyola University Medical Center, Maywood, IL and Geert M. Verleden, MD, PhD, University Hospital Gasthuisberg, Leuven, Belgium

11:05 AM Challenges in Heart Transplantation
Moderator: David W. Markham, MD, University of Texas Southwestern Medical Center, Dallas, TX
Panelists: Stuart D. Russell, MD, Johns Hopkins Hospital, Baltimore, MD and Leslie W. Miller, MD, Washington Hospital Center & Georgetown University Hospital, Washington, DC

11:20 AM Infectious Disease Challenges in Thoracic Transplantation
Moderator: Cynthia J. Gries, MD, MSc, University of Washington, Seattle, WA
Panelists: Aimee Zaas, MD, MHS, Duke University Medical Center, Durham, NC and Kate Gould, FRCPath, Freeman Hospital, Newcastle Upon Tyne, United Kingdom

11:35 AM Challenges in Pulmonary Hypertension
Moderator: Pali D. Shah, MD, Vanderbilt University Medical Center, Nashville, TN
Panelists: Teresa De Marco, MD, FACC, University of California, San Francisco, CA and Raymond L. Benza, MD, Allegheny General Hospital, Pittsburgh, PA

11:50 AM Challenges in Pediatric Thoracic Transplantation
Moderator: Lorriana E. Leard, MD, University of California, San Francisco, CA
Panelists: Cynthia S. Herrington, MD, Children’s Hospital Los Angeles, CA and Lori J. West, MD, D.Phil, University of Alberta, Edmonton, Alberta, Canada
12:30 PM – 2:00 PM
JHLT Editorial Board Luncheon Meeting (Joliet Room)
Scientific Council Chairs Luncheon Meeting (PDR-4)

2:30 PM – 4:00 PM
CONCURRENT SESSION 31: The Menu: Which Device When? (Continental A/B)
Chairs: Steven S. L. Tsui, MD, FRCS and Emma Birks, MRCP

2:30 PM (291) Evaluation of the Minimally Invasive HeartWare® Ventricular Assist System as a Long Term Support Device; M. Strueber, P. Jansz, G. Wieselthaler, G. O’Driscoll, M. Morshuis, A. Khaghani, S. Schueller, R. Hetzer, A. Hoffmeier, D. Duveau. Hannover Medical School, Hannover, Germany; St Vincenz Hospital, Sydney, Australia; Medical University Vienna, Vienna, Austria; Royal Perth Hospital, Perth, Australia; Heart Center NRW, Bad Oeyenhausen, Germany; Harefield Hospital, Harefield, United Kingdom; Freeman Hospital, Newcastle, United Kingdom; German Heart Center, Berlin, Germany; University Hospital Münster, Münster, Germany; Hopital Guillaume, Nantes, France.

2:45 PM (292) Concept of a Catheterization-Lab Implanted Long-Term Circulatory Assist Device: Acute Animal Study Hemodynamic Data; R. Delgado, F. Raissi Shabari. Texas Heart Institute, Houston, TX.

3:00 PM (293) Differential Impact on Post-transplant Outcomes between HeartMate XVE and HeartMate II Left Ventricular Assist Devices; P.A. Ventura, B.B. Reid, B.D. Horne, N.O. Mason, S. Stoker, R. Alharethi, D. Budge, B. Rasmusson, J. Doty, S.E. Clayson, A.G. Kfoury. Intermountain Medical Center, Salt Lake City, UT.

3:15 PM (294) Design and Feasibility Testing of a Miniaturized Transapical Mechanical Circulatory Support Device: MVAD; M.S. Slaughter, G.A. Giridharan, S. Aggarwal, M. Sobieski, D. Tamez, J. LaRose, L. Sherwood, S.C. Koenig. University of Louisville, Louisville, KY; University of Louisville, Louisville, KY; University of Louisville, Louisville, KY; HeartWare International, Inc., Framingham, MA; HeartWare International, Inc., Framingham, MA; University of Louisville, Louisville, KY; University of Louisville, Louisville, KY.

3:30 PM (295) A Single Center Experience with the DuraHeart™ Mag-Lev Centrifugal Left Ventricular Assist System; M.J. Morshuis, L. Arusoglu, M. Schonbrodt, J. Boergermann, J. Gummert. Heart and Diabetic Center North Rhine Westfalia, Bad Oeyenhausen, NRW, Germany.


2:30 PM – 4:00 PM
CONCURRENT SESSION 32: Mechanisms of Inflammation and Repair in the Lung Allograft Airway (Boulevard Room)
Chairs: Marc Estenne, MD and Gregory I. Snell, FRACP, MBB


3:15 PM (300) Lymphocytic Bronchiolitis Is Associated with Inadequate Suppression of Blood T-Cell Granzyme B, IFN and TNF ; C.-L. Liew, G. Hodge, S. Hodge, D. Chambers, P.N. Reynolds, M.D. Holmes, 1,3 1Royal Adelaide Hospital, Adelaide, Australia; 2The Prince Charles Hospital, Brisbane, Australia; 3SA Lung Transplant Service, Adelaide, Australia.

3:30 PM (301) A Novel Approach to the Assessment of Lymphocytic Bronchiolitis – The ’B Score”; D.C. Chambers, S. Hodge, G. Hodge, F. Kermeen, P. Reynolds, M. Holmes, P. Hopkins. 1The Prince Charles Hospital, Brisbane, QLD, Australia; 2Hanson Institute, Adelaide, South Australia, Australia.

3:45 PM (302) Lung Resident Mesenchymal Stem Cells Are Involved in Bronchiolitis Obliterans; S. Aharinejad, M. Salama, O. Andrukhova, S. Taghavi, W. Klepetko, P. Jaksch. 1Medical University of Vienna, Vienna, Austria; 2Medical University of Vienna, Vienna, Austria.

2:30 PM – 4:00 PM CONCURRENT SESSION 33: Heart Transplantation; Immunosuppression Controversies (Continental C)

Chairs: Josef Stehlik, MD, MPH and Ari L. J. Harjula, MD

2:30 PM (303) Gender Mismatch in Non-induction/Triple-Drug Regimens: Poor 10-Year Outcomes; R. Shemin, J. Patel, A. Ardehali, M. Kittleson, M. Kawano, S. Davis, J. Moriguchi, J. Kobashigawa. 1David Geffen School of Medicine at UCLA; 2Cedars-Sinai Heart Institute, Los Angeles, CA.

2:45 PM (304) Alemtuzumab Induction Facilitates Steroid-Free Immunosuppression in Human Cardiac Transplantation: Two Year Outcomes; M.A. Shullo, R. Zomak, J.K. Bhama, C. Bermudez, D.M. McNamara, M. Navoney, R.L. Kormos, Y. Toyoda, J. Teuteberg. 1University of Pittsburgh, Pittsburgh, PA; 2University of Pittsburgh, Pittsburgh, PA; 3University of Pittsburgh Medical School, Pittsburgh, PA.

3:00 PM (305) Mid-Term Results of Campath Induction and Steroid-free Maintenance Immunosuppression in Cardiac Transplantation; S. Aggarwal, K. Luftman, R. Bowles, K. McCants, S. Prabhu, R.D. Dowling, M.S. Slaughter. 1University of Louisville School of Medicine, Louisville, KY; 2University of Louisville School of Medicine, Louisville, KY.

3:15 PM (306) Steroid Minimization Is Associated with Improved Survival in Patients with Diabetes after Heart Transplant; P. Zymek, J.J. Teuteberg, M.A. Shullo, C. Bermudez, R.L. Kormos, J.K. Bhama, Y. Toyoda, D.M. McNamara. 1University of Pittsburgh Medical Center, Pittsburgh, PA; 2University of Pittsburgh Medical Center, Pittsburgh, PA.


3:45 PM (308) Lower Incidence of New Onset Diabetes after Cardiac Transplant with Alemtuzumab Induction; R. Jones, M.A. Shullo, R. Zomak, C. Newman, M. Rebel, C. Yost, M. Navoney, D.M. McNamara, Y. Toyoda, R.L. Kormos, J. Teuteberg. 1University of Pittsburgh Medical School, Pittsburgh, PA; 2University of Pittsburgh, Pittsburgh, PA.

2:30 PM – 4:00 PM CONCURRENT SESSION 34: Healing My Broken Heart (Waldorf Room)

Chairs: Gabor B. Szabo, MD, PhD and Valluvan Jeevanandam, MD
2:30 PM (309) Extended Myocardial Preservation by Polypharmaceutical Supplementation of Celsior; A.J. Watson,1,2 L. Gao,1 J. Tsun,1 L. Sun,1 A. Jabbour,1,2 M. Hicks,3 P.S. Macdonald,1,2 1Victor Chang Cardiac Research Institute, Sydney, NSW, Australia; 2St Vincent’s Hospital, Sydney, NSW, Australia; 3St Vincent’s Hospital, Sydney, NSW, Australia.

2:45 PM (310) Direct Microvascular Endothelial Stabilization by Donor Simvastatin Treatment Prevents Endothelial-to-Mesenchymal Transition and Vascularopathy of Cardiac Allografts; R. Tuuminen,1 A.I. Nykanen,1 S. Syrjala,1 R. Krebs,1 K. Koli,1 K. Lemstrom.1 1Haartman Institute, University of Helsinki, Helsinki, Finland; 2Biomedicum, University of Helsinki, Helsinki, Finland.

3:00 PM (311) Post-Mortem Tissue-Type Plasminogen Activator Preserves Graft Function of Hearts Harvested from Non-Pretreated Non-Heart-Beating Donors; M. Hirota,1,2 I. Kozo,2 T. Tedoriya,1 S. Sano.2 1Showa University Medical School, Tokyo, Japan; 2Okayama University School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan.

3:15 PM (312) Extended Donor Criteria in Heart Transplantation with Pharmacological Stress Echocardiography; G. Arpesella,1 S. Martin-Suarez,1 P.M. Mikus,1 S. Gherardi,2 M. Macherini,3 O. Leone,4 E. Picano,4 T. Bombardini,4 S. Orsola-Malpighi Hospital, Bologna, Italy; 2 Cesena Hospital, Cesena, Italy; 3 Santa Maria Alle Scotte Hospital, Siena, Italy; 4 National Research Center, Pisa, Italy.

3:30 PM (313) Exogenous T3 Causes Acute Pulmonary Hypertension in a Porcine Model of Brain Death; A.J. Watson,1,2 L. Gao,1 L. Sun,1 S. Faddy,3 M. Hicks,1,4 P.C. Jansz,1,2 P.S. Macdonald.1,2 1Victor Chang Cardiac Research Institute, Sydney, NSW, Australia; 2St Vincent’s Hospital, Sydney, NSW, Australia; 3 St Vincent’s Hospital, Sydney, NSW, Australia; 4 St Vincent’s Hospital, Sydney, NSW, Australia.


2:30 PM – 4:00 PM CONCURRENT SESSION 35: New Approaches to the Evaluation and Treatment of Rejection in the Pediatric Transplant (Marquette Room)

Chairs: Okan Elidemir, MD and Olaf Reinhartz, MD

2:30 PM (315) The Impact of HLA-G Polymorphism on Acute Rejection in Pediatric Heart Transplant Recipients; A. Zeevi,1 M. Brooks,1 D. Gimita,1 R. Ferrell,1 R. Chinnock,2 C. Canter,3 L. Addonizio,4 D. Bernstein,4 J. Kirklin,5 D. Naftel,6 S. Webber.7 1University of Pittsburgh, Pittsburgh, PA; 2Loma Linda University, Loma Linda, CA; 3Washington University, St. Louis, MO; 4Columbia University, New York, NY; 5Stanford University, Palo Alto, CA; 6University of Alabama Birmingham, Birmingham, AL.

2:45 PM (316) Minimal (A1) Acute Rejection Episodes are Independent Risk Factors for the Development of Bronchiolitis Obliterans Syndrome in Pediatric Lung Transplant Recipients; O. Elidemir,1 N.P. Varghese,1 E.O. Smith,1 G.B. Mallory,1 E.D. McKenzie,2 J.S. Heine,2 D.L. Morales,2 M.G. Schecter.1 1Baylor College of Medicine, Houston, TX.

3:00 PM (317) Cell Bound Complement Activation Products as Biomarkers of Humoral Rejection in Pediatric Heart Transplantation; B. Feingold,1 J.S. Navratil,2 B. Paul,2 J.M. Ahearn,2 C. Galambos,3 A. Zeevi,4 S.A. Webber.1 1Children’s Hospital of Pittsburgh of UPMC, Pittsburgh, PA; 2University of Pittsburgh School of Medicine, Pittsburgh, PA; 3Children’s Hospital of Pittsburgh of UPMC, Pittsburgh, PA; 4University of Pittsburgh School of Medicine, Pittsburgh, PA.

3:15 PM (318) Comparison of De Novo Everolimus, AZA and MMF in Cyclosporine Based Immunosuppressive Protocol in Pediatric Heart Transplant Patients; S. Schubert,1 H.B. Lehmkuhl,2 M. Huebler,2 R. Hetzer,6 F. Berger.1 1Deutsches Herzzentrum, Berlin, Germany; 2Deutsches Herzzentrum, Berlin, Germany.
3:30 PM (319) Antibody Mediated Rejection (AMR) Predicted by New C1q Assay; C. Chin,1 G. Chen,2 S. Siehr,1 D. Rosenthal,1 O. Reinhardt,1 D. Bernstein,1 F. Sequeira,2 D. Tyan,2 1Stanford University, Palo Alto, CA; 2Stanford University, Palo Alto, CA.

3:45 PM (320) Donor-Specific Antibodies (DSA) Patterns after Pediatric Heart Transplantation with A + and – Crossmatch; C. Reddy,1 E. Riddle,1 P. Checchia,1 C. Huddleston,2 S. Gandhi,2 D. Phelan,3 C. Canter,1 1Washington University School of Medicine, Saint Louis, MO; 2Washington University School of Medicine, Saint Louis, MO; 3Washington University School of Medicine, Saint Louis, MO.

2:30 PM – 4:00 PM
CONCURRENT SESSION 36: Autoimmunity, Tolerance and Inflammation (PDR2)
Chairs: Marlene Rose, PhD and E. Rene Rodriguez, MD

2:30 PM (321) WITHDRAWN

2:45 PM (322) IL-17F Induces a Distinct Form of Anti-MHC Class I Induced Autoimmunity and Playing a Role in Chronic Rejection Post-Lung Transplantation; H. Ilias Basha,1 V. Tiriveedhi,1 M. Takenaka,1 S. Ramachandran,1 G.A. Patterson,2 T. Mohanakumar,1,3 1Washington University School of Medicine, St. Louis, MO; 2Washington University School of Medicine, St. Louis, MO; 3Washington University School of Medicine, St. Louis, MO.

3:00 PM (323) Alloimmune Responses to Mismatched MHC Class I Antigens Induces Immune Responses to Self Antigens Leading to Chronic Rejection; V. Tiriveedhi,1 D.H. Brand,2 D. Saini,1 S. Ramachandran,1 R. Hachem,3 E.P. Trulock,3 G.A. Patterson,4 T. Mohanakumar.1,5 1Washington University School of Medicine, St. Louis, MO; 2University of Tennessee, Memphis, TN; 3Washington University School of Medicine, St. Louis, MO; 4Washington University School of Medicine, St. Louis, MO; 5Washington University School of Medicine, St. Louis, MO.

3:15 PM (324) De Novo Formation of Lymphoid Tissue in the Lung Evolves Post Transplant Obliterative Airway Disease; D. Wagnetz,1 M. Sato,1 J. Yeung,1 S. Hirayama,1 T. Waddell,1 M. Liu,2 S. Keshavjee.1 1Toronto General Hospital, Toronto, ON, Canada; 2Latner Thoracic Research Laboratories, Toronto, ON, Canada.

3:30 PM (325) cKit and MHC Class-I Expression in the Tolerizing Inoculum Dictates Donor-specific Tolerance vs Third-Party Cardiac Allograft Acceptance in a Neonatal Tolerance Model; M. Jeyakanthan, K. Tao, L.J. West. University of Alberta, Edmonton, AB, Canada.


4:00 PM – 4:30 PM
Coffee Break (Southeast Exhibit Hall)
Poster Viewing (Southwest Exhibit Hall)

4:30 PM – 6:00 PM
Concurrent Session 37: Heart Transplantation Clinical Challenges (Continental A/B)
Chairs: Ray E. Hershberger, MD and Gonzalo V. Gonzalez-Stawinski, MD

4:30 PM (327) Gender Does Matter – Gender Specific Outcome Analysis of 1000 Heart Transplants at a Single Centre; I. Kaczmarek, S. Efert, S. Koffler, B. Meiser, B. Reichart. Grosshadem University Hospital, Munich, Germany.

4:45 PM (328) Increased LV Mass and Concentricity as Assessed by Cardiac MRI Are Associated with Increased Mortality in Cardiac Transplant Recipients; P.C. Patel,1 S.C. Reimold,1 F.G. Araj,1 P.A. Kaiser,1
R.M. Peshock,¹ C.W. Yancy,² W.S. Ring,³ S. Gupta,¹ J.D. Mishkin,¹ P.P.A. Mammen,¹ D.W. Markham,¹ M.H. Drazner,¹ ¹University of Texas Southwestern Medical Center, Dallas, TX; ²Baylor University Medical Center, Dallas, TX; ³University of Texas Southwestern Medical Center, Dallas, TX.

5:00 PM (329) Primary Graft Dysfunction Does Not Lead to Increased Cardiac Allograft Vasculopathy in Surviving Patients; S. Wong,¹ J. Moriguchi,¹ M. Kawano,² J. Kobashigawa,² R. Shemin,¹ M. Kwon,¹ ¹David Geffen School of Medicine at UCLA, Los Angeles, CA; ²Cedars-Sinai Heart Institute, Los Angeles, CA.

5:15 PM (330) Blood Product Requirements during Heart Transplantation Are Significantly Higher in Patients Bridged with Continuous Flow Devices Compared to Pulsatile Flow Devices; N. Uriel,¹ S.-W. Pak,² E.M. Sutton,² Y. Naka,² U.P. Jorde,¹ D. Mancini.¹ ¹Columbia University, New York, NY; ²Columbia University, New York, NY.

5:30 PM (331) Cardiac Index, Peak Exercise Oxygen Consumption, and Listing Priority for Cardiac Transplantation; A.B. Methvin, V.V. Georgiopoulou, A.P. Kalogeropoulos, A. Malik, P. Anarado, M. Chowdhury, I. Hussain, W.M. Book, S.R. Laskar, J.D. Vega, A.L. Smith, J. Butler. Emory University Hospital, Atlanta, GA.

5:45 PM (332) The Slope of Renal Function in De Novo HTxR. Can We Improve?; J. Kobashigawa,¹ J. Arizon,² G. Dong,³ H.J. Eisen,⁴ G. Junge,⁵ H. Schwende,⁵ A. Zuckermand,⁶ H.B. Lehmkuhl.⁷ ¹Cedars-Sinai Heart Institute, Los Angeles, CA; ²Hospital Universitario, Cordoba, Spain; ³Novartis Pharmaceuticals Corporation, East Hanover; ⁴Temple University, Philadelphia; ⁵Novartis Pharma, Basel, Switzerland; ⁶Medical University of Vienna, Vienna, Austria; ⁷Deutsches Herzzentrum Berlin, Berlin, Germany.

4:30 PM – 6:00 PM Concurrent Session 38: Lung Transplant for Interstitial Lung Disease (Boulevard Room)

Chairs: Vincent G. Valentine, MD and Christophe Pison, MD

4:30 PM (333) Short-Term Outcomes of Lung Transplant In Idiopathic Pulmonary Fibrosis: An Analysis of the Nationwide Inpatient Sample from the USA; A.T.K. Teo,¹ R. Pietrobon,²,³,⁵ J. Atashili,⁴,⁵ D. Rajgor,²,³ J. Shah,²,³ H. Martins.⁵ ¹National University Heart Centre Singapore, National University Hospital, Singapore, Singapore; ²Duke University Medical Centre, Durham, NC; ³Duke-National University of Singapore Graduate Medical School, Singapore, Singapore; ⁴University of Buea, Cameroon, Cameroon; ⁵Duke University, Durham, NC.

4:45 PM (334) Does Bilateral Versus Single Lung Transplantation Improve Long Term Survival for Patients with Pulmonary Fibrosis?; S.D. Force,¹ A. Pelaez,² D.C. Neujahr,² P.D. Kilgo,³ A.M. Ramirez,² D.L. Miller,¹ A. Pickens,¹ F.G. Fernandez,¹ C. Lawrence.² ¹Emory University, Atlanta, GA; ²Emory University, Atlanta, GA.

5:00 PM (335) Impact of the UNOS Lung Allocation Scoring System on Lung Transplantation for Interstitial Lung Disease; S. Osaki,¹ J. Maloney,¹ R.D. Cornwell,² K.C. Meyer,² N.M. Edwards,¹ N.C. De Oliveira.¹ ¹University of Wisconsin, Madison, WI; ²University of Wisconsin, Madison, WI.

5:15 PM (336) Pre-Obese and Obese Patients with Idiopathic Pulmonary Fibrosis Are at High Risk for Early Mortality after Double Transplantation; C.J. Gries,¹ J.D. Edelman,¹ C.H. Goss,¹ G. Raghu,¹ M.S. Mulligan.² ¹University of Washington, Seattle, WA; ²University of Washington, Seattle, WA.

5:30 PM (337) Lung Transplantation in Patients with Scleroderma: A Single Center Experience; M.M. Crespo,¹ D. Zaldonis,² M.P. George,¹ Y. Toyoda,² B. Johnson,¹ C. Bermudez,² S.S. Haider,¹ J.K. Bhama,² M.R. Morell,¹ J.M. Pilewski.¹ ¹University of Pittsburgh Medical Center, Pittsburgh, PA; ²University of Pittsburgh Medical Center, Pittsburgh, PA.
5:45 PM (338) End Stage Idiopathic Pulmonary Fibrosis: Which Patients Are at Higher Risk of Mortality Awaiting Lung Transplantation?; G. Marulli, M. Loy, F. Di Chiara, E. Balestro, F. Calabrese, E. Perissinotto, F. Lunardi, S. Nicotra, A. Zuin, F. Rea, Thoracic Surgery, Padova, Italy; Pneumology, Padova, Italy; Pathology, Padova, Italy; Biostatistic, Padova, Italy.

4:30 PM – 6:00 PM
Concurrent Session 39: Molecular Mechanisms of Organ Rejection (Continental C)
Chairs: James F. George, PhD and Sonja Schrepfer, MD

4:30 PM (339) Anti-Apoptotic Role of IL-16 Associated with Attenuation of Acute and Chronic Cardiac Rejection; N. Kimura, S. Ito, J.B. Vellota, O.P. Palmer, H. Kosuge, S. Nakae, H. Kornfeld, M.P. Fischbein, Stanford University, School of Medicine, Palo Alto, CA; Stanford University, School of Medicine, Palo Alto, CA; The University of Tokyo, The Institute of Medical Science, Tokyo, Japan; University of Massachusetts, Medical School, Worcester, MA.

4:45 PM (340) IL-6 Plays a Crucial Role in the Induction of Autoimmunity and Development of Chronic Rejection; S. Ramachandran, N. Fukami, N. Benshoff, T. Mohanakumar, Washington University in St Louis, St. Louis, MO; Washington University in St Louis, St. Louis, MO.

5:00 PM (341) Explaining the Bronchiolitis Obliterans Syndrome (BOS) Phenotype – Epithelial-Mesenchymal Transition (EMT) Occurs More Readily in Small Airway Epithelium; B. Banerjee, A. Kicic, M.M. Musk, S. Stickle, D.C. Chambers, University of Western Australia, Crawley, Western Australia, Australia; Western Australia Lung Transplant Unit, Royal Perth Hospital, Perth, Western Australia, Australia; Telethon Institute of Child Health Research, Subiaco, Western Australia, Australia; Princess Margaret Hospital for Children, Subiaco, Western Australia, Australia; Queensland Centre for Pulmonary Transplantation, Vascular Disease, Brisbane, QLD, Australia.

5:15 PM (342) Obliterative Airway Disease (OAD) Induced by Antibodies to MHC- Class I is B Cell Dependent: An Obligatory Role for Antibodies to Self Antigens in the Pathogenesis of OAD; S. Ramachandran, N. Fukami, D. Saini, T. Mohanakumar, Washington University in St Louis, St. Louis, MO; Washington University in St Louis, St. Louis, MO.


5:45 PM (344) A Novel Approach To Generate Regulatory T Cells Using CD103 Depletion; S.D. Moffatt-Bruce, N. Zikri, E. Schumer, D. Bobek, G. Hadley, The Ohio State University, Columbus, OH.

4:30 PM – 6:00 PM
Concurrent Session 40: Expert Consensus Definitions in Cardiothoracic Transplantation and Mechanical Circulatory Support Infections (Waldorf)
Chairs: Stephan Schueler, MD, PhD and Jose G. Montoya, MD
This session will present a summary of the completed consensus document on infections in cardiac transplantation and mechanical circulatory support, which will form the basis for a set of international standardized variables for entry of infection data into the ISHLT Registry and for future research.

4:30 PM Definitions of Infection in Mechanical Circulatory Support, Margaret M. Hannan, MD, Mater Hospital, Dublin, Ireland

5:00 PM Definitions of Infection in Heart and Lung Transplantation, Martha L. Mooney, MD, Sentara Norfolk Transplant Center/EVMS, Norfolk, VA

5:30 PM Panel Discussion with Taskforce Members

4:30 PM – 6:00 PM
Concurrent Session 41: Philip K. Caves Award Candidate Presentations (Marquette Room)
Chairs: Stuart D. Russell, MD and Luciano Potena, MD
4:30 PM (345) Blocking VEGF Receptors 1 and 2 Prevents Inflammatory Response and Experimental Obliterative Airway Disease; R. Krebs, J.M. Tikkanen, M. Hollmen, Y. Wu, D.J. Hicklin, P.K. Koskinen, K.B. Lemstrom, University of Helsinki, Helsinki, Finland; ImClone Systems Incorporated, New York, NY.

4:45 PM (346) Constantly Stable Hypoxia Inducible Factor-1 in Myeloid Cells Prevents Acute Rejection in Mouse Cardiac Allografts; M.A.I. Keranen, R. Krebs, R.S. Johnson, A.I. Nykanen, K.B. Lemstrom, University of Helsinki, Helsinki, Finland; University of California, San Diego, CA; University Central Hospital, Helsinki, Finland.

5:00 PM (347) Generation of Genetically Engineered Low-Antigenicity MHC I Knock-Down Human Embryonic Stem Cells To Prevent Immune Rejection; T. Deuse, M. Seifert, A. Fire, N. Phillips, M. Kay, H. Reichenspurner, R.C. Robbins, S. Schrepfer, Stanford University School of Medicine, Stanford, CA; University Heart Center, Hamburg, Germany; Charite Berlin, Berlin, Germany; Stanford University, Stanford, CA; Stanford University, Stanford, CA.


5:30 PM (349) Lentivirus-Mediated Long-Term Gene Transduction in the Lung Attenuates Allograft Airway Obliteration after Mouse Intra-Pulmonary Trachea Transplantation; S. Hirayama, M. Sato, G. Zehong, M. Liu, T.K. Waddell, J.A. Medin, S. Keshavjee, University of Toronto, Toronto, ON, Canada; Ontario Cancer Institute and the Institute of Medical Sciences, University of Toronto, Toronto, ON, Canada.

5:45 PM (350) Osteopontin mRNA as a Biomarker for Heart Failure after Left Ventricular Assist Device Support and Heart Transplantation; M.E.I. Schipper, M.R. Scheenstra, J. van Kuik, D.F. van Wichen, P. van der Weide, N. de Jonge, R.A. de Weger, University Medical Center, Utrecht, Netherlands; University Medical Center, Utrecht, Netherlands.

4:30 PM – 11:59 PM
Exhibit Hall/Poster Tear Down

6:00 PM – 7:00 PM
New ISHLT Board Members Orientation Meeting (PDR-4)

8:00 PM – 10:00 PM
GALA ANNIVERSARY RECEPTION (Grand Ballroom)

SATURDAY, APRIL 24, 2010

6:30 AM – 10:30 AM
Registration Desk Open (6th Street Registration)

7:00 AM – 7:00 PM
Slide Ready Room Open (Grand Tradition)

7:00 AM – 8:00 AM
SUNRISE SYMPOSIUM 6: Linking Outcomes and Quality of Life After Lung Transplant (Boulevard)
Chairs: Selim M. Arcasoy, MD and Martin P. Iversen, MD, MPH
There has been a major focus on survival and physical outcomes after lung transplant. This has, however, under-estimated the importance of quality of life assessment of outcomes. It is important that the wider lung transplant community recognize the value of quality of life assessment and its impact on outcomes after lung transplant. This session will investigate the associations between patient quality of life and outcomes after lung transplant.

7:00 AM Interventions to Improve Adherence After Thoracic Organ Transplantation, Fabienne Dobbels, MSc, PhD, University Hospital Leuven, Belgium
7:15 AM Integrated Survival and Quality of Life Outcomes in Lung Transplantation, Roger D. Yusen, MD, MPH, Washington University School of Medicine, St. Louis, MO
7:30 AM Patient-Reported Outcomes in Lung Transplantation, Lianne G. Singer, MD, FRCPC, Toronto General Hospital, Ontario, Canada
7:45 AM Integrating Palliative Care in Lung Transplantation, Annette J. DeVito Dabbs, RN, PhD, University of Pittsburgh School of Nursing, Pittsburgh, PA

7:00 AM – 8:00 AM
SUNRISE SYMPOSIUM 7: Crossing the Lines (Continental C)
Chairs: Reynolds M. Delgado, MD and Margaret M. Hannan, MD

7:00 AM Central Lines Infections In Cardiothoracic Transplantation, Jose G. Montoya, MD, Stanford University School of Medicine, Stanford, CA
7:20 AM VAD Infections – Going Into the Future and Learning From the Past, Aly El Banayosy, MD, Penn State Hershey Medical Center, Hershey, PA
7:40 AM Definitions of VAD Infections, Drive-Line Infections, Pocket Infections, and Device Infections, and their Application into Databases for Future Research, William L Holman, MD, University of Alabama at Birmingham, AL

7:00 AM – 8:00 AM
SUNRISE SYMPOSIUM 8: Disasters Early After Lung Transplant (Waldorf)
Chairs: Thomas M. Egan, MD, MSC and John Dark, MB FRCS
Unexpected events and early disasters continue to challenge all centres, with a range of possible responses. A range of acute surgical and medical problems and specific solutions to these problems will be discussed.

7:00 AM Unexpected PGD 1 Hyperacute Rejection, Duane Davis, MD, Duke University Medical Center, Durham, NC
7:10 AM Unexpected PGD 2 Left Heart Failure, David C. McGiffin, MD, University of Alabama at Birmingham, AL
7:20 AM Kinked PA/PV, Joshua Sonett, MD, Columbia Presbyterian Medical Center, New York, NY
7:30 AM Unexpected Donor Anatomy, Martin Strueber, MD, Hannover Medical School, Hannover, Germany
7:40 AM Technical Aspects of ECMO, Clemens Aigner, MD, Medical University of Vienna, Austria

7:00 AM – 8:00 AM
SUNRISE SYMPOSIUM 9: Tough Cases in the Management of the Sensitized Patient Case Presentations (Marquette)
Chairs: Jacqueline Lamour, MD and Elaine F. Reed, PhD
This symposium will address a practice gap in the diagnosis and management of the patient who has evidence of anti-HLA antibodies undergoing transplantation. There is a significant amount of controversy in surrounding the appropriate management of the highly sensitized patient and this symposium will allow participants to understand the state-of-the-art thinking in the field. This symposium will use a practical case-based approach to highlight the issues raised in the transplantation of the highly sensitized patient undergoing heart or lung transplantation.

Invited Discussants: Linda J. Addonizio, MD, Columbia Presbyterian Medical Center, New York, NY and Stephan M. Ensminger, MD, PhD, University of Erlangen-Nurnberg, Germany
7:00 AM Treatment of the sensitized lung transplant patient, Susan D. Moffatt-Bruce, MD, PhD, Ohio State University Medical Center, Columbus, OH
7:15 AM Discussion
7:20 AM Rising Donor Specific Antibodies after Transplant despite Excellent Graft Function: To Treat or Not to Treat, Jeffrey G. Gossett, MD, Children’s Memorial Hospital, Chicago, IL
7:35 AM Discussion
7:40 AM Cardiac Transplantation in a Highly Sensitized Pediatric Patient with Congenital Heart Disease, Chesney D. Castleberry, MD, Medical College of Wisconsin, Wauwatosa, WI
7:55 AM Discussion

8:00 AM – 10:15 AM
PLENARY SESSION (International Ballroom)
Chairs: John Dark, MB FRCS and Richard N. Pierson, III, MD

8:00 AM INVITED LECTURE, New Therapies for Sensitized Renal Allograft Recipients, Patrick G. Dean, MD, Mayo Clinic Transplant Center, Rochester, MN
8:20 AM FEATURED ABSTRACT (351) Are DCD Lungs Superior? Excellent Intermediate Results from a Donation after Cardiac Death Lung Transplant National Collaborative; B. Levey,1 M. Harkess,2 D. Chambers,3 E. Granger,2 I. Ahmed;2 P. Hopkins,3 A. Glanville,2 G. Snell.1 1The Alfred Hospital, Melbourne, Vic, Australia; 2St. Vincent’s Hospital, Sydney, NSW, Australia; 3Prince Charles Hospital, Brisbane, QLD, Australia.
8:30 AM INVITED DISCUSSANT, Andres Varela, MD, Hospital Universita Puerta de Hierro
8:35 AM FEATURED ABSTRACT (352) Cardiac Resuscitation Following Circulatory Arrest in the Organ Donor Is Associated with Excellent Functional and Metabolic Recovery: Implications for Clinical Heart Transplantation; A.A. Ali,1 B. Xiang,2 P. White,1 S. Tsui,1 E. Ashley,3 S.R. Large,1 T.W. Lee,2 R. Arora,2 G. Tian,2 D.H. Freed.1 1Papworth Hospital, Cambridge, Cambridgeshire, United Kingdom; 2University of Manitoba, Winnipeg, MB, Canada; 3Stanford University Medical Center, Palo Alto, CA.
8:45 AM INVITED DISCUSSANT, Carmelo A. Milano, MD, Duke University Medical Center, Durham, NC
8:50 AM INVITED LECTURE, Stem Cell Tissue Engineering, Prof. Dr. Thomas Eschenhagen, University Hospital Hamburg-Eppendorf, Hamburg, Germany
9:10 AM FEATURED ABSTRACT (353) United States Lung Allocation Score Predicts Hospital Charges Post-Transplant; G.J. Arnaoutakis,1 J.G. Allen,1 C.A. Merlo,2 W.A. Baumgartner,1 J.V. Conte,1 A.S. Shah.1 1The Johns Hopkins Hospital, Baltimore, MD; 2The Johns Hopkins Hospital, Baltimore, MD.
9:20 AM INVITED DISCUSSANT, Edward R. Garrity, Jr., MD, University of Chicago Medical Center, Chicago, IL
9:25 AM FEATURED ABSTRACT (354) Serum IgA Deficiency Is Common in Lung Transplantation and Is Independently Associated with Bronchiolitis Obliterans Syndrome (BOS); D.C. Chambers, B. Davies, S. Yerkovich, P.M. Hopkins. The Prince Charles Hospital, Brisbane, QLD, Australia.
9:35 AM INVITED DISCUSSANT, Andrew J. Fisher, MD, Institute of Cellular Medicine, Newcastle Upon Tyne, United Kingdom
9:40 AM AWARDS PRESENTATIONS
9:55 AM DEBATE: Mechanical Circulatory Support is IN, Heart Transplantation is OUT
Pro: O. Howard, Frazier, MD, Texas Heart Institute, Houston, TX
Con: Mandeep R. Mehra, MD, University of Maryland School of Medicine, Baltimore, MD

10:15 AM – 10:30 AM
Coffee Break (Registration Area)

10:30 AM – 12:00 PM
Concurrent Session 42: Blood, Clots and Antibodies (Continental A/B)
Chairs: Darren H. Freed, MD, PhD, FRSCC and Roland Hetzer, MD, PhD

10:30 AM (355) Morbidity and Mortality Due to Thrombotic and Haemorrhagic Complications in Children Receiving Mechanical Cardiac Support Using the Berlin Heart Device; T. Biss, J. Cassidy, A. Hasan, P.


11:15 AM (358) Desensitization Therapies Are Ineffective and May Increase Infection Rates in VAD Patients; E. Feller, E. Sorensen, B. Griffith. University of Maryland, Baltimore, MD; University of Maryland, Baltimore, MD; University of Maryland, Baltimore, MD.

11:30 AM (359) Highly Sensitized Patients on VAD Support Awaiting Heart Transplant on a Ventricular Assist Device (VAD) Appear To Have a Less Robust Immune Response Compared to Non-VAD Patients; M. Kittleson, J. Moriguchi, M. Kwon, E. Reed, S. Davis, M. Kawano, C. Burch, A. Velleca, E. Stimpson, J. Patel, A. Ardehali, J. Kobashigaw. David Geffen School of Medicine at UCLA, Los Angeles, CA; Cedars-Sinai Heart Institute, Los Angeles, CA.

11:45 AM (360) In Vivo Assessment of Thrombogenicity of the Penn State Pediatric Ventricular Assist Device; W.J. Weiss, E.L. Carney, J.B. Clark, T. Cooper, R. Peterson, T.P. Nifong, C. Siedlecli, B. Lukic, G. Rosenberg. Penn State Milton S. Hershey Medical Center, Hershey, PA.

10:30 AM – 12:00 PM Concurrent Session 43: Lung Transplantation Complications (Boulevard Room) Chairs: Marc A. Stern, MD and Peter M. Hopkins, FRACP

10:30 AM (361) Retinoid Therapy Is Ineffective in Preventing Cutaneous Malignancy Complicating Lung Transplantation; T. Tse, D.C. Chambers, P.M.A. Hopkins. The Prince Charles Hospital, Brisbane, QLD, Australia.

10:45 AM (362) PTLD after Lung Transplantation – Influence of CMV Prophylaxis on Incidence – Multicentre Centre Analysis and Review of the Literature; P. Jaksch, J. Gottlieb, C. Geltner, A. Simon, J. Ankersmit, W. Klepetko. Medical University Vienna, Vienna, Austria; LKH Natter, Innsbruck, Austria; Medical University Hannover, Hannover, Germany; Medical University Hannover, Hannover, Germany.


11:15 AM (364) Posterior Reversible Encephalopathy Syndrome after Lung Transplantation; L. Hatos-Agyi, A. Scheed, M. Keplinger, P. Jakusch, W. Klepetko. Medical University of Vienna, Vienna, Austria; Medical University Vienna, Vienna, Austria.

11:30 AM (365) Ambulatory Muscle Strength Recovery Is Significantly Delayed When Compared to Improvements in Lung Function and Six Minute Walk Distance after Lung Transplantation; J.R. Walsh, D.C. Chambers, R.J. Davis, H.E. Seale, N.R. Morris, F.D. Kermeen, P.M.A. Hopkins. The Prince Charles Hospital, Brisbane, QLD, Australia; Griffith University, Gold Coast, QLD, Australia.

10:30 AM – 12:00 PM
Concurrent Session 44: Late Complications Post Heart Transplantation (Continental C)
Chairs: Marian Zembala, MD, PhD, FESC and Daniel R. Goldstein, MD

10:30 AM (367) Lung Cancer after Heart Transplantation: Incidence and Prognosis. Data from the Spanish Post-Heart-Transplant Tumour Registry; M.G. Crespo-Leiro,1 N. Manito,2 G. Rabago,3 L. Almenar-Bonet,4 L.A. Alonso-Pulpon,5 S. Mirabet,6 J. Fernandez-Yanez,7 B. Diaz-Molina,8 F. Gonzalez-Vilchez,9 N. Romero,10 J.M. Arizon,11 J.F. Delgado,12 E. Roig,13 T. Blasco,14 D.A. Pascual-Figal,15 L. de la Fuente-Galan,16 J. Muniz,17 1Hospital Universitario A Coruña, A Coruña, Spain; 2Hospital Universitario de Bellvitge, Barcelona, Spain; 3Clinica Universitaria de Navarra, Pamplona, Spain; 4Hospital Universitario La Fe, Valencia, Spain; 5Hospital Universitario de Hierro, Madrid, Spain; 6Hospital Santa Creu i Sant Pau, Barcelona, Spain; 7Hospital General Universitario Gregorio Marañon, Madrid, Spain; 8Hospital Universitario Central de Asturias, Oviedo, Spain; 9Hospital Universitario Marques de Valdecilla, Santander, Spain; 10Hospital Virgen del Rocío, Sevilla, Spain; 11Hospital Universitario Reina Sofia, Córdoba, Spain; 12Hospital Universitario 12 de Octubre, Madrid, Spain; 13Hospital Clinic i Provincial, Barcelona, Spain; 14Hospital Universitario Miguel Servet, Zaragoza, Spain; 15Hospital Virgen de la Arrixaca, Murcia, Spain; 16Hospital Clinico de Valladolid, Valladolid, Spain; 17Instituto de Ciencias de la Salud, A Coruña, Spain.

10:45 AM (368) Outcomes after Chemotherapy for Post Transplant Lymphoproliferative Disorder in Pediatric Heart Transplant Recipients; M.E. Spotnitz,1 M.E. Richmond,2 J.D. Dayton,2 M.A. Orjuela,3 J.M. Chen,4 L.J. Addonizio.1,4 Columbia University College of Physicians and Surgeons, New York, NY; 2Columbia University Medical Center, Children's Hospital of New York-Presbyterian, New York, NY; 3Columbia University Medical Center, Children's Hospital of New York-Presbyterian, New York, NY; 4Columbia University Medical Center, Children's Hospital of New York-Presbyterian, New York, NY.


11:15 AM (370) The Incidence and Outcome of Sensitization in Patients Awaiting Re-do Heart Transplantation; M. Kawano,2 J. Patel,2 M. Kittleson,2 E. Reed,1 D. Gjertson,1 M. Cecka,1 A. Velleca,2 E. Stimpson,2 C. Burch,1 S. Davis,2 J. Moriguchi,2 A. Ardehali,7 J. Kobashigawa.2 1David Geffen School of Medicine at UCLA, Los Angeles, CA; 2 Cedars-Sinai Heart Institute, Los Angeles, CA.

11:30 AM (371) First Angioplasty Does Not Appear To Alter Outcome in Heart Transplant Patients with Newly Diagnosed Transplant Coronary Artery Disease; M. Kittleson,2 J. Patel,2 B. Azarbal,2 J. Moriguchi,2 M. Kawano,2 S. Davis,2 A. Hage,2 A. Ardehali,7 J. Kobashigawa.2 1David Geffen School of Medicine at UCLA, Los Angeles, CA; 2 Cedars-Sinai Heart Institute, Los Angeles, CA.

11:45 AM (372) Asymptomatic Positive CMV Serology Is Associated with Increased Risk for the Development of Transplant Coronary Artery Disease (TCAD): Who Needs Symptoms?; J. Patel,2 M. Kittleson,2 B. Kubak,1 M. Kawano,2 S. Davis,2 J. Moriguchi,2 A. Ardehali,7 J. Kobashigawa.2 1David Geffen School of Medicine at UCLA, Los Angeles, CA; 2 Cedars-Sinai Heart Institute, Los Angeles, CA.

10:30 AM – 12:00 PM
Concurrent Session 45: Transplantation for Pediatric Cardiomyopathies (Waldorf)
Chairs: Kimberly L. Gandy, MD, PhD and Charles E. Canter, MD
This symposium will provide important information about the specific outcomes of heart transplantation in children with different classes of cardiomyopathies. This information will be used to provide clinicians with a better understanding of the risks and benefits of transplantation in children with pediatric cardiomyopathies. This symposium will review the indications and outcomes of transplantation in patients with all forms of cardiomyopathy.
10:30 AM Classification of Cardiomyopathies and Impact of Genetic Diagnosis on Prognosis, Jeffrey A. Towbin, MD, Cincinnati Children’s Hospital Medical Center, Cincinnati, OH
10:45 AM Indications and Outcomes of Listing for Transplantation in Pediatric Cardiomyopathies, Daphne Hsu, MD, Children’s Hospital at Montefiore, Bronx, NY
11:00 AM Which Patients, What Device, and When to Use Mechanical Assist Support in Pediatric Cardiomyopathies? Robert D. B. Jaquiss, MD, Arkansas Children’s Hospital, Little Rock, AR
11:15 AM Outcomes of Transplantation in Patients With Dilated Cardiomyopathy, Richard Kirk, MA FRCP FRCPCH, Freeman Hospital, Newcastle Upon Tyne, United Kingdom
11:30 AM Outcomes of Transplantation in Patients With Restrictive Cardiomyopathy, Steven D. Zangwill, MD, Children's Hospital of Wisconsin, Milwaukee, WI
11:45 AM Outcomes of Transplantation in Patients With Hypertrophic Cardiomyopathy, Robert J. Gajarski, MD, CS Mott Children’s Hospital, Ann Arbor, MI

10:30 AM – 12:00 PM
Concurrent Session 46: What’s Hot! Best Abstracts from Mechanical Circulatory Support, Heart Transplantation, Lung Transplantation (Marquette)
Chairs: Richard N. Pierson, III, MD and Hermann Reichenspurner, MD, PhD

12:15 PM – 1:15 PM
Council Reports to the Membership and Board (Continental C)

1:30 PM – 4:30 PM
ISHLT Board of Directors Meeting (PDR 4)

GENERAL POSTER SESSION
Wednesday, April 21 – Friday, April 23, 2010
Southwest Exhibit Hall

(373) Does Race Mismatch Have an Impact on Outcome after Heart Transplantation?; S. Montgomery,2 M. Kawano,2 D. Lockhart,2 A. Velleca,2 C. Burch,1 J. Patel,2 S. Davis,2 M. Kittleson,2 J. Moriguchi,2 A. Ardehali,1 J. Kobashigawa,21 David Geffen School of Medicine at UCLA, Los Angeles, CA; 2Cedars-Sinai Heart Institute, Los Angeles, CA.

(374) The Threat of Medication Miscommunication in Non-English Speaking Heart Transplant Recipients; A. Velleca,2 C. Burch,1 S. Montgomery,2 D. Lockhart,2 J. Patel,2 M. Kittleson,2 M. Kawano,2 S. Davis,2 J. Moriguchi,2 A. Ardehali,1 J. Kobashigawa,21 David Geffen School of Medicine at UCLA, Los Angeles, CA; 2Cedars-Sinai Heart Institute, Los Angeles, CA.

(375) Impact of Ventricular Assist Device (VAD) Implantation on Clinical and Economic Outcomes of Heart Transplantation (HT) in the United States (US) from 2001-2006; H.K. Song,1 B. Diggs,1 F. Mcneil,1 K. Caddell,1 M. Slater,1 F. Tibayan,1 S. Guyton,1 E. Adler,2 A. Kim,2 Oregon Health and Science University, Portland, OR; 2Oregon Health and Science University, Portland, OR.


(377) Children’s Conceptions of Their Parent’s Lung Transplant; T.M. Leisfield,1 K. Wiggins,1 P. Fulbrook,21 The Prince Charles Hospital, Brisbane, QLD, Australia; 2The Prince Charles Hospital, Brisbane, QLD, Australia.

(379) Improved Bloodcompatibility of a Poly-4-Methyl-1-Pentene Gas Exchange Membrane by Endothelialization; B. Wiegmann, C. Hess, A. Hilfiker, A. Haverich, S. Fischer. Hannover Medical School, Hannover, Germany; Leibniz Research Laboratories for Biotechnology and Artificial Organs, Hannover, Germany.

(380) Non-Volume-Loaded Heart Provides a More Relevant Heterotopic Transplantation Model; K.R. Tang-Quan, J. Bartos, T. Deuse, R.C. Robbins, H. Reichenspurner, S. Schreper. University Heart Center Hamburg, Hamburg, Germany; Stanford University School of Medicine, Stanford, CA.


(382) Reduced Transplant Arteriosclerosis after Treatment with MMF and MMF in Combination with Ganciclovir in a Mouse Aortic Transplant Model; J. Hoffmann, M. Bohm, S. Abee-Ohl, M. Weyand, M.M. Ensminger. Friedrich-Alexander-University of Erlangen-Nürnberg, Erlangen, Germany.

(383) MyD88-Independent Signaling Pathway Is Involved with Lung Ischemic Preconditioning; A. Shimamoto, Y. Yajima, S. Shomura, M. Takao, H. Shimpo. Mie University Graduate School of Medicine, Tsu, Japan.

(384) Eglf7 Prevents Coronary Endothelial ICAM-1 Expression in Response to Calcineurin Inhibition; M.V. Badiwala, L.C. Tumiati, A. Ghashghai, J.M. Joseph, V. Rao. Toronto General Hospital, Toronto, ON, Canada.

(385) Expression of a Stabilized Hypoxia Inducible Factor-1 Reduces Cardiomyocyte Apoptosis and Prevents Cardiac Allograft Vasculopathy; M.A.I. Keranen, A.I. Nykanen, R. Krebs, K. Pajusola, K. Alitalo, K.B. Lemstrom. University of Helsinki and Helsinki University Central Hospital, Helsinki, Finland; Biomedicum Helsinki, University of Helsinki and Helsinki University Central Hospital, Helsinki, Finland; University of Helsinki and Helsinki University Central Hospital, Helsinki, Finland.

(386) Contribution of Pre-Existing Vascular Disease to Allograft Vasculopathy in Mice; A. Zaki, J. Jordan, G. Hirsch, B. Ross, T. Lee. Dalhousie University, Halifax, NS, Canada.

(387) The Role of Plaque Haemorrhage in Progression of Coronary Allograft Vasculopathy; C. Castellani, A. Angelini, Q. de Boer, C. van der Loos, M. Fedrigo, A. Gambino, G. Gerossi, G. Thiene, A.C. van der Wal. University of Padua, Padua, Italy; Academic Medical Center/University of Amsterdam, Amsterdam, Netherlands; University of Padua, Padua, Italy.


(389) The Indirect Alloimmune Response Causes Endothelial Dysfunction without Endothelial Replacement after Cardiac Transplantation; Y. Xu, A. McCormack, A. Chester, B. Hariri, P. Sarathchandra, M.L. Rose. Imperial College London, London, United Kingdom.

(390) Impact of Topically-Applied Preservation Solutions on Mucociliary Clearance and Tracheal Ischemic Injury in Rats; A.E. de Azevedo-Pereira, K.A. Oliveira, R. Pazetti, J. Saka, M. Cantian, P.M. Pego-Fernandes, F.B. Jatene. Heart Institute, University of São Paulo Medical School, São Paulo, Brazil; Heart Institute, University of São Paulo Medical School, São Paulo, Brazil.
(391) T-Bet Deficiency Alters Murine Obliterative Airway Disease Immunopathology and Is Associated with Both Type 1 and Type 17 Effector T Cell Responses; E.A. Lendermon, E.R. John, H. Miller, P.D. Shah, J.B. Orens, A.C. Myers, J.F. McDyer, Johns Hopkins, Baltimore, MD; Johns Hopkins, Baltimore, MD.

(392) Interaction between -1-Antitrypsin (AAT) and A-Defensins in Regulating Immune Responses Leading to Chronic Rejection Following Human Lung Transplantation; D. Saini, S. Ramachandran, N. Steward, A. Aloum, R. Hachem, E. Trulock, A. Patterson, T. Mohanakumar, Washington University in St Louis, St. Louis, MO; Washington University in St Louis, St. Louis, MO.

(393) The Gender Divide: Does Donor Gender Matter for Mesenchymal Stem Cell Transplantation; C. Pahrmann, K.R. Tang-Quan, M. Yamada, T. Deuse, R. Robbins, H. Reichenspumger, S. Schreperia, University Heart Center Hamburg, Hamburg, Germany; Stanford University School of Medicine, Stanford, Germany.

(394) The Role of CCR4 during the Pathogenesis of Murine Obliterative Bronchiolitis Post-Transplantation; V. Palchevskiy, Y.Y. Xue, R. Kern, S.S. Weigt, S. Hu, A. Derhovanessian, S.X. Song, A. Gregson, R. Elashoff, J.P. Lynch, J.A. Belperio, University of California, Los Angeles, CA; University of California, Los Angeles, CA; University of California, Los Angeles, CA; University of California, Los Angeles, CA.


(396) Coronary Intervention in Lung Transplant Candidates – Does It Impact Survival; C. Chaparro, W. Karolak, C. Volling, L. Daniel, D. Delgado, F. Chen, M. Cypel, C. Guiterrez, C. Whytehead, L.G. Singer, M. Hutchaeon, C.-W. Chow, K. McRae, V. Rao, R.J. Cusimano, M. de Perrot, T. Waddel, A. Pierre, K. Yasufuku, S. Keshavjee, Toronto General Hospital, University of Toronto, Toronto, ON, Canada; Toronto General Hospital, University of Toronto, Toronto, ON, Canada; University of California, Los Angeles, CA; University of California, Los Angeles, CA.

(397) Post Lung Transplant Cardiovascular Complications – Role of Cardiovascular MRI; H. Seethamraju, D. Shah, R. Kesavan, S. Bollineni, J. Estep, M. Loebe, G.P. Noon, A. Shahr, S. Scheinin, S. Jyothula, G. Torre, Baylor College of Medicine, Houston, TX; Methodist Debackey Heart and Vascular Center, Houston, TX.

(398) Reduction in Venous Thromboembolism Following Prophylaxis Modification in Lung Transplantation Patients; J.P. Gagermeier, C.G. Alex, D.F. Dilling, T. Patel, C.H. Wigfield, R.B. Love, Loyola University Medical Center, Maywood, IL; Loyola University Medical Center, Maywood, IL.


(400) Aggressive Skin Cancers Associated with Prolonged Voriconazole Therapy in 3 Lung Transplant Patients; S. Quetant, C. Saint-Raymond, A. Hugon, P. Bedouch, O. Epaulard, C. Pison, M.-T. Leccia, Grenoble University Hospital, Grenoble, France; Grenoble University Hospital, Grenoble, France; Grenoble University Hospital, Grenoble, France; Grenoble University Hospital, Grenoble, France; Grenoble University Hospital, Grenoble, France.

(401) Post Transplant Neoplastic Disease Following Lung Transplant: 17-Years Single Centre Experience; P. Tofaro, C. Pellegrini, M. Savasta, S. Nicolardi, T. Oggiorno, G. Orlando, A.M. D’Armini, M. Vigan, IRCCS Foundation S Matteo, Pavia, Italy; IRCCS Foundation S Matteo, Pavia, Italy; IRCCS Foundation S Matteo, Pavia, Italy; University School of Medicine, Pavia, Italy.

(403) The Incidence of Oropharyngeal Dysphagia and Associated Risk Factors Following Double Lung Transplantation: A Retrospective Study; S.A. Skoretz,1,2 M. Graham,2 G. Kamitomo,2 R. Martino.1,3 1University of Toronto, Toronto, ON, Canada; 2University of Alberta Hospital, Edmonton, AB, Canada; 3Toronto Western Research Institute, Toronto, ON, Canada.

(404) Comparative Outcome of Transplantation for Eisenmenger Syndrome and Other Pulmonary Arterial Hypertension Indications; E. Fadel, O. Mercier, S. Mussot, D. Fabre, P. Dartelove. Hopital Marie Lannelongue, Le Plessis Robinson, France.

(405) Peri-Operative Hyperglycemia and Acute Cellular Rejection 12 Months after Lung Transplantation; S. Indacochea,1 A. DePorre,2 D.F. Dilling,1 N.V. Emanuele,1 J.P. Gagermeier,1 C.H. Wigfield,2 C.G. Alex,1 R.B. Love,2 M.A. Emanuele.1 1Loyola University Medical Center, Maywood, IL; 2Loyola University Medical Center, Maywood, IL; 3Loyola University Stritch School of Medicine, Maywood, IL.

(406) The Clinical Relevance of Mannose-Binding Lectin (MBL) in Long Term Survival of Lung Transplant Recipients; J.M. Kwakkel-van Erp,1 E.A. van de Graaf,1 A.W.M. Paantjens,2 D.A. van Kessel,3 J.M.M. van den Bosch,3 J.C. Grutters,3 H. Otten.1 1Universitary Medical Center Utrecht, Utrecht, Netherlands; 2Universitary Medical Center Utrecht, Utrecht, Netherlands; 3Antonius Hospital, Nieuwegein, Netherlands.

(407) Comparison of Outcome Following Heart/Lung Transplantation for Chronic Thromboembolic Pulmonary Hypertension and Idiopathic Pulmonary Arterial Hypertension; R.V. Venkateswaran, D. Jenkins, J. Dunning, S. Tsui, J. Wallwork, J. Parmar. Papworth Hospital NHS Foundation Trust, Cambridge, United Kingdom.

(408) Benefits of a Structured Lung Transplant Curriculum in Pulmonary/Critical Care Fellowship; D. Hayes, Jr.,1 R. Berger,2 E. Diaz-Guzman,2 T.W. Mullett,3 S.S. Kraman.1 1University of Kentucky College of Medicine, Lexington, KY; 2University of Kentucky College of Medicine, Lexington, KY; 3University of Kentucky College of Medicine, Lexington, KY.

(409) Minimizing Post Operative Ventilation Times in Lung Transplant Recipients; J.D. Maloney,1 S. Osaki,1 H. Thomas,1 R.D. Cornwell,2 K.C. Meyer,2 N.C. De Oliveira.1 1University of Wisconsin, Madison, WI; 2University of Wisconsin, Madison, WI.

(410) Outcome of Lung Graft Volume Reduction for Oversized Donors during Pulmonary Transplantation; S. Shanmuganathan, B. Tanveer, S. Clark. The Newcastle upon Tyne Hospitals NHS Trust, Newcastle upon Tyne, United Kingdom.


(412) Antibiotic Desensitisation in Cystic Fibrosis Patients with a History of Hypersensitivity Undergoing Lung Transplantation Is Not Mandatory; T. Tse,1 P.M.A. Hopkins,1 M.W. France,2 P.J. Masel,2 S.C. Bell,2 F.D. Kermeen,1 D.C. Chambers.1 1The Prince Charles Hospital, Brisbane, QLD, Australia; 2The Prince Charles Hospital, Brisbane, QLD, Australia.

(413) Impact of the UNOS Lung Allocation Score on Lung Transplantation for Chronic Obstructive Pulmonary Disease; S. Osaki,1 J.D. Maloney,1 R.D. Cornwell,2 K.C. Meyer,2 N.M. Edwards,1 N.C. De Oliveira.1 1University of Wisconsin, Madison, WI; 2University of Wisconsin, Madison, WI.
(414) Lung Transplantation in Lithuania: Two Years Experience; K. Malakauskas,1 L. Jankauskiene,2 E. Gasiuniene,1 A. Vitkauskiene,3 V. Sarasauskas,4 N. Vaguliene,5 E. Sirvinskis,2 R. Bolys,2 R. Benetis,2 R. Sakalauskas.1 1Kaunas University of Medicine, Kaunas, Eiveniu 2, Lithuania; 2Kaunas University of Medicine, Kaunas, Eiveniu 2, Lithuania; 3Kaunas University of Medicine, Kaunas, Eiveniu 2, Lithuania; 4Kaunas University of Medicine, Kaunas, Eiveniu 2, Lithuania; 5Kaunas University of Medicine, Kaunas, Eiveniu 2, Lithuania.

(415) Pre-Transplant Allosensitization Is a Barrier to Lung Transplantation; J.T. Weber,1 B.F. Meyers,2 A. Patterson,2 E.P. Trulock,1 R.R. Hachem.1 1Washington University School of Medicine, Saint Louis, MO; 2Washington University School of Medicine, Saint Louis, MO.


(417) Analysis of Nontuberculous Mycobacteria Infections in Lung Transplant Recipients; R.R. Pillai,1 V.G. Valentine,1 S.D. Lick,1 G.A. Lombard,2 S.G. LaPlace,2 K.J. McNally,2 L. Seoane.2 1University of Texas, Medical Branch, Galveston, TX; 2Ochsner Medical Center, New Orleans, LA.

(418) Extracorporeal Membrane Oxygenation as a Bridge to Lung Transplantation in Severe End Stage Pulmonary Disease; P. Hammainen,1 H. Schersten,2 K. Lemstrom,2 G.C. Riise,3 S. Kukkonen,5 K. Sward,4 J. Sipponen,1 M. Silverborn,2 G. Dellgren,3 1Helsinki University Hospital, Helsinki, Finland; 2Sahlgrenska University Hospital, Göteborg, Sweden; 3Sahlgrenska University Hospital, Göteborg, Sweden; 4Sahlgrenska University Hospital, Göteborg, Sweden; 5Helsinki University Hospital, Helsinki, Finland.

(419) Significant Side Effect Burden of Voriconazole Curtails Clinical Utility in Lung Transplantation; C.A. Beck, D.C. Chambers, F.D. Kermeen, T. Tse, P.M.A. Hopkins. The Prince Charles Hospital, Brisbane, QLD, Australia.

(420) The Impact of Repeat HLA Mismatch on Pulmonary Re-transplantation; A. Zeevi,1 D. Zaldonis,1 K. Spichy,1 A. Girmeta,2 J. Howe,1 L. Jelinek,1 J. Lomago,1 M. Crespo,2 J. Pilewski,1 C. Bermudez,1 Y. Toyoda.1 1University of Pittsburgh, Pittsburgh, PA; 2University of Cincinnati Academic Health Center, Cincinnati, OH.


(422) First Year Body Mass Index Trajectory Predicts Subsequent Survival in Lung Transplant Recipients; J.L. McMillan, P.M.A. Hopkins, S.T. Yerkovich, K.M. Herd, D.C. Chambers. The Prince Charles Hospital, Brisbane, QLD, Australia.


(424) Impact of Pharmacokinetics on the Anticipated Duration of Calcineurin Inhibition after Inhalation of Cyclosporine Solution; R.W. Niven, T.E. Corcoran.1 APT Pharmaceuticals, Burlingame, CA; 2University of Pittsburgh Medical Center, Pittsburgh, PA.

(425) Impact of Body Mass Index on Survival Following Lung Transplantation; J.K. Bhama,1 D. Zaldonis,1 N. Shigemura,1 T. Horai,1 S. Tabata,1 P. Bonde,1 B. Sareyyuoglu,1 J.M. Pilewski,2 M. Crespo,2 B.A. Johnson,2 P. George,2 S. Gilbert,2 C.A. Bermudez,2 M.A. Zenati,2 Y. Toyoda.1 1University of Pittsburgh Medical Center, Pittsburgh, PA; 2University of Pittsburgh Medical Center, Pittsburgh, PA.
(426) The Combined Australian Experience with Human Swine Influenza H1N1 in Lung Transplant Recipients; B.J.H. Ng,1 A.R. Gianville,2 J. D’Costa,2 G. Snell,3 M. Musk,4 M. Holmes,5 D.C. Chambers,1 P.M.A. Hopkins.1,7 The Prince Charles Hospital, Chermside, QLD, Australia; 2St Vincents Hospital, Darlinghurst, NSW, Australia; 3The Alfred Hospital, Melbourne, Vic, Australia; 4Royal Perth Hospital, Perth, Western Australia, Australia; 5Royal Adelaide Hospital, Adelaide, South Australia, Australia.

(427) Reduced Survival in Lung Transplant Recipients with Bile Acids Aspiration Despite Azithromycin Therapy; V. Mertens,1 K. Blondeau,1 B. Vanaudenaerde,2 R. Vos,2 A. Pauwels,1 G. Verleden,2,3 D.E. Van Raemdonck,1 D. Sifrim,1,4 L.J. Dupont,2,3 1University Hospital Gasthuisberg, Leuven, Belgium; 2Katholieke Universiteit Leuven, Leuven, Belgium; 3University Hospital Gasthuisberg, Leuven, Belgium; 4Barts and The London School of Medicine and Dentistry, University of London, London, United Kingdom.

(428) Initial Experience with Concomitant Surgery of Lung Transplantation and Tricuspid Valve Repair for Patients with Severe Pulmonary Hypertension; N. Shigemura,1 B. Sareyyupoglu,1 K. Jackson,2 J. Pilewski,2 J. Bhama,1 S. Gilbert,1 C. Bermudez,1 Y. Toyoda.1 1University of Pittsburgh Medical Center, Pittsburgh, PA; 2University of Pittsburgh Medical Center, Pittsburgh, PA.

(429) Long Term Outcome of Lung Transplantation in Previous Intravenous Drug Users with Talc Lung Granulomatosis; J.G. Weinkauf,1 R. Nador,1 A. Kapasi,1 K. Jackson,2 K. LaBranche,2 L. Puttagunta,3 K.C. Stewart,4 J. Mullen,4 D.L. Modry,4 D.C. Lien.1 1University of Alberta, Edmonton, AB, Canada; 2University of Alberta, Edmonton, AB, Canada; 3University of Alberta, Edmonton, AB, Canada; 4University of Alberta, Edmonton, AB, Canada.


(432) Near-Infrared Spectroscopy in Lung Transplant Patients: Correlation with Invasive Hemodynamic Measurements; A.N. Ibrahimiya,1 G. Singh,1 H. Kim,1 A. Iribarne,1 R. Sladen,2 J. Sonett,1 M. Bacchetta,1 1Columbia University College of Physicians and Surgeons, New York, NY; 2Columbia University College of Physicians and Surgeons, New York, NY.


(434) Statin Therapy Is Associated with Reduced Pulmonary Artery Pressures in Lung Transplant Candidates with COPD; R.M. Reed, R. Girgis. Johns Hopkins University School of Medicine, Baltimore, MD.

(435) Pulmonary Artery Hypertension: Endothelial Dysfunction and Statin Treatment; E.M. Bader,7 R. Zolty.2 1Jacobi Medical Center, Albert Einstein College of Medicine, Bronx, NY; 2Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, NY.

(436) Mortality and Readmission Rates in Hyponatremic Patients with Pulmonary Hypertension and Right Ventricular Failure; A. Rabinovitz,7 R. Zolty.2 1Jacobi Medical Center, Bronx, NY; 2Montefiore Medical Center, Bronx, NY.


(439) Does Diastolic Dysfunction Contribute to Pulmonary Hypertension in Patients with Advanced COPD Awaiting Lung Transplantation?; N. Selimovic, B. Andersson, M. Lomsky, G.C. Risse, B. Rundqvist. Sahlgrenska University Hospital, Gothenburg, Sweden.


(441) Predictors of Right Ventricular Function in Lung Transplant Candidates; N. Selimovic, B. Andersson, M. Lomsky, G.C. Risse, B. Rundqvist. Sahlgrenska University Hospital, Gothenburg, Sweden.

(442) Lower Weight Related to Elevated Liver Enzymes in Pulmonary Hypertension Patients Treated with Bosentan; E.A. Kobashigawa, J.B. Schwartz, W.-C. Hsueh, N. Bendjilali, A. Wu, T. De Marco. University of California San Francisco, San Francisco, CA; San Francisco General Hospital, San Francisco, CA.

(443) WITHDRAWN

(444) Severe Hypoxia in Eisenmenger Syndrome Does Not Preclude Performance of the Six Minute Walk Test; R.J. Davis, K. Hall, J.R. Walsh, H.E. Seale, J.E. Harris, D.J. Radford, F.D. Kermeen. The Prince Charles Hospital, Brisbane, QLD, Australia; The Prince Charles Hospital, Brisbane, QLD, Australia.


(446) Quantitative Analysis of Nerve Density across Airway Anastomosis in Lung Transplant Recipients; A.G. Duarte, G.A. Campbell, V.G. Valentine, A.C. Myers. University of Texas Medical Branch, Galveston, TX; Johns Hopkins University, Baltimore, MD.

(447) Quilty Is a Risk Factor for Microvasculopathy in Biopsy Following Heart Transplantation – Evidence from a Prospective Clinical Study; N.E. Hiemann, E. Wellnhofer, H.B. Lehmkuhl, C. Knoßalla, R. Hetzer, R. Meyer. Deutsches Herzzentrum Berlin, Berlin, Germany; Deutsches Herzzentrum Berlin, Berlin, Germany.

(448) Tissue Plasminogen Activator Is the Most Important Component of a Novel Thrombosis/Activation (TA) Score for Predicting Cardiac Allograft Vasculopathy Following Heart Transplantation; C.A. Labarrere, J.R. Woods, J.W. Hardin, G.L. Campana, M.A. Ortiz, B.R. Jaeger, B. Reichart, L.A. Baldridge, J.M. Bonnin, A. Currin, S.K. Cosgrove, P.C. Kirlin, J.A. O’Donnell, D.A. Hormuth, T.C. Wozniak. Methodist Research Institute, Clarian Health Partners, Indianapolis, IN; University of South Carolina, Columbia, SC; Dr Stein und Kollegen, Monchengladbach, Germany; Ludwig-Maximilians-Universitat, Munchen, Germany; Indiana University School of Medicine, Indianapolis, IN; Clarian Health Partners, Indianapolis, IN; Krankert Institute of Cardiology, Indianapolis, IN.
Relating Microarray Results from 105 Heart Allograft Biopsies to Pathology and Function: Molecular Phenotypes of Myocardial Inflammation and Injury Correlate with Impaired Function and Histological Signs of Microcirculation Injury; M. Mengel, J. Chang, D. Kim, B. Sis, J. Burton, W. Tymchak, P. Halloran. University of Alberta, Edmonton, Canada.

Characterization of IgM and Complement within CAV Lesions; E.L. Moseley, M.J. Goddard, J. Wallwork, C. Atkinson. Papworth Hospital NHS Trust, Cambridge, United Kingdom; Medical University of South Carolina, Charleston; Papworth Hospital NHS Trust, Cambridge, United Kingdom.


Differential Leukocyte Gene Expression in Cardiac Transplant Recipients Receiving Tacrolimus Compared to Cyclosporine; J. Patel, A.J. Hicks, T. Rowe, S.R. Hankins, H.J. Eisen. Drexel University College of Medicine, Philadelphia, PA; Hahnemann University Hospital, Philadelphia, PA.

Lack of Association between Pre-Transplant MICA Antibodies and Cardiac Allograft Dysfunction; M.A. McDonald, J. Braga, P. Billia, S. Tapiawala, H.J. Ross, K.J. Tinckam. University Health Network, Toronto, ON, Canada; University Health Network, Toronto, ON, Canada; Edmonton, AB.


Heart Transplant Therapy in United States Veterans: 16-year Experience at A Single Center; D.R. Murray, S. Osaki, P. Jewel-Ripp, M.R. Johnson, L. Lozonschi, N.M. Edwards, T. Kohmoto. University of Wisconsin School of Medicine and Public Health, and William S. Middleton Memorial Veterans Hospital, Madison, WI; University of Wisconsin School of Medicine and Public Health, and William S. Middleton Memorial Veterans Hospital, Madison, WI.

Does Listing Status Affect Cost of Heart Transplantation?; W. Sherman, J. Kobashigawa, M. Hamilton, D. Gjertson, J. Gomez Abraham, H. Laks, A. Ardehali. David Geffen School of Medicine at UCLA, Los Angeles, CA; David Geffen School of Medicine at UCLA/Cedars-Sinai Heart Institute, Los Angeles, CA.

Positive Flow Crossmatches Associated with Poorer Survival; V. Kasirajan, M. Flattery, P. Kimball. Medical College of Virginia Hospitals, Richmond, VA.

Positive Flow Cytometry Crossmatches and HLA Antibodies May Not Be Contraindications to Heart Transplantation; R.H. Kerman, R. Radovancevic, P.A. Allison, E. McKissick, R. Bogaev, A.W. Bracey, S. Allison, I. Gregoric, O.H. Frazier. University of Texas Health Science Center–Houston, Houston, TX; St. Luke’s Episcopal Hospital, Houston, TX.

Long-Term Follow-Up (>20 Years) after Orthotopic Heart Transplantation: Our Experience; S. Mastrobuoni, A.M. Dell’Aquila, P.M. Azcarate, G. Basterri, G. Rabago, J. Herreros. Clínica Universidad de Navarra, Pamplona, Navarra, Spain; Clínica Universidad de Navarra, Pamplona, Navarra, Spain; Clínica Universidad de Navarra, Pamplona, Navarra, Spain.

Does MFI Quantitation of Circulating Antibodies Correlate with Positive Cytotoxicity?; M. Kittleson,2 J. Patel,1 E. Reed,1 Q. Zhang,1 M. Cecka, E. Stimpson,1 A. Velleca,2 C. Burch,1 M. Kawano,2 S. Davis,1 J. Moriguchi,1 A. Ardehali,1 J. Kobashigawa,2 1David Geffen School of Medicine at UCLA, Los Angeles, CA; 2Cedars-Sinai Heart Institute, Los Angeles, CA.

RVSWI Is an Independent Predictor of Need for MCS and/or HT in Stable Outpatients with NYHA Class III HF; G.R. Stevens,1 J. Peacock,1 A. Levin,1 P. Pak,2 N. Uriel,1 P.C. Schulze,1 P. Colombo,1 U. Jorde,1 Y. Naka,2 D. Mancini,1 M. Farr,1 1Columbia University Medical Center, New York, NY; 2Columbia University Medical Center, New York, NY.


Should Aprotinin Be Used in Heart and Lung Transplantation?; M.I. Mydin,1 M. Hawari,1 R. Venkateswaran,1 J. Parmar,1 C. Sudarshan,1 A. Vuylsteke,2 D. Jenkins,1 J. Dunning,1 S. Tsu,1 1Papworth Hospital, Papworth Everard, Cambridge, United Kingdom; 2Papworth Hospital, Papworth Everard, Cambridge, United Kingdom.

Low Immune Cell Function Assay Value Predicts Increased Risk for Cytomegaloviral, But Not Other Opportunistic Infections in Heart Transplant Patients: A Mid America Experience; T.M. Khumri,1 K. St Clair,1 S.L. Lawhorn,1 A. Magalski,1 T.L. Stevens,1 A.M. Borkon,2 A. Kao.1 1Mid America Heart Institute, Kansas City, MO; 2Mid America Heart Institute, Kansas City, MO.

High Plasma N-Terminal Brain Natriuretic Propetide Levels Are a Strong Predictor of Death in Patients after Orthotopic Heart Transplantation; T. Zielinski, M. Piotrowska, M. Sobieszczanska-Malek, K. Komuda, J. Korewifici. Institute of Cardiology, Warsaw, Poland.


Are There Differences in Gene Expression as Reflected by Molecular Diagnostic Testing between African-American and Non-African American Cardiac Transplant Recipients?; A.J. Hicks,1 T. Rowe,2 J. Patel,1 G. Mwandia,1 S.R. Hankins,1 H.J. Eisen.1 1Drexel University College of Medicine, Philadelphia, PA; 2Hahnemann University Hospital, Philadelphia, PA.

CD4+ CD25+ Regulatory T-cell Levels Are Associated with Cardiac Allograft Vasculopathy; S. Aharinejad,1,2 M. Gmeiner,2 S. Rodler,1 A. Thomas,2 T. Lucas,2 G. Lauffer,1 A. Zuckermann,1 M. Grimm.1 1Medical University of Vienna, Vienna, Austria; 2Medical University of Vienna, Vienna, Austria.
(474) Interaction of CMV Prophylaxis and Pre-Emptive Strategies with Immunosuppressive Therapy: Potential Antiviral Effect of Everolimus; L. Potena,1 C. d’Agostino,2 D. Abate,4 G. Magnani,1 F. Baccolini,3 T. Ionico,7 F. Grigioni,1 A. Gambino,2 D. Sgarabotto,5 G. Toscano,2 A. Branzi,1 G. Gerosa.2 1University of Bologna, Bologna, Italy; 2University of Padua, Padua, Italy; 3University of Bologna, Bologna, Italy; 4University of Padua, Padua, Italy; 5University of Padua, Padua, Italy; 6University of Padua, Padua, Italy.

(475) Graftvasculopathy: Have We Learned Something after All These Years?; S.L. Mahr, A.Z. Aliabadi, D. Dunkler, F. Eskandary, M. Grommer, D. Zimpfer, G. Lauffer, A.O. Zuckermann. Medical University of Vienna, Vienna, Austria.

(476) Acute Kidney Injury in Heart Transplant Patients Assessed by RIFLE, AKIN, and Delta-Creatinine: Implications on Outcome; A. Schiferer,1 D. Hutschala,1 D. Dunkler,2 M. Hiesmayr,1 A. Zuckermann,3 E. Tschemko.7 1Medical University of Vienna, Vienna, Austria; 2Medical University of Vienna, Vienna, Austria; 3Medical University of Vienna, Vienna, Austria.

(477) Levosimendan for Primary Graft Failure after Heart Transplantation: A Three-Year Follow up; A. Beiras-Fernandez,1 F. Weis,2 K. Kaczmarek,4 M. Weis,5 P. Uberfuhr,1 F. Kur,1 B. Reichart.1 1LM-University, Munich, Germany; 2LM-University, Munich, Germany.

(478) Late Gadolinium Enhancement Patterns on Cardiac Magnetic Resonance Images in Heart Transplant Patients; C. Vittori,1 M. Cipriani,1 P. Pedrotti,1 S. Dellegrottaglie,7 S. Pedretti,1 G. Bruschi,1 A. Roghi,1 M. Frigerio,1 Niguarda Ca’ Granda Hospital, Milano, Italy; 2Federico II University, Napoli, Italy.


(480) Feasibility of Alikiren for Treatment of Refractory Arterial Hypertension in Heart Transplant Recipients; M. Adam,1 S. Meyer,1 F.M. Wagner,2 T. Deuse,2 H. Reichenspurner,2 A. Costard-Jaeckle.1 1University Heart Center, Hamburg, Germany; 2University Heart Center, Hamburg, Germany.


(482) Prevalence of Kidney Function in Heart Transplant Recipients Using New CKD-EPI Formula; P. Przybylowski,1 J.M. Małyszko,4 J. Małyszko.2 1Collegium Medicum, Jagiellonian University, Krakow, Poland; 2Medical University Białystok, Białystok, Poland.

(483) Significance of Pre Transplant Donor Specific HLA Antibodies and Post Transplant Cardiac Allograft Vasculopathy; M.J. Gandhi,1 S.R. De Goey,1 N. Periera,2 S. Kushwaha,2 B. Edwards,2 S. Park,2 A. Clavell,2 J. Schirger,2 R. Rodeheffer,4 R. Frantz,2 R.C. Daly,2 Mayo Clinic, Rochester, MN; 2Mayo Clinic, Rochester, MN.


(485) Inadequate Blood Pressure Control in Orthotopic Heart Transplant Recipients (OHT); P. Przybylowski,1 J.M. Małyszko,4 J.M. Małyszko.2 1Collegium Medicum, Jagiellonian University, Krakow, Poland; 2Medical University Białystok, Białystok, Poland.
The Influence of VAD Bridging in Different Gender on Outcome Following Heart Transplantation; S. Klotz, H. Welp, J.R. Sindermann, H.H. Scheld. University Hospital Muenster, Muenster, Germany.


The Etiology of Allograft Vasculopathy; M.H. Hart-Matyas, S. Nejat, B.M. Ross, G.M. Hirsch, T.D.G. Lee. Dalhousie University, Halifax, NS, Canada; Dalhousie University, Halifax, NS, Canada; Dalhousie University, Halifax, NS, Canada.

Cilostazol as an Adjunct to Cyclosporine Prevents Neointimal Hyperplasia after Vascular Injury; M.V. Badiwala, L.C. Tumiati, D.H. Delgado, H.J. Ross, V. Rao. Toronto General Hospital, Toronto, ON, Canada.


Everolimus for the Prevention of Microvascular Injury in Biopsy in Cardiac Transplant Recipients; Preliminary Results from Re-Evaluation of the RAD B253 Trial; N.E. Hiemann, C. Bara, J. Segovia, S. Simonsen, M. Crespo-Leiro, H. Eiskjaer, J. Vanhaecke, A. Poncelet, P. Przybysłowski, M. Frigerio, H.B. Lehmkuhl, R. Meyer. Deutsches Herzzentrum Berlin, Berlin, Germany; Medizinische Hochschule Hannover, Hannover, Germany; Hospital Puerta de Hierro Majadahonda, Madrid, Spain; Oslo University Hospital, Rikshospitalet, Oslo, Norway; Hospital Universitario Juan Canalejo, La Coruna, Spain; Aarhus University Hospital, Skejby, Denmark; University Hospital Gasthuisberg, Leuven, Belgium; Cliniques Universitaires Saint-Luc, Brussels, Belgium; Jagiellonian University, John Paul II Hospital, Krakow, Poland; Az. Ospedaliera Ospedale Niguarda-Ca’ Granda, Milan, Italy.

Incidence of Tacrolimus-Associated Hyperammonemia in a Cohort of Lung Transplant Recipients; J. Rusinak, E. Greenhalgh, D.F. Dilling, C.H. Wigfield, J.P. Gagermeier, R.B. Love, C.G. Alex. Loyola University Medical Center, Maywood, IL; Loyola University Medical Center, Maywood, IL; Loyola University Medical Center, Maywood, IL.


Anti-Thymocyte Globulin Preserves Renal Function in Heart Transplantation; A.B. Cochrane, M.C. Chu, S.E. Fedson. Univ of Chicago, Chicago, IL; Univ of Chicago, Chicago, IL.


Tacrolimus Versus Cyclosporine in Pediatric Lung Transplantation; O. Elidemir, S.M. Moonnumakal, E.D. McKenzie, J.S. Heinle, D.L. Morales, J.A. Rama, E.O. Smith, G.B. Mallory, M.G. Schecter. Baylor College of Medicine, Houston, TX; Baylor College of Medicine, Houston, TX.

Cardiac MRI in the Assessment and Management of Heart Failure; D. Arumugam, R. Slaughter, M. Brown, G. Javorsky, D. Platts. The Prince Charles Hospital, Brisbane, QLD, Australia.

WITHDRAWN

Montreal Heart Institute, Montreal, QC, Canada; Montreal Heart Institute Coordinating Center, Montreal, QC, Canada.


Montreal Heart Institute, Montreal, QC, Canada; Montreal Heart Institute Coordinating Center (MHICC), Montreal, QC, Canada.

Efficacy of Immunoadsorption as Bridge-to-Transplant Therapy in Patients with Idiopathic Dilated Cardiomyopathy and Evidence of Beta-1 Adrenoceptor Autoantibodies; M. Dandel, G. Wallukat, A. Englert, H.B. Lehmkuhl, R. Hetzer.

Deutsches Herzzentrum Berlin, Berlin, Germany; Max Delbrück Centrum für Molekulare Medizin, Berlin, Germany.


Columbia University Medical Center, New York, NY; Columbia University Medical Center, New York, NY.


Newcastle University, Newcastle upon Tyne, Tyne and Wear, United Kingdom; Freeman Hospital, Newcastle upon Tyne, Tyne and Wear, United Kingdom; University of Edinburgh, Edinburgh, Scotland, United Kingdom.

Retrograde Flush Is More Effective Than Heparinization in the Uncontrolled Non-Heart-Beating Donor; C. Van De Wauwer, A. Neyrinck, F. Rega, G.M. Verleden, T. Lerut, D. Van Raemdonck.


Effect of N-Acetylcysteine on Acute Allograft Rejection after Lung Transplantation; B.V. Erne, W. Jungraithmayr, S. Arni, W. Weder, I. Inci. University Hospital Zurich, Zurich, Switzerland.


Queen Elizabeth Hospital, University Hospital Birmingham NHS Foundation Trust, Birmingham, United Kingdom; University Hospital Birmingham NHS Foundation Trust, Birmingham, United Kingdom; Bristol Heart Institute, University of Bristol, Bristol, United Kingdom; NHS Blood and Transplant, Bristol, United Kingdom; Harefield Hospital, Royal Brompton and Harefield Hospital NHS Trust, Harefield, Middlesex, United Kingdom; On Behalf of the Steering Group, UK Cardiothoracic Transplant Audit, United Kingdom.


(512) Increasing the Donor Pool by the Use of a Lung Donor Quality Score; J.M. Smits, W. van der Bij, D. Van Raemdonck, A.O. Rahmel. Eurotransplant, Leiden, Netherlands;

(513) Tachycardia but Not T Wave Inversion or QTc Duration Is Associated with Donor Heart Injury; V.B. Dronavalli, J.N. Townend, C.A. Rogers, H. Thomas, N.R. Banner, R.S. Bonser. Queen Elizabeth Hospital, University Hospital Birmingham NHS Foundation Trust, Birmingham, United Kingdom; Royal Brompton and Harefield Hospital NHS Trust, Harefield, Middlesex, United Kingdom; Bristol Heart Institute, University of Bristol, Bristol, United Kingdom;

(514) The Effect of Direct Hemoperfusion with a Polymyxin B-Immoviblized Fiber Column (DHP-PMX therapy) on Pulmonary Ischemia-Reperfusion Injury in a Canine Model; K. Oshima, T. Akao, K. Kobayashi, K. Matsumoto, I. Takeyoshi. Gunma University Hospital, Maebashi, Gunma, Japan;

(515) Mitochondrial Behavior in Warm Pulmonary-Ischemia Reperfusion Injury; S.-P. Sommer, V. Lange, I. Aleksic, B. Sinha, C. Schimmer, R.G. Leyh. University Hospital Würzburg, Würzburg, Germany;


(519) Predictors of Complications after Heart Transplantation in Pediatric Patients with Restrictive Cardiomyopathy; T. Shindo, J.C. Alejos, N. Halnon. David Geffen School of Medicine and Mattel Children’s Hospital, UCLA, Los Angeles, CA.

(520) Sudden Cardiac Death (SCD) in Pediatric Patients with Transplant Coronary Artery Disease (TCAD): Does Intravascular Ultrasound have a Role in Early Diagnosis of TCAD and Prevention of SCD in These Patients?; D.P. Bhat, C. Nasman, S. Worley, G.J. Boyle. Cleveland Clinic Children's Hospital, Cleveland, OH; Metrohealth Medical Center, Cleveland, OH.
(521) Evaluation of Safety and Efficacy of Exercise Stress Echocardiography To Screen for Coronary Allograft Vasculopathy in Pediatric Heart Transplant Recipients; M.H. Chen,1 F.I. Lunze,2 T.P. Singh,2 L. Bergersen,4 L. Smoot,5 C.S. Almond,6 K. Gauvreau,1 T. Geva,6 S.D. Colan,6 K.E. Hall,9 E.D. Blume.11 1Children’s Hospital Boston, Boston, MA; 2Children’s Hospital Boston, Boston, MA; 3Children’s Hospital Boston, Boston, MA; 4Children’s Hospital Boston, Boston, MA; 5Children’s Hospital Boston, Boston, MA; 6Children’s Hospital Boston, Boston, MA; 7Children’s Hospital Boston, Boston, MA; 8Children’s Hospital Boston, Boston, MA; 9Children’s Hospital Boston, Boston, MA; 10Children’s Hospital Boston, Boston, MA; 11Children’s Hospital Boston, Boston, MA.

(522) Pediatric Heart Transplant Recipients with Transplant Coronary Artery Disease Show a Show Increase in Filling Pressures over Time; C. Tissot, B.A. Pietra, D.D. Ivy, M.B. Mitchell, D.N. Campbell, D.J. Gilbert, S.D. Miyamoto. The Children’s Hospital, Aurora, CO.

(523) Diagnosis, Treatment and Outcome of Hodgkin Like Post-Transplant Lymphoproliferative Disease after Pediatric Heart Transplantation: A Single Center Experience; K. Behnke-Hall,1 H.-J. Wagner,2 J. Bauer,1 J. Thul,1 M. Hom,1 A. Reiter,2 D. Schranz.1 1Children’s University Hospital, Giessen, Germany; 2Children’s University Hospital, Giessen, Germany.

(524) The Use of Rituximab for Antibody Mediated Rejection after Pediatric Heart Transplantation; M.E. Richmond,1 R.K. Singh,1 L.A. Gilmore,1 K. Beddows,1 J.M. Chen,2 L.J. Addonizio,1 1Columbia University, College of Physicians & Surgeons, New York, NY; 2Columbia University, College of Physicians & Surgeons, New York, NY.

(525) Pre-Emptive Treatment for CMV in Paediatric Heart Transplantation- The Newcastle (UK) Experience; J.R. Samuel, K. Gould. Freeman Hospital, Newcastle upon Tyne, United Kingdom.

(526) Asymptomatic Rejection Diagnosed by Surveillance Endomyocardial Biopsy in Pediatric Heart Transplant Recipients: Do We Need To Treat?; C. Tissot, B.A. Pietra, D.D. Ivy, D.N. Campbell, M.B. Mitchell, B.A. Diamond, S.D. Miyamoto. The Children’s Hospital, Aurora, CO.


(528) The Doppler Derived Myocardial Performance Index (MPI) May Detect Patients with Coronary Allograft Vasculopathy (CAV) in Pediatric Heart Transplant Recipients; S. Schubert,1 H.B. Lehmkuhl,2 M. Yegitbasi,1 M. Huebler,3 N. Hiemann,2 R. Hetzer,2 F. Berger.1 1Deutsches Herzzentrum, Berlin, Germany; 2Deutsches Herzzentrum, Berlin, Germany.

(529) A Non-Invasive Assessment of Cardiac Output in Pediatric Heart Transplant Patients; M.L. Likes, J.C. Alejos. Mattel Children’s Hospital UCLA, Los Angeles, CA.

(530) Postoperative Extracorporeal Membrane Oxygenation (ECMO) As a Bridge to Recovery in Infants Immediately after Heart Transplantation (HTX) 1999-2009; R. Nubani,1 S. Kaushal,2 J.G. Gossett,1 K.L. Matthews,1 C.L. Backer,2 D. Wang,3 E. Pahl.1 1Children’s Memorial Hospital, Northwestern University Feinberg School of Medicine, Chicago; 2Children’s Memorial Hospital, Northwestern University Feinberg School of Medicine, Chicago; 3Children’s Memorial Research Center, Chicago.

(531) Lobar Versus Conventional Whole Lung Transplantation for Children with Advanced Lung Disease; K. Moneghetti,1 D.T. Keating,1 S. Marasco,1 J.H. Burton,1 M. Buckland,1 B. Levey,1 C. Robertson,2 T.J. Williams,1 G.I. Snell,1 G.P. Westall.1 1Alfred Hospital, Melbourne, Vic, Australia; 2Royal Children’s Hospital, Melbourne, Vic, Australia.

(532) Bilateral Bronchial Anastomosis Versus Tracheal Anastomosis with Bronchial Revascularization in Pediatric Lung Transplantation; M.G. Schecter,1 S. Das,1 E.D. McKenzie,2 J.S. Heinle,2 D.L. Morales,2 G.B. Mallory,1 O. Elidemir.1 1Baylor College of Medicine, Houston, TX; 2Baylor College of Medicine, Houston, TX.
Recovery of Right Heart Function with Temporary Extracorporeal Membrane Oxygenation in Patients with Severe Biventricular Failure; S. Saito, G. Matsumiya, T. Sakaguchi, S. Miyagawa, Y. Yoshikawa, T. Yamauchi, T. Kuratani, Y. Sawa. Osaka University Graduate School of Medicine, Suita, Osaka, Japan.

Major Neurological Events after Ventricular Assist Device (VAD) Implantation Are Device Specific but Are Also Related to Pre-Implant Factors; T. Horai,1 N.C. Ku,1 E.A. Genovese,1 C.A. Bermudez,1 J.K. Bahma,1 J.J. Teuteberg,2 S. Winowich,1 A. Weimer,1 G.C. O'Shea,1 Y. Toyoda,1 D.M. McNamara,2 R.L. Kormos.1 1University of Pittsburgh, Pittsburgh, PA; 2University of Pittsburgh, Pittsburgh, PA.

Cerebrovascular Bleeding during Ventricular Assist Device Support Is Highly Associated with Pre-Existing Right Heart Failure and Systemic Infection; T.S. Kato,1 K. Komamura,2 T. Shishido,4 K. Hashimura,3 T. Nakatani,3 M. Yanase,3 K. Toda,3 T. Funatsu,7 T. Fujita,3 K. Niwaya,6 N. Oda,5 I. Nakajima,1 A. Takahashi.1 1National Cardiovascular Center, Osaka, Japan; 2Takeda Pharmaceutical Company Limited, Osaka, Japan; 3National Cardiovascular Center, Osaka, Japan; 4National Cardiovascular Center, Osaka, Japan; 5Hiroshima University School of Medicine, Hiroshima, Japan; 6Garatia Hospital, Osaka, Japan; 7Osaka Rosai Hospital, Osaka, Japan.

Continuous Flow Ventricular Assist Devices Do Not Reverse the Gene Expression Program Typical of Heart Failure; A. Nair,1 A. Anyanwu,1 C. Nwasike,1 S. Pinney,1 E. Adler.2 1Mount Sinai Heart, New York City, NY; 2Oregon Health School of Medicine, New York City, NY.

Creating a Safe and Effective Method for First Responders To Identify Mechanical Circulatory Support Patients in the Community Setting; D. Rivard, T. Elliott, C. Hanny Gilbert, A. Wolfe, T. Van de Bussche. Johns Hopkins Hospital, Baltimore; INOVA Fairfax, Fairfax; Washington Hospital Center, Washington, DC.

Delayed Sternal Closure Following Left Ventriicle Assist Device Implantation; Z.A. Hashmi,1 G.B. Pelz,1 R.J. Moraca,1 S. Murali,2 R.L. Benza,2 G.G. Sokos,2 A. Hopwood,1 S. Stutz,1 G.J. Magovern, Jr.,1 S.H. Bailey,1 D.A. Dean,1 Allegheny General Hospital, Pittsburgh, PA; 2Allegheny General Hospital, Pittsburgh, PA.

Characterization of Gastrointestinal Bleeding in HeartMate II Left Ventricular Assist Device Patients; N.O. Mason, B.B. Reid, G. Hamstan, J. Jones, S. Stoker, D. Budge, R. Alharethi, G. Thomsen, S.E. Clayson, W. Caine, A.G. Kfoury. Intermountain Medical Center, Salt Lake City, UT.


Cardiac Performance in Patients without Early Native Aortic Valve Opening; O.H. Frazier, S.M. Parnis, R. Stainback, X. Quan, Z.T. Demirozu, W.E. Cohn, I. Gregoric. Texas Heart Institute, Houston, TX.

Effect of Fibrosis at Implantation on Clinical Outcome in Patients with HeartMate II Ventricular Support; A.M. Segura, L.M. Buja, M.A. Elayda, S. Wang, O.H. Frazier. Texas Heart Institute, Houston.

Long Term Outcome of Bridge to Recovery Versus Bridge to Transplantation; E.J. Birks,1 R.S. George,1 M. Noor,1 T. Bahrami,1 M. Amrani,1 J. Pepper,1 G. Dreyfus,1 M. Petrou,1 M.H. Yacoub,2 A. Khaghani.1 1Harefield Hospital, Harefield, Middlesex, United Kingdom; 2Harefield Hospital, Harefield, Middlesex, United Kingdom.

Continuous Flow-Type VADs Induce Lower Levels of Unloading but Exert Similar Effects on Cellular Remodeling Compared to Pulsatile-Type VADs; L.J. Garcia, A.R. Trevino, K.A. Youker, B.A. Bruckner, M. Loebe, J.E. Estep, C. Orrego, G. Torre-Amione. The Methodist Hospital, Houston, TX.

Localization and Distribution of Micro-RNAs in the Myocardium of Heart Failure Patients before and after LVAD Support; J. Van Kuik, S. Lok, M.E.I. Schipper, H. Dullens, L. De Windt, P.A. Da Costa Martins, N. De Jonge, R.A. de Weger. University Medical Center Utrecht, Utrecht, Netherlands; University Medical Center Utrecht, Utrecht, Netherlands; Cardiovascular Research Institute Maastricht, Maastricht, Netherlands.


Early Severe Post Operative Liver Dysfunction after Heartmate II® LVAD Placement: Incidence, Risk Factors, and Outcomes; E.A. Ziemb, J.M. Aho, K. Liao, M.A. Kuskowski, M.M. Colvin-Adams, P. Echman, M.R. Pritzker, R. John. University of Minnesota, Minneapolis, MN; University of Minnesota, Minneapolis, MN; University of Minnesota, Minneapolis, MN; Chicago Medical School, Chicago, IL; VA Medical Center, Minneapolis, MN.

Percutaneous LVAD Support in Refractory Cardiogenic Shock Rapidly and Disparately Modulates Serum Biomarkers of Apoptosis, Neurohormonal Activation, Inflammation, and Extracellular Matrix Remodeling; N.R. Shah, M.C. Bieniarz, P. Loyalka, D.L. Mann, B. Kar. Baylor College of Medicine, Houston, TX; Texas Heart Institute at St. Luke’s Episcopal Hospital, Houston, TX; Washington University School of Medicine, St. Louis, MO.

Use of Extracorporeal Membrane Oxygenation (ECMO) in Patients with Chronic Cardiomyopathy: A Word of Caution; C. Bermudez, Y. Toyoda, F. Avila, S. Mulukutla, O. Marroquin, J. Teuteberg, R. Kormos. University of Pittsburgh Medical Center, Pittsburgh; University of Pittsburgh Medical Center, Pittsburgh.

LVAD Support Results in a Significant Improvement in the Myocardial Sympathetic Nervous System, as Assessed by 123Il-Metaiodobenzylguanidine (123Il-MIBG), Independent of Ventricular Function; R.S. George, M.H. Yacoub, A. Cheetham, A. Kelion, E.J. Birks. Royal Brompton and Harefield NHS Foundation Trust, Harefield, Middlesex, United Kingdom; Imperial College, Harefield, Middlesex, United Kingdom; Royal Brompton and Harefield NHS Foundation Trust, Harefield, Middlesex, United Kingdom; Royal Brompton and Harefield NHS Foundation Trust, London, United Kingdom.


DNA-Methylation of the Human b1-Adrenergic Receptor Core Promoter Pre and Post VAD-Support and Its Putative Role for Gene Silencing in the Terminal Failing Myocardium; A. Kassner, Bohms, M.
Morshuis, S. Schulte-Eistrup, J. Gummert, H. Milting. Herz- und Diabeteszentrum NRW, Bad Oeynhausen, NRW, Germany; Herz- und Diabeteszentrum NRW, Bad Oeynhausen, NRW, Germany.


(557) Improved Right Heart Function Secondary to Favorable Loading Conditions after Axial Flow Left Ventricular Assist Device Implantation; R. Rasalingam, K.R. Bilhorn, S.N. Johnson, C.B. Kapadia, M. Makan, J.E. Perez, N. Moazami. Washington University in St Louis, St. Louis, MO; Washington University in St Louis, St. Louis, MO; Barnes Jewish Hospital, St. Louis, MO.

(558) The Effect of Continuous, Nonpulsatile Flow on Renal Function in Patients Supported by the HeartMate II Left Ventricular Assist Device; Z.T. Demirozu, R. Radovancevic, O.H. Frazier. Texas Heart Institute at St. Luke’s Episcopal Hospital, Houston, TX.


(560) Longitudinal Fibre Shortening Velocity Measured by Tissue Doppler Imaging Reflects Exercise-Induced Increase in Cardiac Output during LVAD Support; M. Andersen, F. Gustafsson, A.S. Jensen, P.L. Madsen, C. Hassager, N.H. Secher, J.E. Moller. Rigshospitalet, Copenhagen, Denmark; Rigshospitalet, Denmark.

(561) The Effects of Clenbuterol on the Left Ventricular Wall Thickness and Function in Patients Recovered on Left Ventricular Assist Device (LVAD); R.S. George, M.H. Yacoub, H. Lister, C. Webb, A. Khaghanil, E.J. Birks, Royal Brompton and Harefield NHS Foundation Trust, Harefield, Middlesex, United Kingdom; Imperial College, Harefield, Middlesex, United Kingdom; Royal Brompton and Harefield NHS Foundation Trust, Harefield, Middlesex, United Kingdom; Royal Brompton and Harefield NHS Foundation Trust, Harefield, Middlesex, United Kingdom.


(564) Trends in Body Mass Index Following Long Term Mechanical Circulatory Support; Y. Ravi, A. Knapkie, S. Wissman, T. Yanssens, B. Sun, L. Louis, M. Firstenberg, B. Needleman, A. Hasan, C.B. Sai Sudhakar. The Ohio State University Medical Center, Columbus, OH.

(565) Less Invasive Surgery with Circulite® Synergy® Pocket Micro-Pump Reduces Adverse Events Verses Traditional VADs; B. Meyns, F. Rega, A. Simon, S. Klotz, C. Schlensak, T. Wittwer, D. Burkhoff. Gasthuisberg University Hospital, Leuven, Belgium; Hannover Medical School, Hannover, Germany; University Hospital, Muenster, Germany; University Medical Center, Freiburg, Germany; University Hospital of Cologne, Cologne, Germany; Columbia University, New York, NY; CircuLite, Inc., Saddle Brook, NJ.

(567) Single-Center Experience Using the Heartmate II Left Ventricular Assist Device as a Bridge to Decision; M. Toma,1 G.V. Gonzalez-Stawinski,2 D. Schmuhl,1 N.G. Smedira,2 R.C. Starling,1 M.M. Mountis.1 1The Cleveland Clinic Foundation, Cleveland, OH; 2The Cleveland Clinic Foundation, Cleveland, OH.


(570) Safety of EBV-DNA-Load Guided Pre-Emptive Reduction of Immunosuppression To Prevent PTLD; E.A. Verschuuren,1 M.E. Erasmus,2 B.L. Rottier,3 G.D. Nossent,1 W. van der Bij.1 1University Medical Centre Groningen, Groningen, Netherlands; 2University Medical Centre Groningen, Groningen, Netherlands; 3University Medical Centre Groningen, Groningen, Netherlands.

(571) Activity of Colistin Against Filamentous Fungi isolated from Lung Transplant Recipients; G. Short,1 C. Rennison,1 K. Gould,1 A. Fisher.2 1Freeman Hospital, Newcastle upon Tyne, United Kingdom; 2Freeman Hospital, Newcastle upon Tyne, United Kingdom.


(573) Is Targeted Antifungal Prophylaxis Effective in Lung Transplants?; S.M. Hosseini,1 L. Singer,2 C. Chaparro,2 M. Hutcheon,2 C. Rotstein,1 S. Keshavjee,2 S. Husain1 1University Health Network, Toronto, ON, Canada; 2University Health Network, Toronto, ON, Canada.

(574) Risks of Invasive Hemodynamics in UNOS 1A Patients; E.C. DePasquale, D.L. Jacoby, F.A. Lee. Yale University School of Medicine/Yale-New Haven Hospital, New Haven, CT.


(576) Hyponatremia on Admission Predicts Longer Length of Stay in Patients with Pulmonary Hypertension and Right Ventricular Failure; A. Rabinovitz,1 R. Zolty.2 1Jacobi Medical Center, Bronx, NY; 2Montefiore Medical Center, Bronx, NY.

(577) Th17 Cells and Their Role in Acute Rejection in Heart Transplant Patients; C.C. Baan,1 A.H.M.M. Balk,2 A.M.A. Peeters,1 E. Dijke,1 A.P.W.M. Maat,2 K. Caliskan,2 W. Weimar,1 Erasmus MC, Rotterdam, Netherlands; 2Erasmus MC, Rotterdam, Netherlands; 3Erasmus MC, Rotterdam, Netherlands.

(578) Cysteinyl Leukotrienes/Prostaglandin E2 Balance Following Lung Transplantation; S. Ptaszynski,1 E. O’Carroll,1 S. Al-Mot,1 A. Al-Rabea,1 C. Poirier,2 C. Bergeron,1 Centre de Recherche CHUM- Hotel-Dieu, Montreal, QC, Canada; 2CHUM- Notre-Dame, Montreal, QC, Canada.

(579) IL35 Is Released by T Cells of Lung Transplant Recipients; F. Meloni,1 N. Solari,1 M. Morosini,1 P. Draghi,1 A. Grasso,1 S. Giuliano,2 V. Conio,1 A.M. Fietta.1 1University of Pavia Foundation IRCCS San Matteo, Pavia, Italy; 2University of Pavia, Pavia, Italy.
Poly I:C Abrogates Murine Airway Allograft Tolerance Induced by CD154 Costimulation Blockade and Enhances Allospecific CD8+ T Cell Effector Responses; P.D. Shah, E.A. Lendermon, E. John, A.B. Whitlock, J.B. Orens, J.F. McDyer. Johns Hopkins University School of Medicine, Baltimore, MD; Vanderbilt University Medical Center, Nashville, TN.